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V. Summary 
 
Extracellular matrix (ECM) formation and remodeling play a central role in the 
processes of lung alveolarization and secondary septation. A key component of ECM 
structure is a complex collagen and elastin network of fibers. Formation and maintenance of 
this crucial structure is perturbed in aberrant lung development in patients with 
bronchopulmonary dysplasia (BPD) as well as in experimental animal models of BPD. Lysyl 
oxidases comprise a family of five members, which facilitate the covalent cross-linking of 
collagen and elastin molecules, thus controlling ECM structural homeostasis. Moreover, 
alternative non-matrix gene regulatory roles for these enzymes have been proposed. Recently, 
lysyl oxidases have been implicated in the pathogenesis of various lung diseases, including 
cancer, fibrosis, pulmonary hypertension and BPD. Although several studies report 
perturbations to lysyl oxidase expression, and elastin and collagen deposition associated with 
the arrest of alveolarization in BPD, a causal role for lysyl oxidases in this processes has not 
yet been fully addressed.   
In the study presented here, lysyl oxidase activity was neutralized in vivo in a murine 
hyperoxia-based model of BPD. In addition, non-matrix roles for three of the five family 
members, Lox, Loxl1 and Loxl2 were explored on the primary mouse fibroblasts background. 
 In the first part of the study, an arrest in alveolarization in developing mouse lungs was 
induced by hyperoxia exposure. Damage to alveolar formation was accompanied by an 
increase in lysyl oxidase activity, and an increase in the abundance of collagen and collagen 
cross-links. In contrast, the abundance of the insoluble elastin and elastin cross-links 
desmosine and isodesmosine was decreased, resulting in a substantial shift in collagen-to-
elastin ratio. Normalization of lysyl oxidase catalytic activity partially restored normal levels 
of collagen. The abundance of elastin cross-links and the formation of elastin foci was also 
improved. However, no significant improvement in lung alveolarization was observed. In the 
second part of the study, a microarray analysis after small interfering (si)RNA knockdown in 
primary mouse lung fibroblasts revealed a dysregulation of expression of a large group of 
genes, including several ECM-relevant players, such as Mmp3, Mmp9, Rarres1 or Eln. 
Moreover, the expression patterns of these genes in an in vivo animal model of BPD 
correlated with observations made in vitro. Importantly, the gene regulatory roles of lysyl 
oxidases were independent of lysyl oxidase catalytic activity. 
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VI. Zusammenfassung 
 
Die Entstehung und Umwandlung von extrazellulärer Matrix (EZM) spielt eine zentrale 
Rolle bei der Lungenalveolarisierung und der sekundären Septierung. Die 
Schlüsselkomponente der EZM Struktur ist ein komplexes Netzwerk aus Kollagen- und 
Elastinfibrillen. Die Entstehung und Aufrechterhaltung dieser wichtigen Strukturen ist bei 
Patienten, die an bronchopulmonaler Dysplasie (BPD) leiden, genauso wie in 
tierexperimentellen Modellen von BPD, im Sinne einer gestörten Lungenentwicklung, 
verändert. Lysyloxidasen sind eine Enzymfamilie, die aus fünf Mitgliedern besteht und für 
die Kontrolle der strukturellen Homöostase der EZM zuständig sind, indem sie die kovalente 
Quervernetzung von Kollagen- und Elastinmolekülen übernehmen. Zudem wurden weitere 
nicht-EZM bezogene genregulatorische Funktionen dieser Enzyme vermutet. Kürzlich konnte 
gezeigt werden, dass Lysyloxidasen eine Rolle in der Pathogenese verschiedener 
Lungenerkrankungen, einschließlich Tumorerkrankungen, Fibrose, pulmonale Hypertonie 
und BPD, spielen. Obwohl verschiedene Studien von der Veränderung der 
Lysyloxidasenexpression und der veränderten Einlagerung von Kollagen und Elastin im 
Zusammenhang mit dem Alveolarisierungsstopp bei BPD berichten, wurde die kausale Rolle 
der Lysyloxidasen in diesen Prozessen bisher nicht untersucht. 
In der hier vorgestellten Studie, wurde die Aktivität der Lysyloxidase in vivo in einem 
Hyperoxie basierten Mausmodell der BPD ausgeschaltet. Außerdem wurde die nicht Matrix 
bezogene Rolle von drei der fünf Familienmitglieder Lox, Loxl1 und Loxl2 in primären 
Mausfibroblasten untersucht. 
Im ersten Teil der Studie wurde der Alveolarisierungsstopp in sich entwickelnden 
Mauslungen durch Hyperoxie Exposition ausgelöst. Der Schaden an der alveolären 
Formation wurde von einer gesteigerten Lysyloxidasenaktivität begleitet, genauso wie von 
einer erhöhten Kollagenmenge und vermehrten Kollagenquervernetzungen. Im Gegensatz 
dazu, waren der Überschuss von unlöslichem Elastin und die Anzahl der 
Elastinquervernetzungen mit Desmosin und Isodesmosin verringert, was in einer deutlichen 
Veränderung des Kollagen/Elastin-Verhältnisses resultierte. Die Ausschaltung der 
enzymatischen Aktivität der Lysyloxidase konnte die Kollagenmenge immerhin teilweise 
normalisieren. Ebenso verbesserten sich die Zahl der Elastinquervernetzungen und die 
Entstehung der Elastinfoci. Dennoch konnte kein förderlicher Effekt auf die 
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Lungenalveolarisierung beobachtet werden. Im zweiten Teil der Studie zeigte eine 
Microarray Analyse nach Ausschaltung der Enzyme durch small interfering (si)RNAs in 
primären murinen Lungenfibroblasten die Dysregulation einer großen Gruppe von Genen, 
inklusive einiger EZM-relevanter Gene, wie Mmp3, Mmp9, Rarres1 oder Eln. Zudem 
korrelierten die Expressionsmuster dieser Gene in vitro mit Daten aus einem in vivo Modell 
der BPD. Interessanterweise waren diese genregulatorischen Eigenschaften der 
Lysyloxidasen unabhängig von ihrer katalytischen Aktivität. 
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1 INTRODUCTION 
 
1.1 Development and structure of the lung 
The primary function of the lung of all air-breathing mammals is the transport of inspired 
oxygen from the atmosphere into the bloodstream and simultaneous clearance of accumulated 
carbon dioxide from the blood. This process, which occurs in smallest respiratory units of the 
lung, the alveoli, takes place across a double alveolo-capillary barrier, composed of the 
alveolar epithelium, capillary endothelium and adjacent structures of the extracellular matrix 
(ECM). In order to achieve maximal efficiency of gas exchange, this barrier must be as thin 
as possible and the alveolar surface area must be as large as possible. Therefore, the main 
objectives of lung development, namely late lung development, are the formation of a 
complex structure comprising a large number of alveoli and the formation of thin 
alveolo-capillary barrier facilitating an effective gas exchange [1-6].  
The process of lung development consists of five developmental stages, which are 
traditionally divided into two phases - early (mainly prenatal) and late (mainly postnatal) lung 
development (Figure 1) [7, 8]. 
 
1.1.1 Early (prenatal) lung development 
In order to produce a fully-functional organ, enabling breathing and gas exchange in 
postnatal environment, the fetal lung must undergo rapid anatomical changes within a 
relatively short period of time. Based on their morphological and histological characteristics, 
four developmental stages are usually distinguished within early lung development in humans 
(three stages in mice) [6]. 
 
Embryonic stage 
The core lung structure is derived from the endoderm of the primitive foregut at 
approximately three to seven weeks post-conception in humans (embryonic day [E]9–E12 in 
the mouse) and undergo main conducting airway branching during the embryonic stage of the 
early lung development. First, epithelial cells migrating into the surrounding mesenchyme 
form a primitive trachea, which further branches into two main, epithelium-lined, bronchial 
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buds. This early left and right main bronchus subsequently divides into further lobar and 
segmental bronchi [1, 6, 9, 10]. 
 
 
 
Figure 1. Progression of prenatal and postnatal lung development. 
Schematic illustration of major stages of early and late lung development and their timing in 
human and in mouse. E, embryonic day; P, postnatal day; W, week. In addition, 
representative lung sections from mouse lungs at E14.5, E16.5, E18.5, P1, P14 and adult 
mice are illustrated. Synthesized from several sources [5-7, 9, 11-13]. 
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Pseudoglandular stage 
Airway branching continues during the pseudoglandular stage, which occurs between 
the 5th and 17th week post-conception in humans (E12–E17 in mice) and the formation of the 
conducting airways and terminal bronchioles is fully completed. Pulmonary arteries and veins 
are developed during this period, and the cartilage begins to form around the large airways. 
The first ciliated epithelial cells and immature, cuboidal type II cells appear [3, 6, 9, 14].  
 
Canalicular stage 
The canalicular stage, which occurs between the 16th and 27th week post-conception in 
humans, is mainly characterized by the thinning of the interstitial tissue and formation of 
acinar units, marking the beginning of the alveolarization process. The thinning of the 
interstitial mesenchyme leads to closer contact between the forming capillaries and the 
differentiating epithelium and the formation of the thin air-blood barrier. The primitive 
cuboidal epithelium is now visibly differentiated into flattened type I alveolar epithelial cells, 
and the lamellar bodies-containing type II alveolar epithelial cells. The presence of surfactant 
protein can be detected by week 24 [6, 9, 13]. Due to advances in perinatal medicine, the 
canalicular stage became the earliest possible period for a successful preterm birth in humans 
[9, 15]. Canalicular stage is also the last  period of prenatal lung development in mice, 
spanning E17 and E18 [5].  
 
Saccular stage 
The last fully prenatal stage of lung development in humans and the first stage of 
postnatal lung development in mice (24–38 weeks post-conception in humans, and 
E18-postnatal day [P]4 in mice) is characterized by the enlargement of the peripheral 
airways, formation of saccular units, further thinning of air-blood barrier and the start of 
secondary septation.  
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1.1.2 Late (postnatal) lung development 
Alveolar stage 
This stage of alveolar formation is the last stage of lung development in both humans and 
mice. Although the alveolar stage in humans starts prenatally (36 weeks post-conception), it 
is largely a postnatal process, taking place during the first 36 months of postnatal life (and 
possibly beyond). Unlike in humans, alveolarization in mice is entirely postnatal process, 
taking place between P4-P28 [6, 7, 9, 16]. Alveolar stage is characterized by two, largely 
interconnected events: secondary septation and microvascular maturation. 
The main contribution of secondary septation is increasing the number and reducing the 
size of the alveoli, eventually leading to an increase of the gas exchange surface area of the 
lung [5, 16]. While a human lung at birth contains up to 50 million alveoli [17-19], this 
number increases greatly postnatally, with an average of 480 million alveoli (range of 
300-800 million) reported in an adult lung [7, 20, 21]. The dramatic increase in the number of 
alveoli and overall surface area happens through the formation of secondary septa. At this 
stage of lung development, distal airspaces are lined by thick walls consisting of two external 
capillary layers and a single central connective tissue layer. Ridges of secondary septa (or 
crests) arise from primary septa just before term in humans, and at P7 in mice. Initiation sites 
of these crests are typically rich in elastic fibers and myofibroblasts expressing α-smooth 
muscle actin (αSMA), which secrete numerous proteins of the extracellular matrix (ECM) 
facilitating crest protrusion [1, 5, 7, 13, 22]. 
The process of microvascular maturation occurs in parallel with alveolarization and is 
mainly concluded within the first two to three years of age. During this process double 
capillary layer matures into a single capillary network facilitating the faster gas diffusion [7, 
13]. It is largely accepted, that once the single capillary network is formed, no more 
alveolarization can occur in the lung [9].  
The process of alveolarization remains poorly understood but is thought to be carefully 
coordinated by the combined action of various gene expression programs (comprised of 
transcription factors and epigenetic effects) and both contact-mediated and growth 
factor-mediated cell-to-cell communication. The development and maturation of the lung 
structure is also driven in part by physical forces caused by breathing motions and the 
production and remodeling of the ECM scaffold [1, 2, 23-26].  
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1.2 Bronchopulmonary dysplasia 
Multiple diseases are either caused by, or by themselves cause disturbances to lung 
development resulting in malformation of the lung architecture, and defects in gas exchange. 
Depending on the severity of the damage, serious disturbances to respiratory function, as well 
as long-term consequences may occur [3].  
The most common neonatal form of chronic lung disease (CLD) is bronchopulmonary 
dysplasia (BPD) [27], which was first described in study by William Northway in 1967, in 
the lungs of prematurely born infants, treated for the severe respiratory distress syndrome 
(RDS) [28]. Oxygen  supplementation and positive pressure mechanical ventilation received 
by these patients, however lifesaving, was associated with oxygen toxicity and disturbed 
postnatal lung development, leading to a consecutive injury, characterized by an interstitial 
and alveolar edema, persistent inflammation and parenchymal fibrosis [5, 28, 29].  
Characteristics of BPD have gradually changed over the past several decades. 
Improvements in the medical management of BPD led to a considerable increase in the 
survival of infants with extremely low birth weight, resulting in an increase in BPD 
incidence. On account of these changes, the definition as well as diagnostic criteria of BPD 
have been eventually altered [3, 27, 29, 30]. Nowadays, the disease, also known as “new 
BPD”, is clinically defined by the need for supplemental oxygen and/or mechanical 
ventilation for more than 28 days, or at the 36th week postmenstrual age [27]. Lungs of BPD 
patients are now histologically characterized less by fibrosis and fibroproliferative airway 
damage. Instead, the lung structure is more often characterized by defects in alveolar and 
septal formation (leading to alveolar hypoplasia), thickening of alveolar walls, a dysmorphic 
pulmonary circulation and ECM remodeling. In comparison to “old BPD”, BPD today is 
therefore described largely as a disease of arrested lung development (Figure 2) [3, 27, 31, 
32]. 
Despite improvements in clinical care, BPD still remains one of the major causes of 
morbidity and mortality of infants in a neonatal intensive care unit [3, 27, 29, 30]. Moreover, 
studies suggest possible long-term consequences of BPD persisting later into the adulthood 
[33-35]. Although the pathogenic pathways involved in BPD are not well-understood, several 
hypotheses have been formed about the processes involved in the development of BPD. 
Processes known to play role in the pathology of BPD include: abnormal shifts in physical 
forces, failures in the development of pulmonary vasculature, altered cellular composition of 
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the developing alveoli, increase of inflammatory cell infiltration, perturbed gene expression 
and growth factor signaling, aberrant cell-to-cell communication, and disfunctional ECM 
architecture and metabolism, particularly changes in the abundance and organization of 
collagen and elastin fibers and deregulation of ECM-remodeling enzymes [5, 36-40].  
 
 
 
Figure 2. Histological structure of the lung of a patient with bronchopulmonary 
dysplasia and a healthy age-matched control lung. 
Comparison of hematoxylin and eosin stained peripheral lung structure in a 12-year old male 
patient with bronchopulmonary dysplasia (A) and a comparable area of lung tissue from an 
age-matched control lung with normal alveolarization (B) [41]. Asterix marks abnormally 
enlarged air space. BR, bronchiole. 
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1.3 The extracellular matrix in context of normal and aberrant lung 
development 
Branching morphogenesis and alveolarization are characterized by intensive growth 
and remodeling of newly forming parenchymal structures. This process requires precisely 
timed mesenchymal-to-epithelial interactions, which cannot occur in the absence of a 
functional ECM compartment [42, 43]. 
The first observations regarding the remodeling of ECM structures during lung 
development, namely collagen and elastin, were made in the 1970’s and 1980’s [44, 45]. 
While the ECM plays a mainly supporting role in adult lung, it provides a crucial mechanical 
support for the developing epithelium, mesenchyme and the capillary network [4, 5]. During 
the alveolar stage of lung development, collagen is mainly present within the alveolar walls, 
while elastin is deposited more specifically in areas of so-called “foci” at the tips of 
protruding secondary septa, suggesting the importance of elastin in the process of septal 
formation [13, 46] (Figure 3). The expression of collagen and elastin is strongly regulated 
throughout the course of lung development in various experimental animals, including mice 
[46-49]. While expression of both basement membrane and fibrillary collagens peaks at P7, 
the peak of elastin expression coincides with the burst of secondary septation around P14 [5, 
48]. The importance of collagen and elastin in postnatal lung maturation was further proven 
in studies using lathyrogens, pharmaceutical lathyrism-inducing agents, namely 
β-aminopropinitrile (BAPN), which disrupted normal ECM deposition and led to an arrest in 
alveolarization [50, 51]. 
A failure of alveolar septation in both a clinical and an experimental setting is 
accompanied by changes in ECM production and deposition. Perturbed ECM structures have 
been repeatedly reported in disorders of lung development, including BPD. Collagen fibers in 
the lung parenchyma in these studies are often described as “disorganized, tortuous, and 
thickened” [37, 38]. Elastin fibers also exhibit an abnormal structure formation both in the 
parenchyma [52-54] and the vasculature [55] of patients with BPD, and animal models of 
BPD alike (Figure 3). 
Despite the considerable effort made in order to understand the changes in ECM 
production and metabolism in the developing lung parenchyma, the underlying reasons for 
these perturbations are still not fully known [5]. However, ECM homeostasis throughout lung 
development and a balance between ECM production by cells and degradation and 
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remodeling of ECM components by enzymatic machinery seems to play a key role in 
processes of alveolar and septal formation.  
 
 
 
Figure 3. Elastin deposition during lung formation in bronchopulmonary dysplasia and 
in the hyperoxia-based mouse model of bronchopulmonary dysplasia. 
(A-C) Schematic representation of elastin deposition and capillary network formation during 
normal and aberrant alveolarization. (A) Initial elastin deposition within the alveolar wall, 
prior to the formation of secondary septa in the normally developing lung. A double capillary 
network is present. (B) Elastin localizes to the top of newly forming secondary septa in the 
normally developing lung. A single capillary network is present. (C) Deposition of elastin at 
the top of secondary septa is disturbed during aberrant alveolar formation associated with 
bronchopulmonary dysplasia (BPD). Elastin is partially deposited within thickened septa. The 
alveolar microvasculature is malformed [13]. (D-E) Elastin foci in the hyperoxia-based 
mouse model of BPD. (D) Elastin fibers form foci at the top of secondary septa in mice 
exposed to 21% O2. (E) Elastin fibers fail to form foci in the lungs of mice exposed to 
85% O2 from the day of birth up to, and including postnatal day 28. Elastin fibers appear 
disorganized and malformed. Elastin visualized by Hart’s stain [46]. 
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1.3.1 Key components of extracellular matrix in the context of lung development 
The ECM forms a complex, large network of multiple heterogenous components with 
diverse structural, mechanical and biochemical properties [56]. Within these structural 
elements of ECM the most abundant are collagen and elastin which represent 50% [57] and 
18% [58], respectively, of the lung ECM. Other components include microfibrils, 
glycoproteins fibrillin [59] and fibulin [60], integrins and integrin ligands [61]. 
The ECM structure, which serves as a scaffold, is constantly remodeled during lung 
development [42, 43]. Therefore, the production of structural components which form ECM, 
as well as the enzymatic systems involved in regulation of ECM deposition and stability, 
must be considered. This machinery include members of families of enzymes involved in the 
post-translational modulations of various ECM components on one hand, and degradation of 
the ECM on the other hand. Together this actions of ECM-remodeling enzymes enable 
natural processes of the ECM renewal [5]. 
 
Collagen 
The most abundant protein within the interstitial ECM, collagen, is produced by 
fibroblasts [62-64]. Collagen fibers in the lung, which are represented predominantly by 
collagen types I and III, are found mainly within blood vessels, bronchi and alveolar septa 
[65-67]. Quantity of collagen in the lung fluctuates throughout the period of lung 
development, with a peak in expression at P7 in mice. Parenchymal collagen forms a fine 
network of fibers. Collagen has been attributed with a major role in processes of alveolar 
septation [38, 48]. 
Numerous studies using various animal models of BPD and emphysema have 
demonstrated the presence of abnormal collagen structures and failures in integrity of 
collagen network. These changes are thought to be associated not only with defects in 
formation of new alveoli, but also in the destruction of pre-existing alveoli [38, 46, 68]. 
Furthermore, studies performed in animal models of BPD report an increase in collagen 
production accompanied with a formation of thicker collagen fibers, which was associated 
with decrease in lung elasticity [46, 68]. 
Observations along this line were also made in clinical studies. Lungs of the patients 
diagnosed with BPD exhibited an increase in the abundance of fibrillar collagens (collagen I 
and III) and collagen I/collagen III ratio. In addition the number of collagen-positive cells 
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was also increased [65, 69]. Thickened, disorganized and misshapen collagen fibers were also 
observed in lungs of patients diagnosed with BPD who received positive pressure ventilation. 
It is possible that the increase in the size of the alveoli due to the ventilation causes a 
compression and damage to ECM network surrounding the alveoli, eventually corrupting the 
normal course of septation [38]. 
In vitro, collagen production can be regulated by growth factors, including 
transforming growth factor (TGF)-β [70, 71]. Supporting the findings in vitro are the reports 
of increased levels of TGF-β in preterm infants with BPD [72]. Moreover, TGF-β was 
casually implicated in arrest of alveolar formation in animal model of BPD where an increase 
in TGF-β activation led to an increase in a collagen production by fibroblasts and in the 
consecutive collagen deposition [46, 73, 74]. Similarly, TGF-β over-expressed in the lungs in 
utero led to pulmonary hypoplasia, collagen deposition was increased in the developing 
alveolar septa and animals developed thickened collagen fibers [75]. Furthermore, it has been 
shown that TGF-β modulates expression levels of multiple matrix-remodeling enzymes, 
further regulating collagen formation and metabolism [70, 76-78]. 
 
Elastin 
Elastic fibers are formed by thoroughly cross-linked microfibrils of elastin and 
fibrillin associated with several accessory molecules, including latent TGF-β-binding protein 
(LTBP), fibulins and emilins [59]. Elastin in the developing lungs is produced by fibroblasts 
and smooth muscle cells (SMC). Elastic fibers in the lung are present predominantly in the 
conducting airways, alveolar ducts, alveoli and in the developing lung vasculature [62, 64, 
79]. The expression of elastin and formation of elastin network in lungs begins in the 
pseudoglandular stage. Elastin (Eln) expression peaks between the saccular and alveolar stage 
and remain high throughout the period of secondary septation (P5–P15 in mice). Throughout 
the alveolar stage, elastin is found specifically at the tips of the developing septa, where it 
forms elastin foci. This pattern of deposition indicates that elastin could play a role in the 
formation of secondary septa and in the alveolarization [13, 46, 80]. The expression of elastin 
eventually descreases after the process of alveolarization is completed [48, 81]. 
Although the expression of elastin in adult lungs is low, reactivation of elastin 
synthesis can occur in various pathological situations. For example, disorganized and 
unusually shaped elastic fibers were described in emphysema and pulmonary fibrosis [39, 
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81]. Similarly, abnormal elastin fiber structure and deposition was observed within the 
parenchyma of prematurely-born ventilated neonates [82].  
The importance of elastin in the development of the lung is further emphasized by 
studies on elastin deficient (Eln-/-) or haploinsufficient (Eln+/-) mice. Complete deletion of 
elastin causes perinatal lethality and lungs of Eln-/- mice show an impaired distal airway 
development [83]. While retaining a normal lung development and lung structure, elastin 
haploinsufficient mice express 50% lower elastin levels, and two-fold increase in levels of 
collagen and lysyl oxidase (LOX). This observations were accompanied by an increase in 
lung compliance and decrease in stiffness when compared to wild-type (WT) mice [84, 85]. 
Along the same line, transgenic mice with elastin expression decreased to 37% of normal 
levels, had good survival, but exhibited a significant increase in lung size and a pronounced 
arrest in alveolar formation [85].  
Over the past decade, elastin has been studied at length in multiple animal models of 
lung development and BPD. Both perinatal hyperoxia and mechanical ventilation were shown 
to increase elastin production. Elastin fibers in these lungs are often described as disturbed 
and fragmented and are largly localized within alveolar walls instead of septal tips [46, 64, 
86-88]. Abnormalities in elastin fibers formation probably leads to a further fiber 
disintegration and malfunction.  
 Although the mechanisms behind the elastin regulation are not fully understood, 
multiple studies highlight the possible roles of TGF-β and platelet-derived growth factor 
(PDGF) in these processes. While TGF-β seems to be involved in induction of elastin 
expression [76, 89, 90], certain forms of PDGF suppressed elastin production [91]. This data 
from experimental models supports observations made in clinical studies, where increase in 
the abundance of TGF-β [72] and decrease in abundance of PDGF were observed in BPD 
patients [92]. 
 While both, studies employing mechanical ventilation, and perinatal hyperoxia 
models report an increase in elastin mRNA levels, controversy exists about the status of 
mature elastin, where different observations have been made in respect to the methods 
employed (analysis of tropoelastin by immunoblot, vs. histological staining, vs. analysis of 
elastin cross-links) [88, 93-95]. 
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Extracellular matrix remodeling enzymes 
Although many studies focus on ECM components synthesis and production, only 
few studies to date have explored the subsequent ECM processing and remodeling. However, 
due to the long half-life of ECM fibers in the lung (up to several years in mice), more 
importance has recently been given to formation of elastin and collagen fibers, their 
remodeling and maturation, rather than the gene and protein expression per se [4, 46, 96-98].  
It is likely that the formation of elastin and collagen fibers with abnormal structure 
and properties is a result of dysregulated activity of large amount of matrix-remodeling 
enzymes. Possible candidate enzymes include: matrix metalloproteinases (MMPs), tissue 
inhibitors of matrix metalloproteinases (TIMPs), and members of transglutaminase (TGM), 
lysyl hydroxylase (Procollagen-lysine, 2-oxoglutarate 5-dioxygenase; PLOD) and the lysyl 
oxidase family. Interestingly in addition to an ability to modulate expression levels of elastin 
and collagen itself, TGF-β was also shown to impact the expression levels of above-listed 
matrix remodeling enzymes [70, 76-78, 97, 98]. Therefore, it has been proposed that an arrest 
in lung alveolarization and proper matrix formation may occur as a consequence of a 
protease/anti-protease imbalance and changes in collagen/elastin ratio introduced by 
increased levels of TGF-β [99]. 
 
1.4 The lysyl oxidase family 
Several recent studies have revealed the importance of matrix remodeling enzymes in 
ECM deposition and remodeling during both normal and aberrant lung development 
associated with BPD [46, 58, 97, 98]. Among these are elastin and collagen cross-linking 
enzymes of the lysyl oxidase family.  
The lysyl oxidase family comprises of five copper-dependent amine oxidases: lysyl 
oxidase (LOX) and four lysyl oxidase-like enzymes (LOXL1-LOXL4) [100, 101]. All 
members of the family catalyze the process of oxidative deamination of lysine and 
hydroxylysine residues (Figure 4). Deamination generates semialdehydes, which are highly 
reactive and spontaneously form intramolecular and intermolecular covalent cross-links in 
elastin and collagen molecules [100, 101].  
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Figure 4. Chemical reaction catalyzed by lysyl oxidase. 
Schematic representation of lysyl oxidase (LOX)-mediated oxidative deamination. Primary 
amines in elastin and collagen molecules are oxidized by LOX and other members of lysyl 
oxidase family to reactive semialdehydes. Reactive semialdehydes further form covalent 
intramolecular and intermolecular cross-links [102].  
 
Lysyl oxidases play a crucial role in the processes of normal lung development as 
demonstrated by studies in knock-out animals. Lysyl oxidase-deficient mice exhibit perinatal 
lethality due to aortic aneurism and severe cardio-respiratory dysfunction. Lungs of Lox-/- 
mice are characterized by an arrest in alveolarization and elastic and collagen fibers in these 
lungs were described as “fragmented and disperse” [58, 103, 104]. In addition, desmosine 
(a measure of elastin cross-links) and hydroxylysinonorleucine (HLNL) and hydroxyproline 
(HP) crosslinks (both measures of collagen cross-linking status), were severely decreased in 
lungs of Lox-/- mice when compared to wild-type mice [104]. Moreover, lysyl oxidase 
enzymatic activity was rapidly decreased in the absence of Lox expression. This suggests that 
LOX alone might serve as the main contributor to overall catalytic activity of this enzymatic 
family. Unlike Lox-/- mice, mice deficient in Loxl1 survived to adulthood. However Loxl1-/- 
mice are characterized by decreased connective tissue strength leading to a formation of 
redundant skin and pelvic organ prolapse. Lungs of Loxl1-/- mice also had enlarged airspaces 
and exhibited a decrease in desmosine, but not HP levels, suggesting that LOXL1 plays a role 
exclusively in elastin (but not collagen) metabolism [105]. 
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The role of lysyl oxidases have been implicated in the development of several lung 
diseases, including pulmonary arterial hypertension, lung adenocarcinoma, lung fibrosis, and 
BPD [46, 106-108]. The role of lysyl oxidases in BPD has also been investigated in several 
animal models. Gene expression of Lox and Loxl1 was increased in the lungs of pre-term 
ventilated lambs [109]. Although the expression of Lox in the lung was similarly increased in 
mechanically ventilated mouse puops, Loxl1 levels were decreased [93]. An increase in lung 
gene expression and protein abundance of LOX, LOXL1, LOXL2 and LOXL3 was noted in 
the hyperoxia-based mouse model of BPD, accompanied by increase in overall lysyl oxidase 
enzymatic activity [46]. Exposure of developing mouse pups to increased concentrations of 
oxygen was additionally associated with arrest in alveolar formation and a severe defect in 
elastin foci formation. Similarly, Lox and Loxl1 levels were increased in lung of patients 
diagnosed with BPD [46].  
In addition, localization of LOX in the nuclei of fibrogenic [110] and LOXL2 in the 
nuclei of epithelial cells [111] has recently been discovered. This findings suggests the 
existence of “non-matrix” roles for at least some members of lysyl oxidase family [112]. For 
example, LOX could drive the transcription of collagen IIIα1 (Col3a1) gene in fibroblasts 
[113]. LOX was also found to increase the activity of Eln promoter in human embryonic 
kidney (HEK) 293T cells [114]. Furthermore, LOXL2 was associated with Snail1, suggesting 
a possible role in Cdh expression regulation [111]. LOXL2 was also found to catalyze the 
deamination of trimethylated Lys4 in histone H3, therefore modulating epigenetic effects in 
the nucleus [115], which was associated with epithelial-to-mesenchymal transition (EMT). 
It is therefore possible that lysyl oxidases play a dual role in the processes of lung 
development and pathogenesis of BPD. It is likely that disregulation in the gene and protein 
expression of lysyl oxidases (and potentially expression of other matrix remodeling enzymes) 
leads to formation of over cross-linked elastin and collagen fibers in the parenchyma of the 
developing lung. This way excessively stabilized ECM network would be unable to undergo 
native processes of ECM remodeling leading to an increase in lung stiffness. This would 
impact the elastic properties of the lung, possibly causing an arrest in alveolarization and 
formation of secondary septa. Alternatively, unbalance in expression of lysyl oxidases could 
drive further changes in the expression of potential lysyl oxidase target genes, including 
essential components of ECM network Eln and Col, contributing even more to the 
disturbances in ECM formation and remodeling. However, the causal role of lysyl oxidases in 
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formation of ECM structures and perturbed gene regulation in the context of BPD has not yet 
been fully adressed. 
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2 AIMS OF THE STUDY 
 
Bronchopulmonary dysplasia presents a common complication of preterm birth with 
significant morbidity and mortality. Pathogenic pathways behind the development of BPD are 
not well understood, however, the importance of proper formation and metabolism of the 
ECM in the context of normal and aberrant lung development is well known. Abnormal 
formation and deposition of two main structural components of ECM, collagen and elastin 
fibers, represent a pathological feature of both clinical and experimental BPD.  
The correct temporal and spatial coordination of the activity of matrix remodeling 
enzymes plays a crucial role in elastin and collagen metabolism and remodeling. Among 
these are lysyl oxidases, amine oxidases catalyzing the formation of covalent crosslinks in 
elastin and collagen molecules. Dysregulated expression and activity of lysyl oxidases have 
been reported to play a role in pathogenesis of BPD, as well as in various animal models of 
BPD.  
 
In this context, the main aims of this study were: 
i.) To characterize the expression profile of lysyl oxidase family members in mouse 
lungs during normal and aberrant lung development. 
ii.) To investigate a causal role for the lysyl oxidase family in experimental 
hyperoxia-based mouse model of BPD. 
iii.) To assess the impact of lysyl oxidase activity on the formation of elastin and collagen 
fibers in mice lungs during normal and aberrant lung development. 
iv.) To assess the impact of lysyl oxidase activity on lung alveolarization in mice lungs 
during normal and aberrant lung development.  
v.) To explore the possible “non-matrix” roles for lysyl oxidases in vitro.  
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3 MATERIALS AND METHODS 
3.1 Materials 
3.1.1 Equipment 
Name        Company 
Autoclave       Systec, Germany 
Agar embedding moulds     custom made 
Agar cutting mould      custom made 
Bacteria culture incubator     Heareus, Germany 
Blotting membrane, Trans-Blot® TurboTM Transfer Pack Bio-Rad, Germany 
Camera, D5300      NIKON, USA 
Cell counter, Countess®     Invitrogen, UK 
Cell culture dish, 100 mm     Greiner Bio-One, Germany 
Cell culture dish for bacteria     Greiner Bio-One, Germany 
Cell culture flask, 250 ml     Greiner Bio-One, Germany 
Cell culture incubator      Thermo Fisher Scientific, USA 
Cell culture plates, 6-well     Greiner Bio-One, Germany 
Cell culture plates, 6-well, Snapwell Permeable Support Costar, USA 
Cell culture sterile working bench    Thermo Fisher Scientific, USA 
Cell scrapers, 25 cm      Sarstedt, Germany 
Cell strainers, 100, 40 μm     BD Biosciences USA 
Cover slides       Roth, Germany 
Digital slide scanner, NanoZoomer-XR C12000  Hamamatsu, Germany 
EcoRI enzyme       Promega, USA 
Electrophoresis chambers, Wide Mini-Sub® Cell GT Bio-Rad, Germany 
Electrophoresis chambers, Mini Protean® Tetra system Bio-Rad, Germany 
Espresso personal microcentrifuge    VWR, USA 
Feather® trimming blade     Pfm medical, Germany 
FIA 96-well plate, black     Greiner Bio-One, Germany 
Filter tips, 10 µl, 100 µl, 200 µl, 300 µl, 1000 µl  Sarstedt, Germany 
Fully Automated Rotary Microtome     Leica Biosystems, Germany 
Fume hood       Vinitex, Netherlands 
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Name        Company 
Heating plate       Medax, Germany 
High speed micro centrifuge     Hitachi, Japan 
Histobloc       Heareus, Germany 
Histoform Q mould      Heareus, Germany 
Homogenizing kit for soft tissue, Precellys®   PEQLAB, Germany 
Homogenyzer, Precellys® 24-Dual homogenizer  PEQLAB, Germany 
Imager ImageQuant® LAS 4000    GE health care, USA 
Infinite® 200 PRO multimode reader    TECAN, Switzerland 
Inoculation loops, 10 µl     Sarstedt, Germany 
InoLab® pH meter      WTW, Germany 
Knife holder NZ RM2200 silver    Leica Biosystems, Germany 
Light microscope      Leica, Germany 
Magentic Dynabeads® , streptavidin-coupled   Thermo Fisher Scientific, USA 
Magnetic separator      Thermo Fisher Scientific, USA 
MicroAmp® Optical 96-Well Reaction Plate   Thermo Fisher Scientific, USA 
Microcentrifuge tubes, 0.5, 1.5, 2 ml    Eppendorf, Germany 
Microplate reader,VersaMax ELISA    Molecular devices, USA 
Microscope slides, SUPERFROST ULTRA PLUS®  Thermo Fisher Scientific, USA 
Microtome blade S-35 pfm,      Pfm medical, Germany 
Microtome knife, 16cm long, profile d, steel assy  Leica Biosystems , Germany 
Multifuge 3 S-R centrifuge     Heraeus, Germany 
NanoDrop®  ND-1000 spectrophotometer   Thermo Fisher Scientific, USA 
Nitrocelulose membrane, 0.2 µm    Bio-Rad, Germany 
Objective, AF-S DX Micro NIKKOR, 85mm  NIKON, USA 
Parrafin embedding station     Leica Biosystems, Germany 
Pasteur pipette, 3.5 ml     Sarstedt, Germany   
PCR-thermocycler, peqSTAR    VWR, USA 
Pipetboy®       Integra, Switzerland 
Pipettes, automatic, 10 µl, 100 µl, 300 µl   Eppendorf, Germany 
Pipettes, manual, 10 µl, 20 µl, 100 µl, 200 µl, 1000 µl Eppendorf, Germany 
Pipettes, multichannel, 300 µl    Eppendorf, Germany 
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Name        Company 
Pipettes, serological, 2 ml, 5 ml, 10 ml, 25 ml, 50 ml Falcon, USA 
Polyvinylidene difluoride (PVDF) membranes, 0.2 µm Bio-Rad, Germany 
Real-Time PCR system, StepOnePlus™   Applied Biosystems, USA 
Refrigerated microcentrifuge CT15RE   VWR, USA 
Rotilabo®embedding cassettes    Roth, Germany 
Routine Stereomicroscope      Leica Biosystems, Germany 
Single use needles, FINE-JECT®    HENKE SASS WOLF, Germany 
Snap-cap vials, Rotilabo®     Roth, Germany 
Snap-on lids       Roth, Germany 
Standard analog shaker     VWR, USA 
Standard Clamp w/Adapter 40×40 mm Silver  Leica Biosystems , Germany 
Surgical instruments – scissors, tweezers   F.S.T., Germany 
Thermo shaker, MS-100     Universal labortechnik, Germany 
Test tubes, 15 ml, 50ml     Greiner Bio-One, Germany 
Tissue processor      Leica Biosystems, Germany 
Ultraviolet (UV) Transilluminator, Gel Imager  Intas, Germany 
Unneedled polyamide suture, SUPRAMID   SERAG, Germany 
VisiopharmNewCast software    Visiopharm, Denmark 
Vortex mixer       VWR, USA 
Waterbath, for cell culture     Lauda, USA 
Water bath, for histological slides    Vogel, Germany   
Western blot transfer system, Trans-Blot® TurboTM  Bio-Rad, Germany 
White light transilluminator, TW-26    UVP, UK 
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3.1.2 Reagents 
Name        Company 
Accutase® solution      Sigma-Aldrich, Germany 
Acetone, > 99.7% (vol/vol)     Roth, Germany  
Acrylamide solution, Rotiphorese Gel 30   Roth, Germany 
Agar for microbiology (Agar-agar)    Sigma-Aldrich, Germany 
Agarose       Promega, Germany 
Agarose, low melting point     Sigma-Aldrich, Germany 
Ammonium persulfate (APS)     Promega, Germany 
Ampicillin sodium salt     Sigma-Aldrich, Germany 
Azure II       Sigma-Aldrich, Germany 
Borax, di-Natriumtetraborate Decahydrate   Roth, Germany 
Bovine serum albumin (BSA)    Thermo Fisher Scientific, USA 
Collagenase        Sigma-Aldrich, Germany 
Complete macrophage medium     CellBiologics, USA  
Complete mouse endothelial cell medium   CellBiologics, USA 
Complete® protease inhibitor     Roche, Germany 
Dispase       BD Biosciences, USA 
1,4-Dithiothreitol (DTT)     Promega, USA 
DNase I       Serva, Germany 
Dublecco’s modified Eagle medium (DMEM),  Thermo Fisher Scientific, USA 
1 g/l glucose 
Dulbecco’s modified Eagle's medium (DMEM),  Thermo Fisher Scientific, USA 
4.5 g/l glucose 
Dulbeco’s phosphate buffered saline (DPBS)  Sigma-Aldrich, Germany 
Elastase       Sigma-Aldrich, Germany 
Ethanol, 70% (vol/vol)     Roth, Germany 
Ethanol, absolute      Roth, Germany 
Ethidium bromide      Promega, USA 
Ethylenediaminetetraacetic acid (EDTA)   Sigma-Aldrich, Germany  
Ethylene glycol-bis       Sigma-Aldrich, Germany 
(β-aminoethyl ether)-N,N,N',N'-tetraacetic acid (EGTA)      
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Name        Company 
Fetal bovine serum (FBS)     PAA Laboratories, Austria 
Gelatin-Based Coating Solution    CellBiologics, USA 
GeneRullerTM, DNA ladders     Thermo Fisher Scientific, USA 
Glutaraldehyde      Serva, Germany 
Glycine       Roth, Germany 
Hank’s balanced salt solution (HBSS)   PAA Laboratories, Austria 
Hematoxylin       Waldeck, Germany 
HEPES       Sigma-Aldrich, Germany 
Isofluran-CP®, 1ml/ml     Cp-pharma®, Germany  
LB–Agar, Lurria/Muller     Roth, Germany 
4× Laemmli Sample Buffer     Bio-Rad, Germany 
Lipofectamine®  2000      Thermo Fisher Scientific, USA 
Liquid nitrogen      Air Liquide, Germany 
Magnesium chloride (25 nM)     Applied Biosystems, USA 
Magnesium chloride (50 nM)     Thermo Fisher Scientific, USA 
2-Mercaptoethanol      Bio-Rad, Germany 
Methanol       Sigma-Aldrich, Germany 
Methylene blue      Roth, Germany 
MuLV reverse transcriptase     Applied Biosystems, USA 
m-Xylol, ˃ 98.5% (vol/vol)     Roth, Germany  
NARCOREN®, Pentobarbital Sodium   Merial GmbH 
Non-fat dry milk powder     Roth, Germany 
Nuclease-free water      Ambion, USA 
OptiMEM® medium      Thermo Fisher Scientific, USA 
Osmium tetroxide      Roth, Germany 
Paraformaldehyde (PFA)     Sigma-Aldrich, Germany 
Paraplast®, paraffin      Leica, Biosystems, Germany 
PCR-Buffer II 10×      Applied Biosystems, USA 
PCR Nucleotide Mix (10 mM)    Promega, USA 
pCRTM2.1-TOPO® Gateway Entry    Thermo Fisher Scientific, USA 
Pencillin – Streptomycin (100×)    AppliChem, Germany 
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Name        Company 
Pertex, mounting media     Medite, Germany 
Phosphate buffered saline (PBS) 1×, 10×   Sigma-Aldrich, Germany 
Platinum®  SYBR® Green qPCR SuperMix UDG kit  Invitrogen, USA 
pLenti7.3/V5DESTTM     Thermo Fisher Scientific, USA 
Polybrene, hexadimethrine bromide    Sigma-Aldrich, Germany 
Ponceau S       Sigma-Aldrich, Germany 
Precision Plus Protein® Dual color standard   Bio-Rad, Germany 
Propane/Butane      Campin Gaz, Germany 
2-Propanol        Merck, Germany 
Proteinase K       Promega, USA 
QIAquick gel extraction kit     Qiagen, Netherlands 
QIAquick PCR purification kit    Qiagen, Netherlands 
QIAprep®SpinMiniprep/Maxiprep kit   Qiagen, Netherlands 
QuickStart® Bradford 1×Dye Reagent   Bio-Rad, Germany 
Random hexamers, 50 µM     Thermo Fisher Scientific, USA 
Resorcin-Fuchsin      Waldeck, Germany 
RIPA® buffer       Sigma-Aldrich, Germany 
RNase free water      Qiagen, Germany 
Roti® -Histol       Roth, Germany 
RNase inhibitor       Applied Biosystems, USA 
Select agar       Sigma-Aldrich, Germany 
SmGm-2 Supplements     Lonza, Switzerland 
Smooth muscle growth medium (SmGM)-2    Lonza, Switzerland 
Sodium cacodylate      Serva, Germany 
Sodium dodecyl sulfate (SDS), 10× solution   Promega, USA 
Sodium orthovanadate     Sigma-Aldrich, Germany 
Spectinomycin dihydrochloride pentahydrate  Sigma-Aldrich, Germany 
Super Optimal Broth (S.O.C)     Thermo Fisher Scientific, USA 
SuperSignal® West femto maximum sensitivity substrate ThermoFisher Scientific, USA 
Tris-acetate-EDTA (TAE) buffer, 50×   Roth, Germany  
Tris-EDTA (TE) buffer     ThermoFisher Scientific, USA 
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Name        Company 
Technovit 3040      HeareusKulzer, Germany 
Technovit 7100      HeareusKulzer, Germany 
Technovit, universal liquid     Heareus Kulzer, Germany 
Tetramethylethylenediamine (TEMED)   Bio-Rad, Germany 
Tris        Roth, Germany 
Trypsin-EDTA      ThermoFisher Scientific, USA 
Trypan blue solution 0.4% (vol/vol)    ThermoFisher Scientific, USA 
TurboFectTM       ThermoFisher Scientific, USA 
Tween® 20       Sigma-Aldrich, Germany 
Uranyl acetate       Serva, Germany 
Van Gieson stain      Roth, Germany 
Water for injections      ThermoFisher Scientific, USA 
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3.1.3 Purchased primary cells and cell-lines 
NIH/3T3, fibroblasts, mouse embryonic cells American Type Culture Collection, USA 
HEK 293T, human embryonic kidney cells,   American Type Culture Collection, USA 
epithelial cells 
TheTransform One Shot® DH5α™-T1R,   ThermoFisher Scientific, USA 
TOP10 Competent Cells, E.coli  cells 
Bone marrow macrophages,     Cell Biologics, USA 
bone marrow derived mouse macrophages 
Primary lung vascular endothelial cells,   Cell Biologics, USA 
primary mouse cells 
  
 
 
 
40 
 
 
3.2 Methods 
3.2.1 Animal experiments 
All animal procedures were approved by the local authorities, Regierungspräsidium 
Darmstadt (approval numbers B2/329; B2/1029 and B2/277). 
 
3.2.1.1 Pilot study 
Prior to intervention studies, a pilot study was performed in order to determine the 
tolerance of mice to BAPN treatment. Two different doses of BAPN, as well as control 
injections with vehicle were employed, and animals were observed for duration of five days. 
Three animals per group were injected intraperitoneally (i.p.) daily with either vehicle 
[1× phosphate buffered saline (PBS)], or BAPN (diluted in vehicle) at a dose of 15 or 
150 mg·kg-1·day-1. All animals were euthanized at P5.5 with an overdose of pentobarbital 
(500 mg·kg-1, i.p.). 
 
3.2.1.2 Normobaric hyperoxia-based mouse model of BPD 
An arrest in the alveolarization in the lungs of newborn mouse pups was induced by 
continuous exposure of animals to normobaric hyperoxia, more precisely 85% O2 (FiO2 0.85) 
from the day of birth (P1). This model of BPD recapitulates a several major hallmarks seen in 
human BPD, including morphological changes, such as a decrease in the number of alveoli, 
an associated decrease of overall gas-exchange surface area and an increase in the septal 
thickness, as well as inflammation and perturbations to ECM deposition and remodeling.  
Newborn C57BL/6J mice were randomized to equal-sized litters (average eight pups 
per litter) and placed into either a normoxic (21% O2) or a hyperoxic (85% O2) environment 
within 2 h after birth. Newborn pups were exposed from the day of birth (P1.5), continuously 
up to and including P9.5 or P19.5, when experiments were terminated. 
In order to minimize oxygen toxicity and potential confounders of milk production 
caused by hyperoxia, nursing dams were rotated between normoxia and hyperoxia on 
24 h : 24 h cycle. Mice were maintained on 12 h : 12 h light-dark cycle and received food 
ad libitum. All animals were euthanized at P9.5 or P19.5 with an overdose of pentobarbital 
(500 mg·kg-1, i.p.). 
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3.2.1.3 Treatment of hyperoxia-exposed newborn mice with β-aminopropionitrile 
Based on the observations made during the pilot study BAPN was administered at a 
dose of 15 mg·kg-1·day-1 in a hyperoxia-based BPD model. Newborn C57BL/6J mice were 
randomized to equal-sized litters and placed into either a normoxic (21% O2) or a hyperoxic 
(85% O2) environment within 2 h after birth. Both groups were further subdivided into two 
groups, treated with daily i.p. injections of either vehicle (1×PBS), or BAPN (diluted in 
vehicle) at a dose of 15 mg·kg-1·day-1 for either 9 or 19 days. Experiments were terminated 
on P9.5 or P19.5.  
 
3.2.1.4 Organ isolation 
All animals were euthanized with an overdose of pentobarbital (500 mg·kg-1, i.p.). 
Subsequently, the abdomen was opened and the diaphragm was punctured to allow the lungs 
to retract. The chest wall was opened by cutting through sternum, but ribs remained intact in 
their original position in order to preserve the natural size of the chest cavity. Lungs were 
isolated for further stereological analysis, RNA and protein analysis, collagen and elastin 
measurements or tissue staining. 
 
Lungs isolated for embedding in plastic resin and stereological analysis 
In order to preserve the blood in the tissue, lungs of animals used for stereological 
analysis were not perfused and animals were not exsanguinated. Instead, lungs were 
instillation-fixed via a tracheal cannula under a 20 cm H2O hydrostatic pressure with fixation 
solution containing 1.5% (wt/vol) paraformaldehyde (PFA) and 1.5% (wt/vol) glutaraldehyde 
in 150 mM HEPES-PBS. Lungs were excised and stored at 4 °C in fixation solution for 24 h. 
 
Lungs isolated for future RNA and protein analysis 
 Animals were exsanguinated and lungs were perfused with 1×PBS via the right heart 
ventricle. Lungs were removed and immediately frozen in liquid nitrogen. Samples were kept 
at -80 °C for further processing. 
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Lungs isolated for collagen and elastin crosslinks analysis 
Animals were exsanguinated and lungs were perfused with 1×PBS via the right heart 
ventricle, excised, transferred to 1.5 ml tube containing 1×PBS and frozen in liquid nitrogen. 
Samples were stored at -80 °C for further processing. 
 
Lungs isolated for embedding in paraffin and staining of elastin fibers 
Animals were exsanguinated and lungs were perfused with 1×PBS via the right heart 
ventricle. The trachea was cannulated and lungs were instillation-fixed under a 20 cm H2O 
hydrostatic pressure with 4% (wt/vol) PFA in 1×PBS. Lungs were excised and stored at 4 °C 
in fixation solution for 24 h prior to paraffin embedding. 
 
3.2.1.5 Embedding in agar and lung volume estimation 
Following 24 h of fixation, lungs were cleaned of any remains of the trachea, thymus, 
heart or blood clots and embedded in toto in 2% (wt/vol) agar-agar for at least 6 h. Agar 
blocks were then cut into 2-mm thick sections and always the same side of each section was 
photographed for calculations of lung volume. Individual pieces of each lung were retrieved 
from agar slices for further embedding in plastic resin. 
The reference lung volume was estimated from photographs of lung sections 
embedded in agar by the Cavalieri principle using Visiopharm NewCast computer-assisted 
stereology system. Briefly, point counting was performed on a point grid. Counting was 
performed within 100% of each lung section. Volume of the lung was estimated based on the 
number of points counted, size of the surface area/point and thickness of the section.  
 
3.2.1.6 Embedding in plastic resin 
All individual pieces of one lung were transferred into Snap-cap vials and further 
processed inside a fume hood. Buffers required for treatment of the lungs prior to embedding 
are listed in Table 1. Briefly, lungs were washed 4 × 5 min with 0.1 M sodium cacodylate 
buffer and treated with 1% osmium tetroxide (OsO4) in 0.1 M sodium cacodylate buffer for 
2 h. Afterwards lungs were washed 4 × 5 min with 0.1 M sodium cacodylate buffer, washed 
4 × 5 min with ddH2O. Samples were then protected from light and treated overnight with 
half-saturated uranyl acetate (UrAc) buffer. Afterwards, samples were washed with double 
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distilled (ddH2O) and dehydrated in increasing concentration of acetone. Lungs were first 
incubated overnight in 1:1 solution of 100% acetone and Technovit 7100-Hardener I and 
eventually Technovit 7100-Hardener I solution. Finally, lungs were incubated in 
Technovit 7100-Hardener I-Hardener II solution for 5 min. Over this time vials with samples 
were constantly stirred. Individual pieces of lung, together with the buffer were transferred 
into a Histoform Q mould and allowed to solidify for at least 48 h. Plastic blocks were 
removed from moulds with Technovit universal liquid and Technovit 3040 using the 
Histobloc adaptors. 
 
Table 1. Buffers required for treatment of lungs and embedding in Technovit 7100. 
 
Buffer Dilution 
Sodium cacodylate 0.1 M, in ddH2O 
Osmium tetroxide 
2% (wt/vol) stock solution, in water for injections 
1% (wt/vol) working solution, in 0.1 M sodium cacodylate 
Uranyl acetate 
saturated stock solution, in ddH2O 
half-saturated working solution, in ddH2O 
Acetone 70% (vol/vol), 90% (vol/vol), 100% (vol/vol), in ddH2O 
Technovit 7100 undiluted solution 
Technovit 7100-Hardener I 1% (wt/vol) Hardener I, in Technovit 7100 
Technovit 7100-Hardener I-Hardener II 
200 µl Hardener II 
in 3 ml Technovit 7100-Hardener I 
Technovit 3040-Technovit  
universal liquid 
2:1 ratio 
 
3.2.1.7 Embedding in paraffin 
Lungs were instillation-fixed with 4% (wt/vol) PFA in 1×PBS for 24 h. Afterwards 
lungs were cleaned of any remains of trachea, thymus, heart or blood clots, transferred in 
embedding moulds and stored in 1×PBS for up to 1 week prior to processing. Tissue was then 
dehydrated by ethanol, cleared by xylene to remove alcohol and infiltrated with molten 
paraffin wax. Finally, tissue was embedded in moulds in paraffin and allowed to solidify on a 
cooling plate. Material was stored at 4 °C for further use. 
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3.2.1.8 Paraffin and plastic sectioning 
Paraffin and plastic embedded lungs were sectioned with fully automated rotary 
microtome. For paraffin embedded lungs, 3-µm sections were cut using a Feather microtome 
blade and collected on Superfrost Ultra Plus adhesion slides. Slides were allowed to dry on a 
heating plate at 40 °C overnight. 
For plastic embedded lungs, blocks were cut into 2-µm sections using a, profile d 
steel assy microtome knife. Forty sections were cut and every tenth section was collected for 
staining. In addition, for the estimation of the alveolar number, three consecutive sections 
were cut and first and third sections were collected on the same adhesion slide. Slides were 
allowed to dry on a heating plate at 65 °C. 
 
3.2.1.9 Hart’s elastin staining 
The deposition of elastin fiber structures was visualized in 3-µm thick lung tissue 
sections from paraffin embedded mouse lungs by Hart’s elastin stain. Shortly, paraffin 
sections were brought to water via xylene and ethanol and incubated in Hart´s solution 
overnight. Subsequently, the slides were washed and counterstained with iron hematoxylin 
and van Gieson solution. Finally sections were dehydrated with ethanol, clear with xylene 
and covered with cover slips using a mounting medium. 
 
3.2.1.10 Richardson’s staining 
Lung structure was visualized in 2 µm thick lung tissue sections from 
plastic-embedded mouse lungs by Richardson’s staining. Briefly, plastic sections were 
stained in warm Richardson’s stain (65 °C) for 30 s, washed briefly in cold tap water and 
rinsed in hot tap water. Subsequently, sections were washed briefly in ddH2O and rinsed in 
Xylol. All slides were scanned at 60× magnification using a NanoZoomer-XR C12000 digital 
slide scanner.  
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Richardson’s stain – stock solution: 
ddH2O 
0.25% (wt/vol) methylene blue 
0.22% (wt/vol) Borax (di-Sodium tetraborate) 
0.5% (wt/vol) Azur II 
 
The stock solution must be filtered through filter paper and diluted 1:1 with tap water 
prior to use. 
 
3.2.2 Design-based stereology 
Methods of lung structure analysis were based on the American Thoracic 
Society/European Respiratory Society recommendations for quantitative assessment of lung 
structure [116] and according to systematic uniform random sampling for stereological 
analysis.  
Analyses were performed using Visiopharm NewCast computer-assisted stereology 
system. Analysis of lung structure included four main parameters: gas-exchange surface area, 
septal thickness, mean linear intercept (MLI) and number of alveoli. In addition, lung volume 
was estimated by the Cavalieri principle using the same software. The parenchymal fraction, 
as well as airspace and septal fraction within the parenchyma were counted by point counting 
on a corresponding point grid (Figure 5A-5B). Surface density was assessed by point and 
intersection counting on a “line grid” of known length (Figure 5E-5F). Approximately 40-60 
lung sections were evaluated on total of four scanned slides and 2-3% of each section was 
analyzed. The alveolar density was assessed by counting of newly appearing alveolar bridges 
using a physical dissector, where the height of the dissector was 4 µm (Figure 5C-5D). 
Approximately 10 sections were evaluated for each lung and 2% of each section was 
analyzed. In order to determine the absolute number of alveoli and absolute size of gas-
exchange surface area in the lung, alveolar density and surface density, respectively were 
normalized to reference lung volume.  
For each stereological parameter, the coefficient of error (CE), the coefficient of 
variation (CV), and the squared ratio between both (CE2/CV2) were calculated in order to 
confirm the measurement precision. The quotient threshold was set at 0.5. 
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Figure 5. Visiopharm NewCast counting tools used in the stereological analysis of lung 
structure. 
Lungs were installation-fixed under 20 cm H2O hydrostatic pressure with fixation solution 
and treated with sodium cacodylate, OsO4 and uranyl acetate and embedded in plastic resin. 
Blocks were cut to 2-µm sections, stained with Richardson’s stain and lung structure was 
analyzed using the Visiopharm NewCast computer-assisted stereology system. (A-B) An 
example of a parenchymal fraction estimation (A), and estimation of airspace and septal 
fraction within parenchymal region (B) by point counting on a corresponding point grid. 
Magnification 10× (A) and 20× (B). (C-D) Estimation of alveolar density assessed by two-
sided counting of newly forming alveolar bridges. The height of the physical dissector was 4 
µm. Magnification 40×. (E) Example of surface density estimation by point and intersection 
counting on a line grid. Magnification 20×. (F) Detail of point and intersection counting from 
panel E.  
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3.2.3 Cell culture and cell treatments 
3.2.3.1 NIH/3T3 cell culture 
The mouse embryonic fibroblast cell-line NIH/3T3 was cultured in Dulbecco’s 
modified Eagle’s medium (DMEM) supplemented with 10% (vol/vol) fetal bovine serum 
(FBS) and 1% (vol/vol) penicillin/streptomycin (P/S) in incubator at 37 °C with a humidified 
5% (vol/vol) CO2 atmosphere. When the culture reached a confluency of approximately 70%, 
cells were washed with PBS and treated with 5 ml of acutase solution for 5 min at 37 °C. The 
activity of acutase was inhibited with 5 ml of culture media and required portion of 
de-attached cells was transferred into a new culture flask or a 6-well plate. 
 
3.2.3.2 HEK293T cell culture 
Human embryonic kidney (HEK) 293T cells were cultured in DMEM supplemented with 
10% (vol/vol) FBS in incubator at 37 °C and humidified in 5% (vol/vol) CO2 atmosphere. 
Cells were passaged at 70% confluency. Shortly, cells were washed with 1×PBS and treated 
with 5 ml of acutase solution for 5 min at 37 °C. Acutase activity was inhibited with culture 
media and required portion of cells was transferred into a new culture flask or a Petri dish. 
 
3.2.3.3 Bone marrow-derived macrophages culture 
 Mouse (C57BL/6) bone marrow-derived macrophages were cultured in 
gelatine-coated culture flasks in complete macrophage medium and maintained in incubator 
at 37 °C with a humidified 5% (vol/vol) CO2 atmosphere. 
 
3.2.3.4 Lung vascular endothelial cells culture 
Primary mouse (C57BL/6) lung microvascular epithelial cells were cultured in 
gelatine-coated culture flasks in complete mouse endothelial cell medium and maintained in 
incubator at 37 °C with a humidified 5% (vol/vol) CO2 atmosphere. Cells were passaged into 
a new culture flask when confluency reached approximately 70% using 
trypsin-ethylenediaminetetraacetic acid (EDTA).   
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3.2.3.5 Isolation and culture of primary mouse lung fibroblasts 
Primary mouse lung fibroblasts were isolated from adult female C57BL/6J mice. 
Briefly, mice were euthanized with an overdose of pentobarbital (500 mg·kg-1, i.p), the 
abdomen was opened and mice were exsanguinated. Subsequently, the diaphragm was 
punctured to allow the lungs to retract and the chest was opened. Lungs were perfused with 
1×PBS via the right heart ventricle, and excised. Lungs were then minced using surgical 
scissors, transferred into a 50-ml falcon tube containing pre-heated collagenase and stirred for 
45 min at 37 °C. A crude tissue suspension was then re-suspended using a 20 ml syringe with 
20 G needle and filtered through a 40 µm filter into a new 50-ml falcon tube. The resulting 
suspension was centrifuged at 400 × g for 8 min at 4 °C and the pellet was re-suspended in 
5 ml of DMEM supplemented with 10% (vol/vol) FBS and 1% (vol/vol) P/S.  
Cells were cultured in a cell culture flask in incubator at 37 °C with a humidified 5% 
(vol/vol) CO2 atmosphere. When the culture reached a confluency of approximately 70%, 
cells were washed with 1×PBS and treated with 5 ml of acutase solution for 5 min at 37 °C. 
Activity of acutase was inhibited with 5 ml of culture media and the required portion of 
de-attached cells was transferred into a new culture flask or a 6-well plate. 
 
3.2.3.6 Isolation and culture of primary mouse alveolar epithelial type II cells 
Primary mouse alveolar epithelial type II cells (AECII) were isolated using the 
modified protocol published by Corti and collaborators [117]. Briefly, C57BL/6J female mice 
were euthanized with an overdose of pentobarbital (500 mg·kg-1, i.p), the abdomen was 
opened and mice were exsanguinated. Subsequenly, the diaphragm was punctured to allow 
the lungs to retract and the chest was opened. Lungs were perfused with Hank’s balanced salt 
solution (HBSS) via the right heart ventricle. The trachea was cannulated and 2 ml of dispase 
followed by 0.5 ml of 1% low-melting point agarose was injected into the lungs. Lungs were 
removed after 5 min and incubated in 3 ml of dispase at room temperature (RT) for 45 min.  
The lungs were transferred into a Petri dish containing 7 ml of DMEM without FBS, 
containing DNAseI (isolation medium I) and the bronchial tree was carefully removed. The 
crude tissue suspension was incubated for 10 min at RT and sequentially filtered through 
100 μm and 40 μm cell strainers and a 20 μm nylon membrane. The resulting cell suspension 
was centrifuged twice at 130×g for 8 min at 4 °C and the pellet was re-suspended in 5 ml of 
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DMEM containing FBS (isolation medium II). Cells were stained with trypan blue and 
counted using a Countess® Cell Counter. Cells were than incubated with 0.75 μl biotinylated 
anti-CD16/32, 0.9 μl biotinylated anti-CD45 and 0.4 μl biotinylated anti-CD31 antibodies per 
1 million cells, for 30 min in a water bath at 37 °C, after which cells were centrifuged at 
130×g for 8 min at 4 °C. Antibodies required for AECII selection are listed in Table 2. The 
resulting pellet was resuspended in DMEM without FBS (isolation media III), combined with 
Streptavidin-coupled Dynabeads® magnetic beads and incubated for 30 min at RT followed 
by 15 min of separation in magnetic separator. After the separation, the supernatant was 
carefully collected and centrifuged at 130×g for 8 min at 4 °C. Pellet was resuspended in 
DMEM with 10% (vol/vol) FBS and 1% (vol/vol) P/S (culture media). All media required for 
AECII isolation are listed in Table 3. 
Cells were seeded in 6-well plate with 24-mm diameter Snapwell™ inserts. After 
24 h, the culture medium was removed from the apical compartment and the cells were 
grown on an air-liquid interface. During the culture cells were stored in incubator at 37 °C 
and humidified in 5% (vol/vol) CO2 atmosphere. 
 
Table 2. Antibodies used for alveolar epithelial type II cells isolation. 
Antibody Company Catalog number Amount (µl) Origin 
anti-CD45 BD Biosciences 553078 (cells in millions) × 0.900 rat 
anti-CD16/32 BD Biosciences 553143 (cells in millions) × 0.675 rat 
anti-CD31 BD Biosciences 553371 (cells in millions) × 0.400 rat 
 
Table 3. Media used for alveolar epithelial type II cells isolation and culture. 
Isolation medium I Isolation medium II Isolation medium III Culture medium 
DMEM, 4.5 g/l glucose DMEM, 4.5 g/l glucose DMEM, 4.5 g/l glucose DMEM, 4.5 g/l glucose 
HEPES, 2% (vol/vol) FBS, 10% (vol/vol) P/S, 1% (vol/vol) FBS, 10% (vol/vol) 
P/S, 0.1% (vol/vol) P/S, 1% (vol/vol)  P/S, 1% (vol/vol) 
DNAseI, 0.01% (vol/vol)    
 
3.2.3.7 Isolation and culture of pulmonary arterial smooth muscle cells 
Murine pulmonary arterial smooth muscle cells (PASMC) were isolated from 
C57BL/6J adult mice. Shortly, mice were euthanized with an overdose of pentobarbital 
(500 mg·kg-1, i.p) and the abdomen was open. Mice were then exsanguinated, the diaphragm 
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was punctured to allow the lungs to retract and the chest was opened. Lungs were perfused 
with 1×PBS via the right heart ventricle. Lung, heart and aorta were removed together and 
pulmonary artery was dissected and adventitial layer was removed. Pulmonary arteries were 
then transferred in 2 ml of HBSS with 1 mg/ml collagenase and 10 mg/ml elastase and 
digested by shaking at 37 °C for 25 min. Subsequently, the cell suspension was vortexed and 
supplemented with 1 ml of fresh media. Cells were centrifuged for 5 min at 2,564 × g and 
pellet was washed by centrifugation with additional 2 ml of media. 
Cells were seeded in a cell culture flask coated with 0.75% gelatine in an incubator at 
37 °C with a humidified 5% (vol/vol) CO2 atmosphere. When the culture reached a required 
confluency, cells were washed with PBS and treated with 5 ml of acutase solution for 5 min 
at 37 °C. Activity of acutase was inhibited with 5 ml of culture media and required portion of 
de-attached cells was transferred into a new culture flask. 
 
PASMC culture media: 
Smooth muscle growth medium (SmGM)-2  
SmGm-2 Supplements 
 
3.2.3.8 Treatment of primary mouse lung fibroblasts with β-aminopropionitrile  
Primary mouse lung fibroblasts were cultured in DMEM supplemented with 10% 
(vol/vol) FBS and 1% (vol/vol) P/S in incubator at 37 °C with a humidified 5% (vol/vol) CO2 
atmosphere. Cells were seeded into a 6-well plate and starved for 24 h prior to BAPN 
treatment in DMEM containing 0.1% (vol/vol) FBS and 1% (vol/vol) P/S. Afterwards, cells 
were treated either with vehicle (1×PBS) or 1 mM BAPN, both dissolved in 2 ml of DMEM 
supplemented with 10% (vol/vol) FBS and 1% (vol/vol) P/S for 24 h prior to harvest. 
 
3.2.3.9 Transient transfection with short interfering RNA 
Primary mouse lung fibroblasts were seeded one day prior to transfection into 6-well 
cell culture plates, until they reached confluency of approximately 70%. Cells were 
transfected using TurboFectTM transfection reagent according to manufacturer’s instructions. 
Shortly, cells were incubated with 1900 µl of DMEM medium supplemented with 
10% (vol/vol) FBS and 1% (vol/vol) P/S. Meanwhile, 100 µl of short interfering (si)RNA, 
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TurboFectTM and Opti-MEM® serum-free medium mixture was incubated for 20 min. The 
mixture was added to the cells drop-wise. Overall, cells were transfected with 50 nM siRNA, 
using 6 µl TurboFectTM transfection reagent/well in 2 ml of media. Oligonucleotide 
sequences of siRNA used in knockdown experiments are specified in Table 4. Unspecific, 
scrambled (scr.) siRNA sequence and mock transfection served as a control. Following 
transfection, cells were cultured in incubator at 37 °C with a humidified 5% (vol/vol) CO2 
atmosphere, and harvested 48 h after the transfection.  
 
Table 4. List of siRNA oligonucleotides used in knockdown experiments. 
Target Company Catalog number Duplex sequence, 5' – 3' 
Lox 
Santa Cruz 
Biotechnology, 
USA 
sc-45219 
CCA GUG GAU UGA UAU UAC Att 
UGU AAU AUC AAU CCACUG Gtt 
GUA GAA CGA UCC UUU CAA Att 
UUU GAA AGG AUC GUU CUA Ctt 
CCA AGC UAGUCU AAC CAA Att 
UUU GGU UAG ACU AGC UUG Gtt 
Loxl1 
Santa Cruz 
Biotechnology, 
USA 
sc-45221 
GUG UAC AGC UUGCUC AAC Utt 
AGU UGA GCA AGC UGU ACA Ctt 
GGA UCG ACA UAA CUG AUG Ut 
ACA UCA GUU AUGUCG AUC Ctt 
CGC UAC GUU UCU ACA ACA Att 
UUG UUG UAG AAA CGU AGC Gtt 
Loxl2 
Santa Cruz 
Biotechnology, 
USA 
sc-45223 
CAA GCA CAC UGA AGA CGUUtt 
AAC GUC UUC AGU GUG CUU Gtt 
CAU GUA CCG UCA UGA CAU Utt 
AA UGU CAU GAC GGU ACAUGtt 
GAA GAA AGG UGC UCA UUC Att 
UGA AUG AGC ACC UUU CUU Ctt 
scrambled control  
Santa Cruz 
Biotechnology, 
USA 
sc-37007 unknown 
 
3.2.4 Gene expression analysis 
3.2.4.1 Deoxyribonucleic acid isolation  
Genomic DNA was isolated from tail biopsies. Briefly, tails were digested shaking at 
540 revolutions per minute (rpm) (mixing orbit 2 mm) in 500 µl Tens buffer containing 
1% proteinase K (200 mg/ml) overnight at 56 °C . Samples were than centrifuged and 
supernatant transferred to a new 1.5 ml tube and combined with 400 µl of isopropanol. 
Samples were vortexed and centrifuged at 16,200 × g for 15 min at 4 °C in refrigerated 
microcentrifuge CT15RE. The resulting pellet was diluted in 500 µl of 70% ethanol (EtOH) 
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(70% EtOH in nuclease-free H2O) and centrifuged for 1 min. The EtOH was removed and 
samples were allowed to dry at RT for approximately 10 min, after which the pellet were 
resolved in 80 µl of TE buffer. Finally, samples were shaked for additional 30 min at 56 °C 
and 540 rpm (mixing orbit 2 mm). The purity and quantification of isolated DNA was 
determined with a NanoDrop® ND 1000.  
 
3.2.4.2 Sex determination in mouse pups 
Genomic DNA obtained from tail biopsies was screened by polymerase chain reaction 
(PCR) reaction to detect the presence of the Il3 gene in both male and female sex and the 
male-only Sry locus (primer sequences are listed in Table 5.). The reaction conditions 
were: 95 °C for 4.5 min, followed by 33 cycles of 95 °C for 35 s to achieve denaturation, 
50 °C for 1 min for primers annealing and 72 °C for 1 min to allow product elongation. 
Finally 5 min incubation at 72 °C was performed after the last cycle was concluded. 
Following PCR reaction, resulting amplicons were resolved on a 1.5% (wt/vol) 
agarose gel containing 0.002% (vol/vol) ethidium bromide in 1×TAE buffer using the 
Wide Mini-Sub® Cell GT electrophoresis chambers. Amplicons were visualized in 
Intas UV Transilluminator. 
 
Reaction mix used for sex determination (per one reaction):  
5× Green GoTaq flexi PCR buffer  10 μl 
MgCl2 (25 mM)    4 μl 
dNTP mix (10 mM)    1μl 
GoTaq polymerase (5 U/µl)   0.25 μl 
Il3 primer mix (10 µM)   0.6 µl 
Sry primer mix (10 µM)   1 µl 
Nuclease-free H2O    31.15 μl 
DNA      2 μl  
Total volume/reaction    50 μl 
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Table 5. Primers employed for sex determination. 
Gene Primer Primer sequence, 5' - 3' Primer size, bp Amplicon size, bp 
Il3 Forward GGGACTCCAAGCTTCAATCA 20 544 Reverse TGGAGGAGGAAGAAAAGCAA 20 
Sry Forward TGGGACTGGTGACAATTGTC 20 402 Reverse GAGTACAGGTGTGCAGCTCT 20 
 bp, base pairs 
 
3.2.4.3 Total RNA isolation from cell culture and lung tissue  
For total (t)RNA isolation from cells, cells were homogenized by scraping in RNA 
lysis buffer (part of the PeqGoldTotal RNA Kit). For isolation from lung, approximately 
50 mg of lung tissue was homogenized in RNA lysis buffer using a 
Precellys 24-Dual homogenizer. The resulting suspension was centrifuged for 1 min at 
10,000 × g at RT in an Espresso personal microcentrifuge and supernatant was used for 
subsequent tRNA isolation using the PeqGold Total RNA Kit according to manufacturer’s 
instructions. The final pellet was dissolved in 30 µl of nuclease-free H2O. The purity and 
quantification of isolated tRNA was determined with a NanoDrop® ND 1000.  
 
3.2.4.4 Complementary DNA synthesis 
The complementary (c)DNA was synthesized from RNA preparations with A260/280 
absorbance ratio above 1.90. To perform a cDNA synthesis, 1000 ng of tRNA (diluted in 
nuclease-free H2O) from each sample was transcribed using MuLV reverse transcriptase and 
random hexamer oligodeoxyribonucleotides. Briefly, 20 µl of tRNA was denaturated at 70 °C 
for 10 min and subsequently supplemented with 20 µl of reverse transcription mixture. The 
mixture was than incubated at 21 °C for 10 min, followed by a cDNA synthesis at 43 °C for 
1 h and 15 min. Eventually, MuLV reverse transcriptase was inactivated by 5 min incubation 
at 99 °C. 
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Reverse transcription mixture used for cDNA synthesis (per one reaction): 
10× PCR bufferII      4 μl 
MgCl2 (25 mM)      8 μl 
Nuclease-free H2O      1 μl 
Random hexamers (50 µM)     2 µl 
dNTP mix (10 mM)      2 μl 
RNase inhibitor (20 U/µl)     1 μl 
MuLV reverse transcriptase (50 U/µl)   2 μl  
Total volume/reaction      20 μl 
 
3.2.4.5 Quantitative real-time reverse transcription-PCR 
Quantitative gene expression analyses were performed by quantitative real-time 
reverese transcription (RT)-PCR using a Platinum® SYBR® Green qPCR SuperMix UDG kit 
and a StepOnePlus™ Real-Time PCR System. Primer pairs specific to the target mRNA 
sequence were obtained from previously published publications, from online PrimerBank 
database (https://pga.mgh.harvard.edu/primerbank/) or designed using Primer-BLAST 
software (http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and are listed in Table 6.  
The reaction conditions were: polymerase activation at 50 °C for 2 min, 95 °C for 
5 min, 40 cycles of 95 °C for 5 s to achieve denaturation, primers annealing at 59 °C for 5 s 
and 72 °C for 30 s to allow the product elongation. Melting curve analysis was performed to 
confirm an amplification of a specific product and absence of primer-dimer formation. The 
ΔCT values were calculated as mean Ct (reference gene) – mean Ct (gene of interest), where 
the Polr2a gene always served as reference gene.  
 
Master mix mixture used for real-time RT-PCR (per one reaction): 
Platinum® SYBR® Green qPCR SuperMix-UDG  13 µl   
MgCl2 (50 mM)      1 µl 
Primer mix, forward and reverse primer (10 µM each) 1 µl 
Nuclease-free H2O      8 µl  
cDNA        2 µl  
Total volume/reaction      23 µl  
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Table 6. Primers employed for a real-time RT-PCR analysis. 
Gene Primer Primer sequence, 5' - 3' Primer size, bp Amplicon size, bp Tm, °C Location, bp 
Lox Forward CAG CCA CAT AGA TCG CAT GGT 21 133 60.54 579 - 599 Reverse GCC GTA TCC AGG TCG GTT C 19 60.23 711  -693 
Loxl1 Forward GAG TGC TAT TGC GCT TCC C 19 225 58.98 1675 - 1693 Reverse GGT TGC CGA AGT CAC AGG T 19 60.23 1899 - 1881 
Loxl2 Forward ATT AAC CCC AAC TAT GAA GTG CC 23 130 58.72 2280 - 2302 Reverse CTG TCT CCT CAC TGA AGG CTC 21 59.50 2409 - 2389 
Loxl3 Forward CTA CTG CTG CTA CAC TGT CTG T 22 133 59.77 133 – 154 Reverse GAC CTT CAT AGG GCT TTC TAG GA 23 59.03 265 – 243 
Loxl4 Forward GCC AAC GGA CAG ACC AGA G 19 139 60.37 216 – 234 Reverse CCA GGT CAA GGC TGA CTC AAA 21 60.20 354 - 334 
Lce1 Forward AAG TGC CCT CCT GTG TCT TC 20 223 61.50 118 - 137 Reverse CAC AAC AGT CAC TGC TAC CAC 21 60.80 340 - 320 
Mmp9 Forward GCG TCG TGA TCC CCA CTT AC 20 88 62.60 644 - 663 Reverse CAG GCC GAA TAG GAG CGT C 19 62.20 731 - 713 
Rbm33 Forward TGC AGA ACG GTC CTG GAG AA 20 119 63.00 75 - 94 Reverse CAT CTG ACA AAT CCG ACT GGT T 22 63.00 193 - 172 
Cage1 Forward AAT GTC AAT GGT CCC TCT CAA GA 23 139 61.00 22 - 44 Reverse CAG AGA ACG TGT GTG TAG ACT C 22 60.00 160 - 139 
Rarres1 Forward AAT GTT CTG CGA GGG TGT TTT 21 201 60.40 341 - 361 Reverse ACA GGG GTC TCA GTG AAT TAT CA 23 60.50 541 - 519 
Adra1d Forward CGG ACC TTC TGC GAC GTA TG 20 124 62.60 478 - 497 Reverse TGG CTG GAT ACT TGA GCG AGT 21 63.00 601 - 581 
Prkcz Forward GCG TGG ATG CCA TGA CAA C 19 191 61.80 89 - 107 Reverse AAT GAT GAG CAC TTC GTC CCT 21 61.20 279 - 259 
Cobl Forward CTT AGG GGG AAG CTA TGG ACT 21 92 60.10 2307 - 2327 Reverse ACA CAT CCC TGT CAT AAC ACC T 22 60.80 2398 - 2377 
Lcn12 Forward CAG TTT CAG GGA GAG TGG TTT G 22 142 60.80 112 - 133 Reverse CCC GAG TCA TGG AGT TGG T 19 61.00 253 - 235 
Akr1c18 Forward TCC CAT CGT CCA GAG TTG GT 20 141 62.40 165 - 284 Reverse TCC ATG CTC ATC TTT AGG CAA AA 23 60.20 405 - 383 
Gdf10 Forward CAG GAC ATG GTC GCT ATC CAC 21 128 62.30 202 - 222 Reverse ACA GGC TTT TGG TCG ATC ATT TC 23 61.40 329 - 307 
Mmp3 Forward ACA TGG AGA CTT TGT CCC TTT TG 23 192 60.70 507 - 529 Reverse TTG GCT GAG TGG TAG AGT CCC 21 60.70 698 - 678 
Ifnb1 Forward CAG CTC CAA GAA AGG ACG AAC 21 138 60.90 82 - 102 Reverse GGC AGT GTA ACT CTT CTG CAT 21 60.00 219 - 199 
Cxcl9 Forward CCG AGG CAC GAT CCA CTA C 19 114 59.90 164 - 182 Reverse AGG CAG GTT TGA TCT CCG TT 20 59.30 277 - 258 
Csf2 Forward GGC CTT GGA AGC ATG TAG AGG 21 104 62.50 83 - 103 Reverse GGA GAA CTC GTT AGA GAC GAC TT 23 61.10 186 - 164 
Eln Forward TGT CCC ACT GGG TTA TCC CAT 21 92 62.40 792 - 812 Reverse CAG CTA CTC CAT AGG GCA ATT TC 23 60.70 883 - 861 
Cdh18 Forward ATT ACG AGC ACA TCT TGC ATC TG 23 127 61.00 7 - 29 Reverse TTT CCC CTT CAG TGT GTT TGG 21 60.40 133 - 113 
Oxct2b Forward GGG AGT GTC CAT TTC TAC ACG 21 239 60.10 112 - 132 Reverse CCC AGG TAG GAG CAC ACC A 19 62.90 350 - 332 
Slc15a5 Forward CCG GAA CTG GGG TGG ATT TTC 21 128 63.00 993 - 1013 Reverse GTC CAT CTC TCT TAG AGG GAA GT 23 60.00 1120 - 1098 
Lrig2 Forward AGC CTG GAT TTG AGT CAT AAC CG 23 200 62.20 232 - 254 Reverse GCA GAA TAA AGC TCG AAT GCT TC 23 60.20 431 - 409 
Cd8a Forward CCG TTG ACC CGC TTT CTG T 19 121 62.50 10 - 28 Reverse CGG CGT CCA TTT TCT TTG GAA 21 61.40 130 - 110 
Kcnj11 Forward CCT TTT CTC CAT CGA GGT CCA 21 107 61.20 102 - 122 Reverse GCC CGA CGA TAT TCT GCA CA 20 62.30 208 - 189 
Polr2a Forward CTA AGG GGC AGC CAA AGA AAC 21 209 59.45 808 - 828 Reverse CCA TTC AGC ATA CAA CTC TAG GC 23 59.19 1016 - 994 
bp, base pairs; Tm, melting temperature 
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3.2.4.6 Microarray analysis 
Following siRNA knockdown and BAPN treatment, tRNA was isolated from primary 
lung mouse fibroblasts using a PeqGold Total RNA Kit and subjected to microarray analysis. 
Analysis were performed by IMGM Laboratories (Martinsried, Germany) using an Agilent 
SurePrint G3 Mouse Gene Expression Microarray in combination with a one-color based 
hybridization protocol. Detected induced and repressed genes were further categorized based 
on the PANTHER analysis.  
 
3.2.5 Analysis of protein expression, activity and deposition 
3.2.5.1 Protein isolation from cell culture and lung tissue 
For protein isolation from cells, cells were homogenized by scraping in protein lysis 
buffer (100 µl of buffer/well) and collected in a 1.5 ml tube. For isolation from lungs, 
approximately 50 mg of lung tissue was homogenized in 300 µl protein lysis buffer using a 
Precellys 24-Dual homogenizer. Resulting suspension was centrifuged for 1 min at 
10,000 × g at RT in an Espresso personal microcentrifuge and the supernatant was transferred 
into 1.5 ml tube. Suspensions were incubated on ice for 30 - 60 min, and vortexed every 
10 minutes. Samples were than centrifuged at 16,200 × g for 15 min at 4 °C in refrigerated 
microcentrifuge CT15RE and the supernatant was collected into a new 1.5 ml tube. In order 
to prevent protein degradation, the entire protein isolation procedure was carried out on ice. 
 
Protein lysis buffer:  Immediately before use lysis buffer was supplemented with: 
20 mM Tris-Cl, pH 7.5 1×Complete™ protease inhibitor cocktail 
150 mM NaCl   1 mM Na₃VO₄ 
1 mM EDTA     
1 mM EGTA 
1% (vol/vol) NP-40 
 
3.2.5.2 Bradford assay 
Protein concentration was determined by Bradford assay. Samples, as well as lysis 
buffer (first blank control) were diluted with ddH2O in a 1:10 ratio in case of cell protein 
lysates, or a 1:50 ratio in the case of proteins obtained from tissue homogenates. A total of 
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10 µl of each diluted sample and lysis buffer were transferred to 96-well plate. In order to 
determine the standard curve, 10 µl of bovine serum albumin (BSA) protein standards as well 
as second blank control (ddH2) was included on the plate. All the samples and standards were 
analyzed in triplicates. Subsequently 200 µl of Quick Start™ Bradford dye regent was added 
to each well using a multichannel pipette. After 5 min the absorbance was measured at 
wavelength of 570 nm in a VersaMax ELISA Microplate reader using a 
SoftMax® Pro Software. Protein concentrations were determined using the standard curve. 
 
3.2.5.3 Protein electrophoresis and western blot analysis 
A fixed amount of protein was always mixed with 4× sample buffer supplemented 
with 10% (vol/vol) β-mercaptoethanol. Proteins were resolved in polyacrylamide gel by gel 
electrophoresis at 110 mV in running buffer.  
Proteins were transferred onto a 0.2 µm nitrocellulose or polyvinylidene difluoride 
(PVDF) membrane using the western blot transfer system, Trans-Blot®TurboTM. Successful 
protein transfer was validated by Ponceau S protein staining. In order to avoid unspecific 
binding of antibody, the membrane was ”blocked” for 1 h in blocking buffer at RT and 
subsequently incubated with primary antibody diluted in blocking buffer at 4 °C overnight. 
List of primary antibodies used in the western blot analysis is provided in Table 7.  
After the incubation with primary antibody, the membrane was rinsed in washing 
buffer. Six washings of 5 min each were performed. The membrane was then incubated with 
the horseradish peroxidase-conjugated secondary antibody diluted in blocking buffer for 1 h 
at RT, after which another round of washing was performed. Finally, the membrane was 
incubated in SuperSignal® West Femto chemiluminescent substrate and the protein bands 
were visualized with a LAS-4000 luminescent image analyzer. 
 
SDS-resolving gel (10%):    SDS-stacking gel: 
ddH2O       ddH2O 
10% (vol/vol) acrylamide     5% (vol/vol) acrylamide  
375 mM Tris-Cl, pH 8.8    125 mM Tris-Cl, pH 6.8 
0.05% (vol/vol) SDS     0.1% (vol/vol) SDS 
0.05% (vol/vol) APS     0.1% (vol/vol) APS 
0.065% (vol/vol) TEMED    0.1% (vol/vol) TEMED 
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SDS-running buffer:     Washing buffer: 
ddH2O       1× PBS 
192 mM glycine     0.1% (vol/vol) Tween 20 
25mM Tris-Cl, pH 7.5 
1% (vol/vol) SDS 
Blocking buffer:     Ponceau S staining: 
1×PBS       0.1% (wt/vol) Ponceau S 
5% (wt/vol) non-fat dry milk    5% (vol/vol) acetic acid 
 
Table 7. Primary and secondary antibodies used for western blot analysis. 
Antibody Company Catalog number Dilution Host 
anti-LOX LSBio LS-C143168 1:2,500 rabbit 
anti-LOX Abcam ab31238 
1:500,  
tissue homogenates 
1:1,000,  
cell homogenates 
rabbit 
anti-LOXL1 Abcam ab81488 1:750 rabbit 
anti-LOXL2 Abcam 
ab113960,  
tissue and cell homogenates 
ab179810,  
cell homogenates 
1:750 rabbit 
anti-LOXL3 Abcam ab122263 1:250 rabbit 
anti-LOXL4 Abcam ab130646 1:100 rabbit 
anti-β-ACTIN 
Cell Signaling 
Technology 
4967 1:5,000 rabbit 
Anti-rabbit IgG 
Thermo 
Scientific 
31460 1:3,000 goat 
 
3.2.5.4 Analysis of collagen and elastin protein and cross-links 
For the isolation of material for collagen and elastin measurements in lung homogenates 
lungs were perfused with PBS via the right heart ventricle, excised, transferred to 1.5 ml tube 
containing 1×PBS, and frozen in liquid nitrogen. Samples were stored at -80 °C for further 
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processing. Analysis of collagen and elastin protein and cross-links were performed by Prof. 
Dr. Med. Jürgen Brinckman and Dipl.-Ing. Heiko Steenbock from the Institute of Virology 
and Cell Biology of University of Lübeck. 
 
3.2.5.5 Lysyl oxidase activity assay. 
Lysyl oxidase activity from whole-lung homogenates and cell homogenate extracts 
was assessed using a Lysyl Oxidase Activity Assay Kit. A total of 10 µg of freshly isolated 
protein served as an enzyme source. Lysyl oxidase activity is reported as the BAPN-sensitive 
fraction determined in the presence of 500 mM BAPN. Fluorescence was measured during 
the exponential phase of enzymatic reaction using Infinite® 200 PRO multimode reader. 
 
3.2.6 Cloning and lentiviral production 
 The generation and use of S2-level genetically modified viruses was approved by 
local authorities, the Regierungspräsidium Gießen (approval number 
IV44-53r30.03.MPP07.13.15). The Lox-, Loxl1- and Loxl2-encoding lentivirus particles were 
constructed using the Gateway® cloning technology.  
 
3.2.6.1 Amplification and isolation of Lox, Loxl1 and Loxl2 sequences 
First, cDNA was amplified by RT-PCR from tRNA pools isolated from mouse lung 
or heart tissue homogenates. Murine Lox, Loxl1 and Loxl2 coding sequences were amplified 
with specific primers by PCR reaction. Primer sequences are provided in Table 8. The 
reaction conditions were: 95 °C for 5 min, followed by 39 cycles of 95 °C for 30 s to achieve 
denaturation, 60 °C for 40 s for primer annealing and 72 °C for 1 min to allow product 
elongation. Finally, 10-min final extension at 72 °C was performed after the last cycle in 
order to allow for the clearance of the replication machinery. 
Following the PCR reaction, the resulting amplicons were resolved on a 1.5% (wt/vol) 
agarose gel containing 0.002% (vol/vol) ethidium bromide in 1×TAE buffer using Wide 
Mini-Sub® Cell GT electrophoresis chambers. Amplicons were visualized in an Intas UV 
Transilluminator. Bands migrating at 1,235 bp, 1,823 bp and 2,330 bp corresponding to Lox, 
 
 
 
60 
 
 
Loxl1 and Lox2, respectively, were carefully excised with a scalpel. Excised bands were 
purified using a QIAquick gel extraction kit.  
 
Reaction mix (per one reaction):  
10× PfuUltraTM High Fidelity reaction buffer 5 μl 
dNTP mix (10 mM)     1 μl 
PfuUltraTM High Fidelity polymerase (2.5 U/µl) 1 μl 
Forward primer mix (10 µM)    1.5 µl 
Reverse primer mix (10 µM)    1.5 µl 
Nuclease-free H2O     39.0 μl 
cDNA (100 ng/µl)     1 μl  
Total volume/reaction     50 μl 
 
Table 8. Primers used for amplification of Lox, Loxl1 and Loxl2 sequences. 
Gene Primer Primer sequence, 5' - 3' Primer size, bp Ampliconsize, bp 
Lox Forward ATG CGT TTC GCC TGG GCT 18 1,235 Reverse CTA ATA CGG TGA AAT TGT GCA GCC T 25 
Loxl1 Forward ATG GCT CTG GCC GGA GCC 18 1,823 Reverse TCA GGA CTG GAC GAT TTT GCA GTT TG 26 
Loxl2 Forward ATG GAG CTC CAT TTT GGC TC 20 2,330 Reverse TTA CTG TAC AGA GAG CTG GTT ATT T 25 
bp, base pairs 
 
3.2.6.2 Ligation into the intermediate (entry) vector 
A total of approximately 100 ng gene-specific DNA was mixed in 1.5 ml tube with 
10 ng pCRTM2.1-TOPO® Gateway Entry vector, 1 µl of salt solution (1.2 M NaCl, 
0.06 M MgCl2) and nuclease-free water in total volume of 6 µl and left to ligate for 1 h at RT.  
 
3.2.6.3 Entry plasmid transformation of competent cells 
The Transform One Shot® DH5α™-T1R, TOP10 Competent Cells were transformed 
by heat shock. Briefly, 50 µl of competent cells and 2 - 6 µl of ligation product were first 
incubated on ice for 30 min. Afterwards, cells underwent heat shock in 42 °C for 30 s and 
were subsequently incubated on ice for an additional 2 min. Cells were then mixed with 
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250 µl of Super Optimal Broth (S.O.C.) medium and incubated for 1 h at 37 °C and 200 rpm 
(mixing orbit 2 mm), after which they were centrifuged in microcentrifuge for 4 min at 
1,534 × g. The pellet was re-suspended in approximately 50 µl of media and plated on 10 cm 
Petri dishes coated with LB-Agar, supplemented with 50 µg/ml spectinomycin. Culture was 
incubated overnight in incubator at 37 °C with a humidified 5% (vol/vol) CO2 atmosphere. 
LB media: 
LB media   2.5 g 
Agarose   1.5 g 
Spectinomycin; 50 mg/ml 100 µl 
ddH2O    100 ml 
 
3.2.6.4 Plasmid mini-preparation 
Selected single bacterial colonies were inoculated in 5 ml LB media containing 
50 µg/ml spectinomycin and incubated at 37 °C and shaking at 180 rpm (mixing orbit 2 mm) 
for 8 h. Afterwards, 2 ml of the bacterial culture was transferred into 200 ml of fresh medium 
and incubated overnight at 37 °C with shaking at 180 rpm (mixing orbit 2 mm). Plasmid 
constructs were then extracted from bacterial cultures using a NucleoBond® Xtra Mini kit.   
In order to confirm the presence of the desired sequence in the plasmid, constructs 
were digested with EcoRI enzyme for 2 h at 37 °C and resolved on a 1.5% (wt/vol) agarose 
gel containing 0.002% ethidium bromide in 1×TAE buffer using the 
Wide Mini-Sub® Cell GT electrophoresis chambers. Amplicons were visualized in 
Intas UV Transilluminator. Correct nucleotide sequence of the insert was confirmed by 
sequencing.  
 
Plasmid digestion reaction: 
Plasmid   7 µl 
Buffer H   2 µl 
EcoRI    1 µl 
ddH2O    up to 20 µl of total volume 
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3.2.6.5 Ligation into the final (destination) vector 
A total of approximately 100 ng pCRTM2.1-TOPO® containing the gene of interest 
was mixed in 1.5 ml tube with 150 ng pLenti7.3/V5DESTTM destination vector, 6 µl TE 
buffer and 2 µl LR-clonase and  incubated at RT for 4 h. The reaction was stopped by the 
addition of 1 µl of proteinase K.  
 
3.2.6.6 Final plasmid transformation of competent cells 
Heat shock of competent cells was performed exactly as described above. After 
centrifugation, the pellet was resolved in 50 µl of media and plated on a 10 cm Petri dishes 
coated with LB-Agar, supplemented with 0.1% (vol/vol) ampicillin. The culture was 
incubated overnight in an incubator at 37 °C with a humidified 5% (vol/vol) CO2 atmosphere. 
 
3.2.6.7 Plasmid maxi-preparation 
Selected bacterial colonies were inoculated exactly as described above into LB media 
containing 1 µl/ml ampicillin. Plasmid constructs were then extracted from bacterial culture 
using a NucleoBond® Xtra Maxi kit.   
 
3.2.6.8 Lentivirus production in HEK293T cells 
 First, HEK293T cells were seeded in 10 cm Petri dishes and incubated in DMEM 
supplemented with 10% FBS in an incubator at 37 °C with a humidified 5% (vol/vol) CO2 
atmosphere. After 24 h, medium was carefully aspirated and 10 ml of fresh media was added. 
Cells were then co-transfected with 3 µg Lox-, Loxl1- or Loxl2-encoding 
pLenti7.3/V5DESTTM destination vector together with 9 µg of ViraPowerTM Packaging 
Vector Mix diluted in 3 ml OptiMEM. Transfection was undertaken with 36 µl 
Lipofectamine® transfection reagent. The mixture was added to the cells drop-wise after 
20 min incubation. After 72 h medium was collected and stored at -80 °C for further use. The 
lentivirus particle concentration was not assessed, instead HEK293T cell medium containing 
viral particles was used as a source of virus. 
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3.2.6.9 Lentivirus-mediated overexpression of Lox, Loxl1 and Loxl2 in NIH/3T3 cells 
 Mouse NIH/3T3 cells were seeded into 6-well plates and cultured in DMEM 
supplemented with 10% (vol/vol) FBS and 1% P/S (vol/vol) in incubator at 37 °C with a 
humidified 5% (vol/vol) CO2 atmosphere for 24 h. Afterwards, cell media was aspirated and 
cells were transduced with 500-700 μl of Lox-, Loxl1- or Loxl2-expressing lentivirus particles 
for 72 h. Transduction was carried out using 8 μg/ml polybrene (hexadimethrine bromide).  
Both empty lentivirus and media without lentiviral particles were employed as controls.  
 
3.2.7 Statistical analysis 
Data are presented as mean ± SD. Data in tables 9-12 are presented as mean ± SE. All 
statistical analyses were performed with GraphPad Prism 6.0. The presence of potential 
statistical outliers was determined by Grubbs’ test. Differences in the case of two-group 
comparisons were evaluated by unpaired Student’s t-test, while differences in the case of 
three-group comparisons were evaluated by one-way ANOVA with Tukey’s multiple 
comparisons (post hoc) test. P values ˂ 0.05 were considered as significant.  
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4 RESULTS 
4.1 Exposure of immature mouse lungs to 85% O2 dysregulates lysyl oxidase 
expression 
 Previous studies of lung formation in mice by our group suggested the regulation of 
the lysyl oxidase family members in both normal and aberrant late lung development [46]. 
Therefore, we wanted to confirm the regulation of these enzymes at gene and protein 
expression levels. Newborn mouse pups were exposed to normoxic (21% O2) or hyperoxic 
(85% O2) conditions from the day of birth for either nine or 19 days. Exposure of newborn 
pups to 85% O2 led to an increase in the gene expression of Lox and Loxl2 at both P9.5 and 
P19.5 (Figure 6A-B). Although no apparent change in LOXL2 expression could be detected 
by immunoblot, increase of protein expression of LOX was evident by immunoblot at P19.5 
(Figure 6C). Moreover, an increase of protein expression of LOXL2 and LOXL4 in lungs 
after hyperoxia exposure was also detected (Figure 6C-D). Expression of Loxl3 was not 
significantly altered by hyperoxia exposure.  
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Figure 6. The expression of lysyl oxidase family members is dysregulated during 
aberrant late lung development. 
(A-B) Gene expression levels of all five members of the lysyl oxidase family were assessed 
in lung homogenates from mouse pups exposed to 21% O2, or 85% O2 from the day of birth, 
at P9.5 and P19.5, by real-time RT-PCR. Values represent mean ± SD (n = 3–5, per group). 
The P values were determined by unpaired Student’s t-test. (C) Protein expression levels of 
lysyl oxidases were assessed in lung homogenates from mouse pups exposed to 21% O2 or 
85% O2 from the day of birth, by immunoblot at P9.5 and P19.5. For the detection of lysyl 
oxidases, 50 µg of protein was loaded. Loading equivalence was controlled by β-ACTIN 
abundance. In addition, a Ponceau S-stained immunoblot membrane, as well as a second 
loading control, in which 1/5 of protein (10 µg) was used, are also shown. (D) Densitometric 
analysis of the protein expression in mice at P19.5. Pixel densities for the bands representing 
individual lysyl oxidase family members were normalized for the pixel density of the 
β-ACTIN bands from the same sample. Values represent mean ± SD (n = 3, per group). The 
P values were determined by unpaired Student’s t-test. 
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4.2 Inhibition of lysyl oxidase activity in the lungs of developing mice exposed 
to 85% O2 
 High doses of lathyrogens, including BAPN, can be toxic to multiple organs and are 
known to cause disturbances to lung maturation and normal ECM deposition [50, 51]. To 
avoid any morbidity or mortality associated with potential drug overdose, a five-day long 
pilot study was first performed to evaluate the impact of different doses of BAPN on 
developing mouse pups. Newborn pups were injected intraperitoneally, on a daily basis, from 
the day of birth with either vehicle (1×PBS) or the pan-lysyl oxidase inhibitor BAPN, diluted 
in 1×PBS at two different concentrations. Daily administration at a dose of 150 mg·kg-1 
significantly reduced animal viability and motility. Milk intake of the pups injected with 
150 mg·kg-1 BAPN was visibly reduced, and the body weight was decreased when compared 
with vehicle-treated littermates (Figure 7A-B). However, a ten-times lower dose of BAPN 
(15 mg·kg-1·day-1) was well tolerated by the developing pups, and did not lead to any visible 
perturbations in growth, motility or milk intake (Figure 7A-B). A dose of 15 mg·kg-1·day-1 
was therefore employed in further studies. Newborn mouse pups were divided to two groups 
and exposed from the day of birth continuously for nine or 19 days to either normoxic 
(21% O2) or hyperoxic (85% O2) conditions, as illustrated in Figure 7C. Both groups were 
further subdivided into vehicle (1×PBS) and BAPN-treated group (15 mg·kg-1·day-1 BAPN 
diluted in 1×PBS).   
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Figure 7. Effect of β-aminopropionitrile administration on mouse viability. 
A pilot study was performed, where newborn mouse pups were injected intraperitoneally on 
daily basis, for five days with solvent vehicle or β-aminopropionitrile (BAPN) diluted in 
vehicle at two different doses. (A) Body mass measured at P5.5. (B) Representative images 
of mice from each treatment group observed at P5.5. Arrows indicate the milk spot. (C) The 
experimental protocol employed in subsequent studies. Values represent mean ± SD 
(n = 3, per group). The P values were determined by one-way ANOVA with Tukey’s 
multiple comparisons test. 
 
 
In order to confirm the inhibitory effect of BAPN, a lysyl oxidase activity assay was 
performed. Activity was assessed in whole-lung homogenates from 9-days old developing 
mouse pups exposed to normoxic (21% O2) or hyperoxic (85% O2) conditions and 
concomitantly treated with daily injection (i.p.) of either vehicle alone or 15 mg·kg-1 BAPN.  
As expected, hyperoxia exposure caused a considerable increase in lysyl oxidase activity in 
the developing mouse lungs. Importantly, the daily BAPN treatment at the dose of 15 mg·kg-1 
was sufficient to preserve the normal levels of lysyl oxidase enzymatic activity in the lungs of 
hyperoxia-exposed animals when compared to vehicle-treated normoxia-exposed control 
animals (Figure 8).  
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Figure 8. Lysyl oxidase enzymatic activity was normalized by the administration of 
β-aminopropionitrile. 
Lysyl oxidase enzymatic activity was measured in total of 10 µg of protein extract from lung 
homogenates. Measurements were performed using a Lysyl Oxidase Activity Assay Kit. 
Activity is reported as the β-aminopropionitrile (BAPN)-sensitive fraction in the presence of 
500 mM BAPN. Values are represented as means ± SD. RFU, relative fluorescent units. 
n.s., not significant (P ˃ 0.05). The P values were determined by one-way ANOVA with 
Tukey’s multiple comparisons test. 
 
 
4.3 Cross-linking of collagen and elastin in the lungs of developing mouse pups 
upon hyperoxia exposure and treatment with β-aminopropionitrile 
Lysyl oxidases act as copper-dependent enzymes catalyzing the oxidative deamination 
of lysine and hydroxylysine residues. This process generates reactive semialdehydes, which 
form intramolecular and intermolecular covalent cross-links in both elastin and collagen 
molecules. In order to evaluate the impact of hyperoxia and lysyl oxidase activity inhibition 
on collagen formation we quantified the total amount of collagen and elastin as well as 
different types of collagen and elastin cross-links in lung homogenates of 19 days-old mouse 
pups after the exposure to hyperoxia and/or treatment with BAPN. 
The abundance of the non-collagen-non-elastin proteins was not altered in the lungs of 
developing mouse pups after 19 days of hyperoxia exposure. However, a pronounced 
three-fold increase in the collagen/elastin ratio was observed. This increase was partially 
blunted when BAPN was administered (Table 9). The increase in the collagen/elastin ratio 
was accompanied by a 63%-increase in total lung collagen protein levels. Similarly, collagen 
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fraction in total lung protein was increased by 42% in the animals exposed to hyperoxia when 
compared to normoxia-exposed control animals. This increase was at least partially restored 
when the developing hyperoxia-exposed pups were also treated with BAPN (Figure 9A-9B).  
Both hyperoxia exposure and daily BAPN administration had a considerable effect on 
collagen cross-linking in the developing mouse lungs. Although hyperoxia exposure didn’t 
alter the abundance of hydroxylysinonorleucine (HLNL) and hydroxylysylpyridinoline (HP) 
cross-links, an 11% increase in the abundance of dihydroxylysinonorleucine (DHLNL) 
cross-links was observed. Moreover, exposure of developing mouse pups to hyperoxia led to 
an increase in the DHLNL/HLNL ratio, which reflects the lysyl hydroxylation status in 
collagen cross-links [118] and indicates the fibrotic nature of the tissue [119]. Daily 
administration of BAPN to normoxia-exposed developing mouse pups did not affect neither 
the total collagen levels in the lungs, nor the collagen fraction within the total lung protein 
(Figure 9A-9B). The abundance of DHLNL was also not impacted (Figure 9C), however 
BAPN administration caused a significant increase in the abundance of HLNL cross-links, 
resulting in a decrease of DHLNL/HLNL ratio (Figure 9E-9F). In addition, BAPN 
administration decreased the abundance of HP cross-links in both normoxia-exposed and 
hyperoxia-exposed mouse pups (Figure 9C). Moreover, daily treatment of developing mouse 
pups with BAPN reversed the increase in DHLNL/HLNL ratio induced by exposure of the 
mice to hyperoxia (Figure 9F). 
 
Table 9. Effect of hyperoxia exposure and β-aminopropionitrile administration on 
deposition of collagen in the developing mouse lungs at postnatal day 19.5. 
 21% O2 85% O2 
 Vehicle BAPN Vehicle BAPN 
Parameter mean ± S.E. mean ± S.E. mean ± S.E. P value vs. Vehicle, 21% O2 
mean ± S.E. P value vs. Vehicle, 85% O2 
nc-ne-protein/ 
lung [µg] 2387 ± 128.50 2575 ± 81.40 2784 ± 140.30 0.1763 2440 ± 184.90 0.3143 
collagen/ 
elastin, % 68.29 ± 5.19 64.60 ± 2.11 180.40 ± 12.18 < 0.0001 144.00 ± 15.36 0.0723 
 
Additional cross-link data are presented in Figure 9. BAPN, β-aminopropionitrile; nc-ne 
protein, non-collagen-non-elastin-proteins. Values represent mean ± S.E, (n = 6-7, per 
group). The P values were determined by one-way ANOVA with Tukey’s multiple 
comparisons test. 
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Figure 9. Effect of hyperoxia exposure and β-aminopropionitrile administration on the 
levels of collagen and formation of collagen cross-links in the lungs of developing mouse 
pups at postnatal day 19.5. 
(A) The abundance of total collagen in the lung. (B) Abundance of collagen per unit total 
protein. (C-E) The abundance of collagen cross-links, dihydroxylysinonorleucine (DHLNL) 
(C), hydroxylysylpyridinoline (HP) (D), and hydroxylysinonorleucine (HLNL) (E) per total 
collagen. (F) The DHLNL-to-HLNLratio. Analysis of the lungs of 19 days-old, vehicle or 
β-aminopropionitrile (BAPN)-treated mouse pups concomitantly exposed to either 21% O2 or 
85% O2. Values represent mean ± SD (n = 6-7, per group). n.s., not significant (P ˃ 0.05). 
The P values were determined by one-way ANOVA with Tukey’s multiple comparisons test. 
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 Similar to collagen, the abundance of elastin and elastin cross-links was severely 
altered by exposure of newborn mouse pups to 85% O2. The amount of total insoluble elastin 
protein in the lung was significantly decreased when compared to healthy animals of the 
same age (Table 10), and the proportion of elastin per total lung protein was decreased by one 
third (Figure 10A). Moreover, hyperoxia exposure led to a significant reduction in the levels 
of elastin cross-links; desmosine (by 30%) and isodesmosine (by 21%); as well as the ratio 
between the two (Figure 10B-10D). 
 Daily administration of BAPN to normoxia-exposed animals reduced the levels of 
insoluble elastin in the lungs, although no such effect was observed in the lungs of animals 
concomitantly exposed to hyperoxia (Figure 10A). However, BAPN administration to the 
developing mouse pups had partially recovered the levels of desmosine and isodesmosine 
cross-links, which were decreased by the exposure of vehicle-treated newborn pups to 
85% O2. In addition, increases in desmosine and isodesmosine levels led to an improvement 
in the desmosine/isodesmosine ratio, which was partially restored in hyperoxia-exposed pups 
after BAPN treatment, compared to normoxia-exposed vehicle-treated animals 
(Figure 10B-10D).  
 
Table 10. Effect of hyperoxia exposure and β-aminopropionitrile administration on 
deposition of elastin in developing mouse lungs at postnatal day 19.5. 
 21% O2 85% O2 
 Vehicle BAPN Vehicle BAPN 
Parameter mean ± S.E. mean ± S.E. mean ± S.E. P value vs. Vehicle, 21% O2 
mean ± S.E. P value vs. Vehicle, 85% O2 
elastin/lung [µg] 582.7 ± 16.00 569.1 ± 10.24 359.7 ± 14.75 < 0.0001 350.9 ± 23.14 0.9815 
(des+isodes) 
/elastin[pmol/µg] 14.14 ± 0.364 15.45 ± 0.317 10.55 ± 0.383 < 0.0001 12.28 ± 0.276 0.0098 
 
Additional cross-link data are presented in Figure 10. BAPN, β-aminopropionitrile; des, 
desmosine; isodes, isodesmosine. Values represent mean ± S.E, (n = 6-7, per group). The P 
values were determined by one-way ANOVA with Tukey’s multiple comparisons test. 
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Figure 10. Effect of hyperoxia-exposure and β-aminopropionitrile administration on the 
levels of elastin and elastin cross-links in the lungs of developing mouse pups at 
postnatal day 19.5. 
(A) The abundance of insoluble elastin per unit total protein. (B) Desmosine/isodesmosine 
ratio. (C) The abundance of desmosine per total elastin. (D) The abundance of isodesmosine 
per total elastin. Analysis of the lungs of 19 day-old, vehicle or β-aminopropionitrile 
(BAPN)-treated mouse pups concomitantly exposed to either 21% O2 or 85% O2. Values 
represent mean ± SD (n = 6-7, per group). The P values were determined by one-way 
ANOVA with Tukey’s multiple comparisons test. 
 
4.4 The impact of hyperoxia exposure and β-aminopropionitrile administration 
on elastin fibers formation in the parenchyma of the developing mouse lung 
 During the development of the lung, elastin is organized into specific structures, 
so-called “foci”, deposited on the tips of the developing alveolar septa, suggesting the role of 
elastin in the septal formation [13, 46, 80]. In contrast, elastin fibers in the lungs of 
mechanically ventilated or hyperoxia-exposed animals are often described as disrupted and 
fragmented [46, 64, 86-88]. In the present study the formation of elastin foci in the lungs of 
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the developing mouse pups was considerably altered by hyperoxia exposure (85% O2) at 
both, P9.5 (Figure 11A vs. 11B) and P19.5 (Figure 11E vs. 11F) when compared with control 
normoxia-exposed animals. Elastin fibers in the lungs of hyperoxia-exposed mice formed 
fewer foci and appeared disorganized and “brush-like” (Figure 11F). 
 The daily administration of BAPN did not visibly alter the appearance of the elastin 
foci formation in the lungs of normally-developing mouse pups at P9.5 and P19.5, when 
compared with the vehicle-treated control animals (Figure 11A vs. 11C and Figure 11E vs. 
11G). Daily administration of BAPN to the developing mouse pups concomitantly exposed to 
85% O2 from the day of birth did not improve the formation of the elastin foci in the 
developing alveolar septa at P9.5 (Figure 11C vs. 11D). However, when BAPN was 
administered for an additional ten days (up to and including P19.5), formation of the elastin 
foci was partially preserved (Figure 11H), although overall structure and thickness of the 
alveolar septa remained unchanged when compared with the vehicle-treated 
hyperoxia-exposed animals (Figure 11F vs. 11H). 
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Figure 11. Hyperoxia-exposure and β-aminopropionitrile administration alter the 
formation of elastin foci in developing alveolar septa.  
Representative paraffin embedded lung tissue sections from animals exposed to 21% O2 
(A, C, E, G) or 85% O2 (B, D, F, H), concomitantly treated with either vehicle (A, B, E, F) or 
β-aminopropionitrile (BAPN) (C, D, G, H) for the first 9 (A-D) or 19 (E-H) days of life. 
Arrows indicate elastin foci. 
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4.5 Treatment of hyperoxia-exposed mouse pups did not preserve normal lung 
architecture 
 The exposure of mouse pups to 85% O2 from the day of birth for nine (Figure 12) or 
19 (Figure 13) days resulted in an arrest in alveolarization, characterized by a decrease in 
gas-exchange surface area, thickening of the alveolar septa and a substantial decrease in the 
number of alveoli in lung as seen by visual inspection. We further quantified these 
parameters using the stereological analysis. The full list of stereo-morphometric parameters is 
provided in Table 11 for lungs of mice at P9.5 and in Table 12 for lungs from mice at P19.5.  
 Exposure of developing mouse pups to hyperoxia (85% O2) from day of birth until 
P9.5 had a striking impact on lung architecture (Figure 12A vs. 12B). The gas-exchange 
surface area was decreased in hyperoxia-exposed mouse pups when compared with 
normally-developing animals [57.89 ± 7.26 cm2 vs. 91.98 ± 27.77 cm2 (Figure 12E)]. 
Similarly, number of alveoli decreased from 1.746 ± 0.4495 × 106 in normoxia-exposed 
mouse pups to 1.11 ± 0.27 × 106 in hyperoxia-exposed mouse pups (Figure 12H). In contrast, 
the mean linear intercept (MLI) was increased by hyperoxia exposure from 39.27 ± 7.51 µm 
in normally-developing lungs to 65.39 ± 6.547 µm in the lungs of hyperoxia-exposed pups 
(Figure 12G).  
Although the visual inspection of the lungs from developing mouse pups at P9.5 
suggested a formation of a more complex lung structure in the BAPN-treated 
normoxia-exposed mice (Figure 12C), when compared to vehicle-treated mice (Figure 12A), 
no significant changes assessed by stereological analysis were found (Figure 12E-12H). 
Similarly, treatment with BAPN appeared to improve the lung structure of hyperoxia-exposed 
mice when compared with vehicle-treated hyperoxia-exposed mice (Figure 12B vs. 12D). 
However, no significant improvement in any of the parameters investigated could be 
validated by stereological analysis, where the gas-exchange surface area, septal thickness, 
MLI and number of alveoli remained unchanged upon the BAPN-treatment 
(Figure 12E-12H). However, a tendency towards an improvement was observed in the 
estimates of alveolar surface area (Figure 12E), MLI (Figure 12G) and number of alveoli 
(Figure 12H). Based on the trends toward an improvement in lung structure observed after 
the BAPN-treatment in hyperoxia-exposed lungs on P9.5, and the improvement of elastin foci 
formation observed on P19.5 (Figure 11), it was speculated, that longer intervention with 
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BAPN and analysis at a later time point may emphasize the corrective effects of BAPN on 
the lung structure of hyperoxia-exposed mouse pups.  
 
Table 11. Stereo-morphometric parameters of developing mouse lungs after hyperoxia 
exposure  and  β-aminopropionitrile administration assessed at postnatal day 9.5. 
 21% O2 85% O2 
 Vehicle BAPN Vehicle BAPN 
Parameter mean ± S.E. mean ± S.E. mean ± S.E. P value vs. Vehicle, 21% O2 
mean ± S.E. P value vs. Vehicle, 85% O2 
V (lung) [cm3] 0.16 ± 0.011 0.18 ± 0.013 0.15 ± 0.006 0.9696 0.17 ±0.011 0.4473 
CV [V (lung)] 0.07 0.03 0.06 0.05 
VV (par/lung) [%] 88.81 ± 2.06 90.27 ± 1.11 88.19 ± 1.84 0.9936 87.13 ± 1.38 0.9688 
VV (non-par/lung) [%] 11.19 ± 2,06 9.73 ± 1.11 11.81 ± 1.84 0.9936 12.87 ± 1.37 0.9688 
NV (alv/par)107 [cm-3] 1.25 ± 0.07 1.21 ± 0.07 0.84 ± 0.06 0.0021 0.94 ± 0.08 0.7935 
SV [cm-1] 651.46 ± 22.8 635.00 ± 14.68 438.51 ± 22.05 ˂ 0.0001 491.63 ± 23.47 0.0890 
VV  (alvair/par) [%] 62.99 ± 2,67 61.39 ± 1.11 71.41 ± 1.60 0.0234 70.69 ± 1.73 0.9935 
V (alv air, lung) [cm3] 0.087 ± 0.006 0.098 ± 0.006 0.094 ± 0.005 0.7823 0.106 ± 0.006 0.4985 
CV [V (alv air, lung)] 0.18 0.17 0.13 0.16 
V (sep, lung) [cm3] 0.051 ± 0.007 0.062 ± 0.005 0.013 ± 0.001 ˂ 0.0001 0.016 ± 0.002 0.9392 
CV [V (sep, lung)] 0.38 0.22 0.23 0.33 
BAPN, β-aminopropionitrile V, volume; VV, volume density; SV, surface density; NV, 
numerical density; CV, coefficient of variation; par, parenchyma; non-par, non-parenchyma; 
sep, septa; alv air, alveolar airspaces; alv, alveoli. Values represent mean ± S.E, (n = 6-7, per 
group). The P values were determined by one-way ANOVA with Tukey’s multiple 
comparisons test. 
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Figure 12. Impact of the hyperoxia-exposure and β-aminopropionitrile administration 
on the lung architecture at postnatal day 9.5. 
Representative plastic-embedded lung tissue sections from animals exposed to 21% O2 (A, C) 
or 85% O2 (B, D), concomitantly treated with either vehicle (A, B) or β-aminopropionitrile 
(BAPN) (C, D) for the first 9 days of life. The alveolar surface area (E), septal thickness (F), 
mean linear intercept (MLI) (G) and total number of alveoli in the lung (H) were determined 
by stereo-morphometric analysis. Sex was determined by polymerase chain reaction and no 
clustering on the basis of sex was observed. Values represent mean ± SD (n = 7-8, per group). 
The P values were determined by one-way ANOVA with Tukey’s multiple comparisons test. 
Additional stereo-morphometric parameters are present in Table 11. 
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 The duration of the intervention study was prolonged for an additional 10 days and 
the developing mouse lungs were harvested at P19.5 (Figure 13). As expected, exposure of 
mouse lungs to 85% O2 once again resulted in an arrest in alveolarization 
(Figure 13A vs. 13B). The gas-exchange surface area was decreased from 203.80 ± 11.71 cm2 
in the lungs of normally-developing mouse pups to 115.00 ± 11.36 cm2 in the lungs of the 
hyperoxia-exposed mouse pups (Figure 13F)  and the number of alveoli was decreased from 
7.05 ± 1.10× 106 in normally-developing pups to  2.33 ± 0.43× 106 in hyperoxia-exposed 
animals (Figure 13I). Contrariwise, an increase in both, the thickness of the alveolar septal 
wall [(8.80 ± 0.5µm (21% O2) vs. 13.20 ± 0.96 µm (85% O2); Figure 13G] and MLI 
[28.06 ± 0.69µm (21% O2) vs. 57.75 ± 5.22µm (85% O2); Figure 13H] was observed in the 
hyperoxia-exposed developing pups when compared to normoxia-exposed control animals.  
 
Table 12. Stereo-morphometric parameters of developing mouse lungs after hyperoxia 
exposure  and  β-aminopropionitrile administration assessed at postnatal day 19.5. 
 
 21% O2 85% O2 
 Vehicle BAPN Vehicle BAPN 
Parameter mean ± S.E. mean ± S.E. mean ± S.E. 
P value vs. 
Vehicle, 21% O2 mean ± S.E. 
P value vs. 
Vehicle, 85% O2 
V (lung) [cm3] 0.26 ± 0.007 0.28 ± 0.011 0.27 ± 0.014 0.9669 0.26 ± 0.016 0.9851 
CV [V (lung)] 0.07 0.09 0.12 0.14 
VV (par/lung) [%] 90.30 ± 0.969 90.22 ± 1.354 91.24 ± 0.922 0.9161 89.47 ± 0.767 0.6240 
VV (non-par/lung) [%] 9.70 ± 0.969 9.78 ± 1.354 8.76 ± 0.922 0.9161 10.53 ± 0.767 0.6239 
NV (alv/par) 107 [cm-3] 3.03 ± 0.21 3.44 ± 0.11 0.98 ± 0.10 < 0.0001 1.11 ± 0.06 0.8811 
SV [cm-1] 877.20 ± 13.17 845.10 ± 17.15 476.40 ± 12.09 < 0.0001 437.10 ± 17.85 0.3009 
VV  (alvair/par) [%] 61.50 ± 0.55 61.70 ± 1.46 68.52 ± 1.28 0.0075 66.80 ± 1.65 0.7874 
V (alv air, lung) [cm3] 0.143 ± 0.004 0.157 ± 0.006 0.167 ± 0.013 0.3043 0.156 ± 0.012 0.8356 
CV [V (alv air, lung)] 0.06 0.08 0.17 0.18 
V (sep, lung) [cm3] 0.090 ± 0.002 0.098 ± 0.005 0.076 ± 0.003 0.0543 0.076 ± 0.002 0.9993 
CV [V (sep, lung)] 0.05 0.12 0.09 0.07 
 
BAPN, β-aminopropionitrile V, volume; VV, volume density; SV, surface density; NV, 
numerical density; CV, coefficient of variation; par, parenchyma; non-par, non-parenchyma; 
sep, septa; alv air, alveolar airspaces; alv, alveoli. Values represent mean ± S.E, (n = 5, per 
group). The P values were determined by one-way ANOVA with Tukey’s multiple 
comparisons test. 
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No apparent differences in alveolar formation were observed in the lungs of 
BAPN-treated normoxia-exposed animals when compared to vehicle-treated controls by 
visual inspection (Figure 13B vs. 13D). However, a significant increase in the number of 
alveoli following the administration of BAPN was revealed when stereological analysis of the 
lung structure was employed (Figure 13I). On the contrary, no increase in the number of 
alveoli could be found following the BAPN-treatment in the lungs of hyperoxia-exposed pups 
when compared with vehicle-treated hyperoxia-exposed controls (Figure 13B vs. 13D). 
Moreover, the administration of BAPN to the animals exposed to 85% O2 caused a further 
thickening of the alveolar wall septa from 13.20 ± 0.96µm to 15.18 ± 0.43µm when 
compared to vehicle-treated animals within the same oxygen-exposure group (Figure 13E and 
13G).  
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Figure 13. Impact of the hyperoxia-exposure and β-aminopropionitrile administration 
on the lung architecture at postnatal day 19.5. 
Representative plastic-embedded lung tissue sections from animals exposed to 21% O2 (A, C) 
or 85% O2 (B, D), concomitantly treated with either vehicle (A, B) or β-aminopropionitrile 
(BAPN) (C, D) for the first 19 days of life. (E) Higher magnification images emphasizing the 
changes in septal thickness between vehicle and BAPN-treated hyperoxia-exposed mice. The 
alveolar surface area (F), septal thickness (G), mean linear intercept (MLI) (H) and total 
number of alveoli in the lung (I) were determined by stereo-morphometric analysis. Sex was 
determined by polymerase chain reaction and no clustering on the basis of sex was observed.  
Values represent mean ± SD (n = 5, per group). The P values were determined by one-way 
ANOVA with Tukey’s multiple comparisons test. Additional stereo-morphometric 
parameters are present in Table 12. 
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4.6 Expression profile of lysyl oxidase family members in various cell-types 
present in the lung 
Although the role of lysyl oxidases in ECM formation and metabolism is well known, 
multiple studies have recently focused on so-called “non-matrix” roles for some of the 
members of the lysyl oxidase family. These roles include control of intracellular signaling 
and transcriptional regulation, including regulation of expression of several structural and 
enzymatic components of the ECM network, such as Cdh, Eln and Col3a1. In order to define 
a cell-type suitable for investigation of the possible non-matrix roles for lysyl oxidases in the 
context of lung development, a lysyl oxidase family expression screening was performed in 
different cell-types present in the lung. Cell-types investigated included primary mouse lung 
fibroblasts, epithelial cells, PASMCs, microvascular endothelial cells and bone 
marrow-derived macrophages (Figure 14). 
 
 
Figure 14. Relative expression of lysyl oxidase family members in various mouse lung 
cell-types cultured in vitro. 
The gene expression of Lox, Loxl1, Loxl2, Loxl3 and Loxl4 was evaluated by real-time 
RT-PCR. The total RNA was obtained from various mouse primary cells. AECII, type II 
alveolar epithelial cells; PF, pulmonary fibroblasts, EC, pulmonary microvascular endothelial 
cells; PASMC, pulmonary arterial smooth muscle cells; MΦ, bone marrow-derived 
macrophages. Values represent mean ± SD, (n = 4 cell cultures, per group).  
 
Gene expression analyses in controlled cell culture conditions may lead to various 
artifacts due to the absence of cells natural environment including a functional ECM network. 
However the screening performed in this study outlined a rather constant pattern in the 
expression of members of the lysyl oxidase family. A variable expression of individual 
members was observed in different cell-types, with highest expression levels detected in 
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fibroblasts and lowest expression levels detected in endothelial cells. The first three family 
members, Lox, Loxl1 and Loxl2 all exhibited the most differential expression across the 
various lung cell-types. Moreover, Lox, Loxl1 and Loxl2 all exhibited the highest expression 
in lung fibroblasts, the leading collagen-producing and elastin-producing cell-type in the 
lung. Therefore, the consecutive studies of the possible non-matrix regulatory properties 
focused exclusively on the first three members of the lysyl oxidase family and were limited to 
the context of pulmonary mouse fibroblasts.  
 
4.7 Knockdown of Lox, Loxl1 and Loxl2 expression impacts the transcriptome 
of primary mouse lung fibroblasts 
 In order to assess whether lysyl oxidase family members have any gene regulatory 
roles in primary mouse lung fibroblasts, an siRNA-mediated knockdown of Lox, Loxl1 and 
Loxl2 was performed and any impact on gene regulation was evaluated by subsequent 
microarray screening. Both gene and protein expression levels of LOX (Figure 15A-15B), 
LOXL1 (Figure 15E-15F) and LOXL2 (Figure 15I-15J) were successfully depleted in 
primary mouse pulmonary fibroblasts after a transfection with a respective siRNA.  
In order to explore a possible compensatory regulation of other lysyl oxidase family 
members, the expression of remaining two members of interest was also assessed for each 
knockdown. Interestingly, although a siRNA-mediated knockdown of Lox did not have any 
effect on the gene expression of Loxl1 (Figure 15C), a significant down-regulation in Loxl2 
gene expression was observed (Figure 15D). Both Loxl1 and Loxl2 knockdown caused a 
significant increase of Lox mRNA expression (Figure 15G and 15K). Moreover, the 
knockdown of Loxl1 led to a down-regulation of Loxl2 expression (Figure 15H), while Loxl2 
knockdown had no effect on mRNA expression levels of Loxl1 (Figure 15L), suggesting a 
possible interplay between the Loxl1 and Loxl2 gene expression. It is worth to note, that all 
siRNA sequences used in this experiment did not share any regions of homology with the 
sequences of the other two lysyl oxidase members. The expression levels of Lox, Loxl1 and 
Loxl2 in primary mouse lung fibroblasts therefore influence each other. It is not yet apparent 
whether the interplay between the gene expression of individual lysyl oxidases is a 
compensatory effect, or rather a direct effect, where one member of the family regulates the 
transcription of another member.  
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Figure 15. Short interfering RNA-mediated knockdown of lysyl oxidases in primary 
mouse lung fibroblast cultures. 
The short interfering (si)RNA-mediated knockdown of lysyl oxidase (LOX) was evaluated by 
real-time RT-PCR (A) and immunoblot (B). Additionally, possibility of the compensatory 
effects of LOX knockdown on lysyl oxidase-like 1 (Loxl1) (C) and lysyl oxidase-like 2 
(Loxl2) (D) expression was evaluated by real-time RT-PCR. The siRNA-mediated 
knockdown of LOXL1 was evaluated by real-time RT-PCR (E) and immunoblot (F). 
Additionally, possibility of the compensatory effects of LOXL1 knockdown on Lox (G) and 
Loxl2 (H) expression was evaluated by real-time RT-PCR. The siRNA-mediated knockdown 
of LOXL2 was evaluated by real-time RT-PCR (I) and immunoblot (J). Additionally, 
possibility of the compensatory effects of LOXL2 knockdown on Lox (K) and Loxl1 (L) 
expression was evaluated by real-time RT-PCR. Values represent mean means ± SD, (n = 4, 
per group). The P values were determined by unpaired Student’s t-test. Immunoblots are 
representative of expression observed in at least three immunoblots in total. Loading 
equivalence was controlled by β-ACTIN. 
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After the efficiency of transfection and knockdown were confirmed, total RNA pools 
from transfected mouse primary pulmonary fibroblasts were screened for potential 
transcriptomic changes by microarray. The siRNA-mediated knockdown of Lox led to an 
up-regulation of 85 and down-regulation of 49 genes. Among the dysregulated genes, Lox 
itself was the single most down-regulated gene. The ten most up-regulated and most 
down-regulated genes following the Lox knockdown are listed in Table 13, and others listed 
include the ECM-related genes Mmp9 and Rarres1. Expression changes of four most 
up-regulated and the four most down-regulated genes were evaluated by real-time RT-PCR 
and all but one were confirmed (Figure 16A).  
 
Table 13. List of differentially up- and down-regulated genes after a Lox knockdown as 
assessed by microarray analysis. 
Most up-regulated genes 
n. P (corr) FC Log FC 
Gene 
Symbol Gene name 
      1 0.027154 3.908041 1.966445 Lce1l late cornified envelope 1L 
2 0.016138 3.889547 1.959602 Mmp9 matrix metallopeptidase 9 
3 0.007329 3.464999 1.792855 Rbm33 RNA binding motif protein 33 
4 0.022728 3.405689 
 
1.767947 
 
Gm6712 
 
predicted gene 6712 (Gm6712) 
 5 
0.002383 
 
3.269200 1.708938 Zfp951 
 
zinc finger protein 951 (Zfp951) 
 6 
0.006838 
 
3.257450 1.703743 Zfp960 
 
zinc finger protein 960 (Zfp960), transcript variant 1 
 7 
0.005427 
 
3.240398 1.696171 Zfp458 
 
zinc finger protein 458 (Zfp458) 
 8 
0.029255 2.970390 1.570653 Cage1 cancer antigen 1 
9 0.002799 
 
2.928108 1.549969 Gm14325 
 
predicted gene 14325 (Gm14325) 
 10 
0.044686 
 
2.846928 1.509406 Gm14432 
 
predicted gene, OTTMUSG00000016609 
 Most down-regulated genes 
n. P (corr) FC Log FC 
Gene 
Symbol Gene name 
      1 0.037609 -4.6165500 -2.206820 Lox lysyl oxidase 
2 0.047584 -3.4912100 -1.803730 Rarres1 retinoic acid receptor responder (tazarotene induced) 1 
3 0.027323 -3.1600500 -1.659950 Adra1d adrenergic receptor, alpha 1d 
4 0.031039 -3.1526300 -1.656550 Prkcz protein kinase C, zeta 
5 0.038292 -3.046400 -1.607110 Cobl cordon-bleu WH2 repeat 
6 0.028848 -2.974400 -1.572600 Ces2e carboxylesterase 2E 
7 0.044987 -2.78087 -1.475540 Cbr2 carbonyl reductase 2 
8 0.035204 -2.72894 -1.448340 Serpinb9 serine (or cysteine) peptidase inhibitor, clade B, member 9 
9 0.030026 -2.64904 -1.405470 Mamstr MEF2 activating motif and SAP domain containing transcriptional regulator 
10 0.042531 -2.62607 -1.392910 Adora2a adenosine A2a receptor 
 
n, number; P(corr), corrected P value; FC, fold change;  
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Figure 16. Microarray analysis validation following the short interfering RNA-mediated 
knockdown of lysyl oxidases in primary mouse lung fibroblasts. 
Microarray data presented in tables 13, 14 and 15 were validated by real-time RT-PCR. (A) 
Expression of the most up-regulated and the most down-regulated genes identified by 
microarray analysis after Lox short interfering (si)RNA-mediated knockdown in primary 
mouse pulmonary fibroblasts. (B) Expression of the most up-regulated and the most 
down-regulated genes identified by microarray analysis after Loxl1 siRNA-mediated 
knockdown in primary mouse pulmonary fibroblasts. (C) Expression of the most up-regulated 
and the most down-regulated genes identified by microarray analysis after Loxl2 
siRNA-mediated knockdown in primary mouse pulmonary fibroblasts. scr., control 
scrambled siRNA sequence; si, gene-specific siRNA sequence; Values are represented as 
means ± SD, (n = 4, per group). The P values were determined by unpaired Student’s t-test. 
 
 
 
 
 
86 
 
 
Knockdown of Loxl1 led to a dysregulation of an even higher number of genes than 
the knockdown of Lox. From the pool of dysregulated genes 1,988 were up-regulated and 
1,773 were down-regulated. Loxl1 was identified as the 1222nd most down-regulated gene. 
Ten most up-regulated and most down-regulated genes are summarized in Table 14. Because 
of the importance to ECM formation, it is worth to mention that Mmp3 ranked as the 9th most 
up-regulated and Eln as the 48th most down-regulated gene following the Loxl1 
siRNA-mediated knockdown. Validation of the expression changes of the most up-regulated 
and most down-regulated genes, including Eln is presented in Figure 16B.  
 
Table 14. List of differentially up- and down-regulated genes after a Loxl1 knockdown 
as assessed by microarray analysis. 
Most up-regulated genes 
n. P (corr) FC Log FC 
Gene 
Symbol Gene name 
      1 0.001464 95.236550 6.573443 Lcn12 
 
lipocalin 12 
 2 
0.002228 77.167210 6.269916 Lce3a late cornified envelope 3A 
3 0.000605 66.348680 6.051996 Akr1c18 aldo-keto reductase family 1, member C18  
4 0.000979 59.690400 5.899427 S100a8 S100 calcium binding protein A8 (calgranulin A)  
5 0.000047 
 
48.967690 5.613758 Gdf10 growth differentiation factor 10  
6 0.007833 44.321830 5.469945 Gda guanine deaminase 
7 0.003628 41.499290 5.375015 Bdkrb2 bradykinin receptor, beta 2 
8 0.000482 35.774510 5.160860 Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N 
9 0.000017 
 
34.336160 5.101657 Mmp3 matrix metallopeptidase 3 
10 0.012638 33.232890 5.054540 Snhg11 small nucleolar RNA host gene 11 
Most down-regulated genes 
n. P (corr) FC Log FC 
Gene 
Symbol Gene name 
      1 0.000889 -338.510000 -8.403060 Ifnb1 interferon beta 1  
2 0.001181 -197.405000 -7.625020 Cxcl9 chemokine (C-X-C motif) ligand 9 
3 0.014386 -118.647000 -6.890540 Csf2 colony stimulating factor 2 (granulocyte-macrophage) 
4 0.000154 -107.855000 -6.752950 Pydc3 pyrin domain containing 3 
5 0.000581 -103.021000 -6.686790 Gbp4 guanylate binding protein 4, transcript variant 1 
6 0.002557 -101.103000 -6.659690 Mx1 myxovirus (influenza virus) resistance 1 
7 0.000146 -89.209800 -6.479130 Cxcl10 activated spleen cDNA, RIKEN full-length enriched library 
8 0.011989 -87.902900 -6.457840 Cxcl2 chemokine (C-X-C motif) ligand 2  
9 0.001473 -80.725800 -6.334960 Phf11b PHD finger protein 11B  
10 0.000354 -79.342900 -6.310030 Mx2 myxovirus (influenza virus) resistance 2, transcript variant 1 
48 0.000119 
 
-25.523700 -4.673770 Eln elastin 
  
n, number; P(corr), corrected P value; FC, fold change;  
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The knockdown of Loxl2 expression resulted in up-regulation and down-regulation of 
1,788 and 1,766 genes respectively. Among the down-regulated genes Loxl2 itself was 
identified at the 621st position. A summary of the 10 most up-regulated and the 10 most 
down-regulated genes is listed in Table 15 and evaluation of the most up-regulated and 
down-regulated genes is shown in Figure 16C. Interestingly, the list of genes dysregulated 
after the knockdown of Loxl2 considerably overlaps with the list of genes dysregulated after 
the knockdown of Loxl1, including the above-mentioned genes Mmp3 and Eln. In summary, 
all three investigated lysyl oxidases: Lox, Loxl1 and Loxl2, appear to possess gene regulatory 
functions, at least in primary mouse lung fibroblasts. Full microarray data sets are available 
through the NCBI Gene Expression Omnibus under accession number GSE89121. 
 
Table 15. List of differentially up- and down-regulated genes after a Loxl2 knockdown 
as assessed by microarray analysis. 
Most up-regulated genes 
n. P (corr) FC Log FC 
Gene 
Symbol Gene name 
      1 0.001122 88.125920 6.461494 Lcn12 lipocalin 12 
2 0.000470 58.468300 5.869583 Akr1c18 aldo-keto reductase family 1, member C18 
3 0.006023 52.552980 5.715701 Derl3 Der1-like domain family, member 3 
4 0.007580 47.481460 5.569293 Gda guanine deaminase 
5 0.000564 43.332340 5.437372 Gdf10 growth differentiation factor 10 
6 0.000994 42.335640 5.403801 Serpina3n serine (or cysteine) peptidase inhibitor, clade A, member 3N 
7 0.011145 38.967970 5.284217 Snhg11 small nucleolar RNA host gene 11 
8 0.001575 38.265700 5.257980 S100a8 S100 calcium binding protein A8 (calgranulin A) 
9 0.000010 
 
34.261340 5.098510 Mmp3 matrix metallopeptidase 3 
10 0.004006 31.428730 4.974012 Bdkrb2 bradykinin receptor, beta 2 
Most down-regulated genes 
n. P (corr) FC Log FC 
Gene 
Symbol Gene name 
      1 0.000472 -143.389000 -7.163790 Ifnb1 interferon beta 1, fibroblast 
2 0.014314 -111.505000 -6.800960 Csf2 colony stimulating factor 2 (granulocyte-macrophage) 
3 0.000671 -108.601000 -6.762890 Cxcl9 chemokine (C-X-C motif) ligand 9 
4 0.016682 -88.868600 -6.473600 Cxcl2 chemokine (C-X-C motif) ligand 2 
5 0.001389 -74.860400 -6.226130 Pydc3 pyrin domain containing 3 
6 0.011893 -63.501600 -5.988720 Traf1 TNF receptor-associated factor 1 
7 0.007118 -57.736200 -5.851410 Cxcl1 chemokine (C-X-C motif) ligand 1 
8 0.003343 -50.206200 -5.649790 Col10a1 collagen, type X, alpha 1 
9 0.002425 -46.784100 -5.547950 Cxcl9 chemokine (C-X-C motif) ligand 9 
10 0.001405 -43.906400 -5.456360 Cxcl10 activated spleen cDNA, RIKEN full-length enriched library 
28 0.000278 -20.349400 -4.346910 Eln elastin 
 
n, number; P(corr), corrected P value; FC, fold change;  
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4.8 Lentiviral overexpression of lysyl oxidase family members impacts the gene 
expression in murine fibroblasts 
Knockdown of Lox, Loxl1 and Loxl2 in primary mouse fibroblasts resulted in changes 
in the expression status of numerous genes. In order to explore whether the overexpression of 
lysyl oxidases has a complementary effect on gene regulation as did the knockdown of lysyl 
oxidases, Lox (Figure 17A-17B), Loxl1 (Figure 17E-17F) and Loxl2 (Figure 17I-17J) were 
overexpressed in murine fibroblasts using a lentivirus transduction approach. A mouse 
NIH/3T3 fibroblast cell-line was used in the overexpression study due to technical difficulties 
concerning a lentiviral transduction in primary lung mouse fibroblasts. Following the 
overexpression of individual lysyl oxidases, the gene expression levels of selected potential 
target-genes that were suggested by microarray analysis were evaluated.  
While both Lce1l and Mmp9 (Figure 16A; Table 13) were identified as Lox 
target-genes by microarray analysis in knockdown studies, only the expression of Lce1l was 
significantly impacted upon Lox overexpression (Figure 17D). The gene expression of Lce1l 
was up-regulated after the siRNA-mediated knockdown of Lox, but decreased after a 
lentiviral over-expression of Lox. In contrast, although the gene expression level of Mmp9 
was notably increased after a knockdown of Lox in primary mouse lung fibroblasts, no 
changes in Mmp9 expression were observed after lentivirus-mediated over-expression of Lox 
in NIH/3T3 cells. It is not yet apparent if the knockdown and over-expression of Lox simply 
do not have the corresponding opposite effects on Mmp9 gene expression or the Lox gene 
regulatory mechanisms are not fully comparable between the primary pulmonary mouse 
fibroblasts and mouse fibroblast cell-line.  
The most dysregulated genes after Loxl1 and Loxl2 siRNA-mediated knockdown were 
largely similar (Figure 16B-16C; Tables 14-15). Interestingly, the same changes in selected 
potential target-genes were also observed after the lentivirus-mediated overexpression of 
Loxl1 (Figure 17G-17H) and Loxl2 (Figure 17J-17K). The mRNA levels of Ifnb and Csf2 
were down-regulated after a siRNA-mediated knockdown of Loxl1 and Loxl2 in primary 
mouse lung fibroblasts. Surprisingly the overexpression of Loxl1 and Loxl2 in the mouse 
NIH/3T3 fibroblast cell-line did not resulted in the corresponding opposite effect. Instead, the 
mRNA levels of both Ifnb (Figure 17G and 17K) and Csf2 (Figure 17H and 17L) were again 
down-regulated after the lentivirus-mediated overexpression of Loxl1 and Loxl2. It is possible 
that both increased and decreased levels of Loxl1 and Loxl2 lead to the same regulation of 
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target-genes and a precise equilibrium of Loxl1 and Loxl2 expression levels is required in 
order to maintain the native transcription status of the target-genes. Alternatively, the 
regulation of gene expression by Loxl1 and Loxl2 is not fully comparable between the 
primary mouse fibroblasts and mouse fibroblasts cell-line.  
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Figure 17. Lentivirus-mediated overexpression of lysyl oxidases in the mouse NIH/3T3 
fibroblast cell-line. 
The overexpression of Lox, Loxl1, and Loxl2 in the mouse NIH/3T3 fibroblast cell-line was 
carried out using a lentivirus transduction system. (A-D) Lentivirus-mediated overexpression 
of Lox. The efficiency of Lox overexpression evaluated by real-time RT-PCR (A) and 
immunoblot (B). Additionally, the expression of selected candidate target-genes of Lox, in 
this case Lce1l (C) and Mmp9 (D) was also evaluated by real-time RT-PCR. (E-H) 
Lentivirus-mediated overexpression of Loxl1. The efficiency of Loxl1 overexpression 
evaluated by real-time RT-PCR (E) and immunoblot (F). The expression of selected 
candidate target-genes of Loxl1, in this case Ifnb (G) and Csf2 (H) was also evaluated by 
real-time RT-PCR. (I-L) Lentivirus-mediated overexpression of Loxl2. The efficiency of 
Loxl2 overexpression evaluated by real-time RT-PCR (I) and immunoblot (J). The expression 
of selected candidate target-genes of Loxl2, in this case Ifnb (K) and Csf2 (L) was also 
evaluated by real-time RT-PCR. Mock-transduced and empty vector (ev)-transduced cells 
served as a control. Immunoblot analyses are representative of total of three experiments. 
Protein loading was controlled by β-ACTIN. Values represent mean ± SD, (n = 3 
over-expression experiments, per group). The P values were determined by one-way 
ANOVA with Tukey’s multiple comparisons test for data containing three experimental 
groups and by unpaired Student’s t-test for data containing two experimental groups. 
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4.9 Role of lysyl oxidase enzymatic activity in lysyl oxidase-mediated gene 
regulation 
In order to assess the importance of the catalytic activity of LOX, LOXL1 and LOXL2 
in gene regulation, the activity of lysyl oxidases was inhibited (by approximately 50%) in 
primary mouse lung fibroblasts using the pan-lysyl oxidase inhibitor BAPN (Figure 18A). 
The inhibition of catalytic activity did not have any influence on the mRNA and protein 
levels of LOX (Figure 18B) and LOXL1 (Figure 18C). However a small, but significant 
increase in LOXL2 (Figure 17D) gene and protein expression after the BAPN treatment of 
the cells was observed.  
Subsequently, potential gene regulatory changes caused by BAPN treatment were 
evaluated by microarray analysis. Full microarray data are available via the NCBI Gene 
Expression Omnibus under accession number GSE89119. Although the siRNA-mediated 
knockdown of Lox, Loxl1 and Lox2 resulted in expression changes of large groups of genes, 
only one significant change, in the gene expression of Lrig2, was detected by microarray 
analysis when enzymatic activity alone was blocked (Table 16). Although the microarray 
analysis identified the Lrig2 gene as a potential target-gene, no changes in gene expression of 
Lrig2 could be validated by real-time RT-PCR (Figure 19), indicating that enzymatic activity 
is not required for lysyl oxidase-mediated transcriptomic regulation in primary mouse lung 
fibroblasts.  
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Figure 18. Inhibition of lysyl oxidase enzymatic activity in primary mouse lung 
fibroblasts. 
Lysyl oxidase enzymatic activity in primary mouse lung fibroblasts was inhibited by 
incubation with 1 mM pan-lysyl inhibitor β-aminpropionitrile (BAPN) for 24 h. (A) Lysyl 
oxidase activity 24 h after the inhibition with BAPN. Activity is reported as the 
BAPN-sensitive fraction determined in the presence of 500 µM BAPN. (B-D) Gene and 
protein expression of LOX (B), LOXL1 (C) and LOXL2 (D) 24 h after the inhibition with 
BAPN were evaluated by real-time RT-PCR and immunoblot respectively. Protein loading 
was controlled by β-ACTIN. Lysyl oxidase activity is reported as relative fluorescence units 
(RFU) ± SD, (n = 3, per group). For real-time RT-PCR analysis values are represented as 
means ± SD, (n = 4 cell cultures, per group). The P values were determined by unpaired 
Student’s t-test. 
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Table 16. List of differentially up- and down-regulated genes after β-aminopropionitrile 
administration in primary mouse lung fibroblasts as assessed by microarray analysis. 
Most up-regulated genes 
n. P (corr) FC Log FC 
Gene 
Symbol Gene name 
      1 0.330047 4.580624 2.195544 Vmn2r121 vomeronasal 2, receptor 121 
2 0.372661 4.273113 2.095287 Cdh18 cadherin 18 
3 0.330047 4.221706 2.077826 Oxct2b 3-oxoacid CoA transferase 2B 
4 0.374076 3.981276 1.993231 Slc15a5 solute carrier family 15, member 5 
5 0.361489 3.976678 1.991564 Gm13043 predicted gene 13043 
6 0.330047 3.974019 1.990599 Defb45 defensin beta 45 
7 0.286779 3.967307 1.988160 Speer7-ps1 spermatogenesis associated glutamate (E)-rich protein 7, pseudogene 1 
8 0.353551 3.959652 1.985374 Gm16532 predicted gene, 16532 
9 0.251624 3.950184 1.981920 Vmn1r181 vomeronasal 1 receptor 181 
10 0.357650 3.864533 1.950294 Gm6507 predicted gene 6507 
Most down-regulated genes 
n. P (corr) FC Log FC 
Gene 
Symbol Gene name 
      1 0.021223 -2.114972 -1.080639 Lrig2 
 
leucine-rich repeats and immunoglobulin-like domains 2 
 2 0.330047 
 
-8.348955 
 
-3.061596 Cd8a 
 
CD8 antigen, alpha chain 
 3 0.334554 
 
-7.988594 
 
-2.997942 Kcnj11 
 
potassium inwardly rectifying channel, subfamily J, member 11 
 4 0.376311 
 
-6.387666 
 
-2.675289 Gsx2 
 
GS homeobox 2 
 5 0.339029 
 
-6.379081 
 
-2.673349 Exph5 
 
exophilin 5 
 6 0.353551 
 
-6.363410 
 
-2.669800 Ahsg 
 
alpha-2-HS-glycoprotein 
 7 0.267413 
 
-6.139747 
 
-2.618179 Pnliprp1 
 
pancreatic lipase related protein 1 
 8 0.330047 
 
-5.818665 
 
-2.540688 Gpa33 
 
glycoprotein A33 (transmembrane) 
 9 0.353559 
 
-5.598395 
 
-2.485013 Svs5 
 
seminal vesicle secretory protein 5 
 10 0.339546 
 
-5.598395 
 
-2.485013 Oaz3 
 
ornithine decarboxylase antizyme 3 
  
n, number; P(corr), corrected P value; FC, fold change;  
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Figure 19. Microarray analysis validation following the β-aminopropionitrile 
administration in primary mouse lung fibroblasts. 
Microarray data presented in Table 16 were validated by real-time RT-PCR. The expression 
of the three most up-regulated and the three most down-regulated genes following 
β-aminopropionitrile (BAPN) administration in primary mouse pulmonary fibroblasts is 
illustrated. Values represent mean ± SD, (n = 4, per group). Statistical analyses were 
determined by unpaired Student’s t-test. P-values > 0.05 were regarded not significant and 
are not illustrated. 
 
4.10 The expression of LOX, LOXL1 and LOXL2 target-genes in a murine 
model of aberrant lung development 
To further evaluate the relevance of the data obtained in the in vitro studies in an 
in vivo setting, the expression of selected LOX, LOXL1 and LOXL2 target-genes was 
investigated in a hyperoxia-based mouse model of BPD. In this model, newborn mouse pups 
were exposed to either normal (21% O2) or hyperoxic (85% O2) environments over the first 
two weeks of life and the expression of selected target genes relevant to ECM formation and 
remodeling was assessed in total RNA pools from lung homogenates. 
The mRNA levels of Lox (Figure 20A), Loxl1 (Figure 21A) and Loxl2 (figure 21B) 
were considerably increased in the lung homogenates from the developing mouse pups 
exposed to hyperoxia (85% O2) when compared with the normally-developing control mice. 
The hyperoxia-induced increase in the expression of lysyl oxidases was generally 
accompanied by the tendencies in the expression of investigated ECM-relevant lysyl oxidases 
target-genes. In accordance with an increased Lox expression, the expression of Mmp9 was 
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decreased, and expression of Rarres1 increased upon exposure of developing mice to 
hyperoxia. These observations in vivo reflect the observations made in vitro, where a 
siRNA-mediated knockdown of Lox in primary mouse lung fibroblasts led to an increase in 
Mmp9 and decrease in Rarres1 gene expression (Figure 15A). Similarly, the gene expression 
level of LOXL1 and LOXL2 target-gene Eln was up-regulated in the lungs of the developing 
mouse pups after a hyperoxia exposure when compared to normoxia-exposed control animals 
(Figure 21D), in an accordance with the down-regulation of Eln expression following the 
Loxl1 and Loxl2 knockdown in primary mouse lung fibroblasts (Figure 16B-C). Contrariwise, 
Mmp3 mRNA levels, which were up-regulated in primary mouse lung fibroblasts after the 
siRNA-mediated knockdown of both Loxl1 and Loxl2, were also increased in vivo in the 
lungs of developing mouse pups exposed to hyperoxia (85% O2)  (Figure 21C). 
In vitro studies in primary mouse lung fibroblasts suggested that enzymatic activity of 
lysyl oxidases was not required for lysyl oxidases-mediated gene regulation. To validate this 
observation in vivo, the catalytic activity of lysyl oxidases was neutralized in 
normally-developing normoxia-exposed mouse pups by pan-lysyl oxidase inhibitor BAPN. 
As expected, the neutralization of enzymatic activity by BAPN did not induce any changes in 
the lung mRNA levels of Lox (Figure 20D), Loxl1 (Figure 21E) or Loxl2 (Figure 21F). 
Consistent with the results of the in vitro experiment, no changes in gene expression of 
Rarres1 (Figure 20F), Mmp3 (Figure 21G) and Eln (Figure 21H) were detected following the 
administration of BAPN to developing mice. Interestingly, the mRNA levels of Mmp9 were 
significantly decreased in the lungs of developing mouse pups treated with BAPN when 
compared to vehicle-treated control animals (Figure 20E), suggesting a possible lysyl 
oxidases-independent mechanism of Mmp9 gene regulation in the lung.   
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Figure 20. Gene expression of Lox and selected LOX target-genes in a mouse model of 
an arrested lung development. 
(A-C) The expression of Lox (A) and selected LOX the target-genes Mmp9 (B) and Rarres1 
(C) was determined by real-time RT-PCR in hyperoxia-based mouse model of 
bronchopulmonary dysplasia (BPD). (D-F) The expression of Lox (D) and the selected LOX 
target-genes Mmp9 (E) and Rarres1 (F) was determined by real-time RT-PCR in the lungs of 
mice treated by β-aminopropionitrile (BAPN). Values represent mean ± SD, (n = 4 animals, 
per group). The P values were determined by unpaired Student’s t-test. 
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Figure 21. Gene expression of Loxl1 and Loxl2, as well as selected LOXL1 and LOXL2 
target-genes in a mouse model of an arrested lung development. 
(A-D) The expression of Loxl1 (A), Loxl2 (B) and the selected LOXL1 and LOXL2 
target-genes Mmp3 (C) and Eln (D) was determined by real-time RT-PCR in well-established 
hyperoxia-based mouse model of bronchopulmonary dysplasia (BPD). (E-H) The expression 
of Loxl1 (D), Loxl2 (E) and LOXL1 and LOXL2 target-genes Mmp3 (F) and Eln (G) was 
determined by real-time RT-PCR in the lungs of mice treated by β-aminopropionitrile 
(BAPN). Values represent mean ± SD, (n = 4 animals, per group). The P values were 
determined by unpaired Student’s t-test. 
 
 
 
98 
 
 
5 DISCUSSION 
 
5.1 The expression of lysyl oxidases is dysregulated in animal models of 
bronchopulmonary dysplasia 
Bronchopulmonary dysplasia poses a substantial cause of morbidity and mortality in 
affected patients often with multiple long-time consequences ongoing into the adulthood [3, 
27, 29, 30, 33-35]. Structurally lungs of patients deceased from BPD are generally 
characterized by arrest in alveolar formation, causing a severe increase in the size of alveoli 
accompanied by a decrease in the size of gas-exchange surface area of the lung and 
thickening of the alveolar septa [27, 32, 120]. Moreover, these lungs exhibit failures in the 
deposition of ECM structures, as well as ECM remodeling and metabolism. Among the most 
severelly impacted ECM structures are fibrillar elastin and collagen [37, 38]. Both, elastin 
and collagen fibers in the lungs of patients diagnosed with BPD, as well as in the lungs 
obtained from various experimental animal models are described as disorganized, thickened 
and misshapen [37, 38, 121-123]. The importance of elastin and collagen formation during 
the course of normal lung development is well known and the role of ECM fibers deposition 
and remodeling in processes of alveolarization and secondary septation has been proposed 
[46, 84]. While multiple studies over the last decades have focused on the expression and 
production of individual structural componenets of ECM, only few studies so far have 
addressed the consequitive processes of fiber deposition and remodeling [4, 46, 96-98].  The 
abnormal formation and deposition of elastin and collagen fibers in the lungs of BPD patients 
and experimental animals has recently been accredited to dysregulation of enzymatic activity 
of multiple matrix-remodeling enzymes. This large family of enzymes include members of 
MMP, TIMP, TGM, PLOD and lysyl oxidase families [46, 70, 73, 76-78, 97, 98].  
Lysyl oxidases form a family of five copper-dependent amine oxidases facilitating the 
oxidative deamination of lysyl and hydroxylysine residues. This process leads to formation of 
reactive semialdehydes and subsequent formation of intramolecular, as well as intermolecular 
covalent cross-links in elastin and collagen molecules [100, 101]. Although increases in the 
abundance and catalytic activity of lysyl oxidases have been reportend in both clinical BPD 
[46], and various experimental animal models of BPD [46, 84, 109], no study so far has 
demonstrated a causal relationship between the expression of lysyl oxidases and disturbances 
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in ECM cross-linking and deposition in the context of arrest in alveolar formation associated 
with BPD. 
Arest in alveolarization and secondary septation in the study presented here was 
introduced by an exposure of newborn mice to hyperoxia (85% O2). Exposure of newborn 
mouse pups to hyperoxia resulted in an increase in the abundance of the first three members 
of the family, Lox, Loxl1 and Loxl2 and elevated lysyl oxidase enzymatic activity in the 
developing lungs, indicating the responsiveness of the lysyl oxidase family members to 
hyperoxia. As expected, exposure of newborn mice to increased concentration of oxygen led 
to an arrest in alveolar formation and considerable thickening of the alveolar walls. This 
structural changes were accompanied by perturbations to collagen and elastin deposition and 
cross-linking, and elastin foci formation. 
 
5.2 Lysyl oxidase activity is essential for early postnatal development 
In order to examine the causal role of lysyl oxidases in the context of ECM 
metabolism and alveolar and septal formation, the catalytic activity of lysyl oxidases was 
inhibited in vivo using a well-described pan-lysyl oxidase inhibitor BAPN. Foremost, the 
pilot study was performed to determine the appropriate dosage. The results of the dosage 
study stressed the importance of lysyl oxidases during the period of early postnatal 
development. Daily administration of BAPN at a dose of 150 mg·kg-1 had a negative impact 
on mouse viability and mobility. Furthermore, both body mass and milk intake of 
BAPN-treated mice were seriously impacted by P5.5 when compared to normally 
developing, vehicle (1×PBS)-injected mice. This observation is in conflict with study, where 
BAPN applied at the same dose was well tolerated in adult mice of the same strain [106]. In 
the said investigation, using a murine model of pulmonary hypertension, BAPN administered 
was not only well tolerated, but led to an improvement in right ventricular systolic pressure 
and matrix architecture in lung vasculature of hypoxia-exposed mice. The results obtained in 
the pilot study are however in agreement with observations made in studies of Lox-/- and 
Loxl1-/- mice.  While Lox-/- mice die shortly after birth from cardiorespiratory failure [58, 
104], Loxl1-/- mice were shown to suffer from aortic aneurism and diaphragmatic hernia, 
[105]. A ten-times lower dose of BAPN, 15 mg·kg-1·day-1, was used in the subsequent 
studies. This dose was found to be efficient enough to preserve the normal levels of lysyl 
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oxidase activity in the lung homogenates of hyperoxia-exposed developing mouse pups 
without causing any negative side-effects regarding the growth, mobility or survival of the 
experimental animals.   
 
5.3 Normalization of lysyl oxidase activity improves the formation of elastin 
and collagen cross-links and elastin foci structure in mouse model of 
bronchopulmonary dysplasia 
Exposure to elevated concentration of oxygen (85% O2) significantly increased the 
quantity of insoluble collagen in the lungs of developing mouse pups. Increase was noted also 
in the DHLNL/HLNL cross-links ratio, a marker of fibrotic status of the tissue [119, 124]. On 
contrary, the level of insoluble elastin was decreased by over 30% in the lungs of 
hyperoxia-exposed developing mouse pups when compared to normoxia-exposed control 
animals. This opposing changes in collagen and elastin abundance resulted in a substantial 
three-fold increase in the collagen-to-elastin ratio. Along with total elastin, the abundance of 
both elastin cross-links, desmosine and isodesmosine was similarly decreased in the 
developing lungs following the hyperoxia-exposure. In addition, the formation of elastin foci 
in the lungs of these animals appeared insufficient and the elastic fibers were disorganized 
and misshapen. A substantial shift in collagen-to-elastin ratio and perturbances in fibers 
structural integrity might suggest the formation of less elastic and therefore stiffer ECM 
network, possibly affecting the lung compliance. Decrease in lung compliance could have a 
negative influence on the role of breathing motions in alveolar formation, possibly leading to 
an arrest in alveolarization and formation of secondary crests in the developing lung [73, 84].  
A decrease in the abundance of lysyl oxidases-generated elastin cross-links in the lungs 
of hyperoxia-exposed animals seems unusual considering the increase of lysyl oxidases 
expression and catalytic activity. Although seemingly contradictory, two possible 
explanations of this phenomenon exist. As lysyl oxidases are active on more than one 
substrate, a dramatic change in collagen-to-elastin ratio may lead to a shift in lysyl oxidases 
substrate homeostasis, recruiting lysyl oxidases primarily to collagen substrate. Such a 
change of substrate preference would make lysyl oxidases less available for elastin 
cross-linking. Additionally, some members of lysyl oxidase family were recently accredited 
with gene regulatory functions, including among others, the regulation of the Eln and Col3a1 
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promoters [113, 114]. It is, thus possible that lysyl oxidases regulate larger number of genes, 
including genes encoding other ECM remodeling elements.  
Further supporting this possibility are the observations made in both normoxia-exposed 
and hyperoxia-exposed animals treated with BAPN, where inhibiton of lysyl oxidase activity 
increased the abundance of elastin cross-links. Daily administration of BAPN partially 
normalized levels of desmosine and isodesmosine in the lungs of hyperoxia-exposed 
developing mice. However, no improvement in total abundance of insoluble elastin could be 
detected. Furthermore, levels of lung insoluble collagen were partially restored and 
DHLNL/HLNL cross-link ratio was normalized. Changes in the abundance of insoluble 
collagen following the BAPN administration also resulted in notable, although not significant 
decrease in collagen-to-elastin ratio, possibly affecting the lung elastic properties. Daily 
administration of BAPN during the period of first 19 days of life has also improved the 
structure and abundance of elastic foci in the lung parenchyma of the hyperoxia-exposed 
animals. It can be speculated that restoration in collagen-to-elastin ratio and DHLNL/HLNL 
ratio, together with improvements in desmosine and isodesmosine abundance in the lungs 
after BAPN administration resulted in improved lung compliance and reduced lung stiffness 
enabling a better formation of elastin fiber network and foci structure. 
 
5.4 Normalization of lysyl oxidase activity does not improve alveolarization and 
septal formation in mouse model of bronchopulmonary dysplasia 
Administration of BAPN to developing hyperoxia-exposed mouse pups positively 
impacted the collagen and elastin cross-linking and elastin foci formation. In regard to these 
findings, the potential beneficial effects of the lysyl oxidase inhibition on the lung 
architecture of hyperoxia-exposed animals were further investigated.  
As expected, lungs structure of the mouse pups exposed to increased oxygen levels 
(85%O2) from the day of birth, for nine days was characterized by thickening of septal walls 
and an arrest in alveolarization associated with a decrease in gas-exchange surface area. 
Appearance of lung structure of hyperoxia-exposed mice daily treated with BAPN was more 
complex by visual inspection when compared to vehicle-treated hyperoxia-exposed animals 
and general trends towards an improvement in septal thickness, surface area, MLI and alveoli 
number were observed when assessed by stereological analysis. However, because none of 
the tendencies observed reached a statistical significance, study was prolonged for an 
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additional ten days. Nevertheless, no further improvements in lung architecture were 
observed in hyperoxia-exposed developing mouse pups after 19 days of BAPN 
administration when compared with vehicle-treated hyperoxia-exposed control animals of the 
same age. 
Interestingly, a small, but significant increase in number of alveoli was observed in the 
lungs of BAPN-treated normoxia-exposed mouse pups when compared to vehicle-treated 
animals, which seems to be in conflict with the observations made in developing rat pups, 
where high doses of BAPN (500 mg·kg-1 every second day) have negatively impacted the 
lung alveolarization [50, 125]. This phenomenon, together with observations regarding the 
septal wall thickness and collagen and elastin cross-linking suggested the existence of a 
fragile equilibrium of expression and enzymatic activity of lysyl oxidases necessary to sustain 
the normal processes of lung alveolarization and ECM formation during early postnatal lung 
development. However, although BAPN administration resulted in the partial normalization 
of collagen abundance and collagen and elastin crosslinking, as well as improved elastin foci 
formation, the data presented here do not encourage BAPN inhibition of lysyl oxidase 
catalytic activity as a therapeutic option.  
 
5.5 Lysyl oxidase family members have gene regulatory roles in lung fibroblasts 
Although recent evidence has emerged suggesting gene regulatory roles for lysyl 
oxidase family members [113-115], studies addressing possible non-matrix roles of lysyl 
oxidases in the lung particularly, or in a context of BPD, has yet not been reported. In the 
present study, the possible non-matrix roles of lysyl oxidases were investigated using a 
microarray approach. 
 Three out of five lysyl oxidase family members: LOX, LOXL1 and LOXL2 were 
investigated. As described earlier, the expression of these three lysyl oxidases was increased 
in lungs of hyperoxia-exposed developing mice, implying a possible role for these members 
of the family in lung development and in the pathogenesis of BPD. Moreover, expression 
profile of Lox, Loxl1 and Loxl2 in different lung primary cell types was considerably more 
diverse than the expression profile of remaining two members of the family. In addition, 
among the cell-types screened the expression levels were highest in pulmonary fibroblasts 
which are largely believed to drive the process of secondary septation [126-128]. In order to 
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explore possible gene regulatory roles, Lox, Loxl1 and Loxl2 expression was silenced in these 
cells using an siRNA-mediated knockdown approach. Subsequent analyses by microarray 
revealed a striking gene regulatory impact of all three lysyl oxidases, causing changes in 
regulation of 134, 3,761 and 3,554 genes, respectively. Multiple of dysregulated genes were 
related to ECM either directly as a source of its structural network or as members of 
ECM-remodeling machinery, including elastin, several collagens and matrix proteinases. 
Interestingly, not only did Loxl1 and Loxl2 exhibited more transcriptional activity than Lox, 
but the pool of the genes regulated by Loxl1 and Loxl2 was largely identical between the two, 
while still distinct from the pool of genes regulated by Lox. This similarity in gene regulatory 
effects of Loxl1 and Loxl2 is extraordinary, because structurally LOXL1 is more similar to 
LOX than to LOXL2 [129]. However, Loxl2 itself was among the genes regulated following 
the siRNA-mediated knockdown of Loxl1 while Loxl2 repression had no such effect on Loxl1 
expression levels. The possibility that genes identified as candidate LOXL1 targets, could be 
simply regulated due to the down-regulation of Loxl2 therefore can not be excluded. On the 
other hand, abrogation of Lox also led to a small decrease in Loxl2 expression, as assessed by 
real-time RT-PCR (but not by microarray), implying that similar pattern might be observed. 
Yet, no potential LOXL2 target-genes were affected after Lox knockdown. Alternatively, a 
certain threshold of Loxl2 may be required in order to induce any transcriptional changes.  
It was hypothesized that complementary regulation of target-genes would occur upon 
the over-expression of lysyl oxidases. However, the lentivirus-mediated over-expression of 
lysyl oxidases in NIH/3T3 cells provided mixed results. For example, while knockdown of 
Lox led to an increase in Lce1l expression, Lox over-expression caused Lce1l 
down-regulation, supporting the hypothesis. However no such complementary effect was 
observed in the case of LOXL1 and LOXL2 top target-genes Ifnb and Csf2 which were 
down-regulated regardless of the down-regulation or over-expression of Loxl1 and Loxl2. It is 
possible, that lysyl oxidases do not perform the same gene regulatory roles in NIH/3T3 
fibroblast cell-line and in primary lung fibroblasts. Alternatively, equilibrium in the lysyl 
oxidases expression might be required for the expression of these genes, and both increased 
and decreased levels of lysyl oxidases leads to the same dysregulation effects.  
Although several reports of transcriptional regulatory roles of lysyl oxidases exist, it is 
not yet obvious whether the catalytic activity is necessary for performing the nuclear 
functions of these enzymes or not. In order to determine the mode of function of lysyl 
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oxidases in gene regulation in pulmonary fibroblasts, the pan-lysyl oxidase enzymatic 
inhibitor BAPN was employed. Interestingly, no changes in gene expression were observed 
when lysyl oxidase catalytic activity was inhibited, suggesting that lysyl oxidases may serve 
rather as a scaffold in a transcription regulation complexes. This observation is further 
supported by other studies, where catalytically-inactive LOXL2 successfully repressed the 
expression of Cdh [111] in context of EMT. Similarly, catalytic activity was not required for 
LOXL2-mediated repression of Clnd1 and Lgl2 expression in modulation of tight junctions 
and cell polarity [130].  
 
5.6 Gene regulatory functions for lysyl oxidases in the context of in vivo animal 
model of bronchopulmonary dysplasia 
In order to confirm the observations made in vitro, in the more complex situation 
in vivo, the regulation of expression of potential ECM-relevant target genes of lysyl oxidases 
was explored in an animal model of BPD. Hyperoxia-exposure of newborn mouse pups from 
the day of birth drived a considerable increase in lysyl oxidase expression and enzymatic 
activity. Three out of four genes investigated because of their importance to ECM 
metabolism, Rarres1, Mmp9 and Eln were dysregulated after hyperoxia-exposure in line with 
the regulation observed in vitro after a siRNA-mediated knock-down of lysyl oxidases. For 
example Mmp9 expression was down-regulated when Lox expression was silenced in primary 
lung fibroblasts, but up-regulated when assessed in the lungs of hyperoxia-exposed mice in 
vivo. Similarly Eln expression, which was down-regulated after the knockdown of both Loxl1 
and Loxl2 in vitro, was increased in animals after a hyperoxia-exposure, suggesting a 
correlation between the in vivo and in vitro studies. Moreover, when the lysyl oxidase 
enzymatic inhibitor BAPN was applied to normally developing mice, no effect on gene 
expression was observed in three out of four investigated genes, supporting the hypothesis 
that catalytic activity is not always required for lysyl oxidases in order to carry out the 
regulatory functions.  
In the light of this observation, it is interesting to note, that changes observed in the 
abundance of collagen and elastin, as well as the elastin and collagen crosslinks in the lungs 
of hyperoxia-exposed mice may be partially driven by nuclear activities of lysyl oxidases. For 
example, a total amount of insoluble lung collagen was significantly decreased in lungs of 
hyperoxia-exposed mice, when mice were also treated with BAPN, possibly suggesting a 
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connection between lysyl oxidase activity and collagen expression rather than collagen 
stability. However, no similar phenomenon was observed in the case of normoxia-exposed 
BAPN-treated mice, where insoluble collagen levels were not affected. 
 The notion of the potential catalytic activity-independent gene regulatory functions 
for lysyl oxidases is of great relevance in the translational sense. A large amount of genes 
involved in ECM deposition or metabolism was dysregulated upon a Lox, Loxl1 and Loxl2 
knockdown in pulmonary fibroblasts. Selected ECM-related target-genes of LOX, LOXL1 
and LOXL2 were also accordingly dysregulated in an in vivo hyperoxia-based mouse model 
of BPD. It therefore seems likely, that gene regulatory function of lysyl oxidases in major 
fibrogenic cells in the developing lung could contribute to the pathogenesis of BPD. 
Furthermore, the gene expression of the majority of the investigated target-genes was not 
effected by BAPN administration to the developing mouse pups. First efforts have already 
been made towards the use of pharmacological inhibition of lysyl oxidases in fibrosis and 
cancer [131], as well as pulmonary hypertension [106]. It is possible that the gene regulation 
by lysyl oxidases could be involved in the pathogenesis of these diseases. However, if the 
regulation of the gene expression would be independent of enzymatic activity, potential 
advantage of targeting lysyl oxidases in the context of the pathogenesis of the disease would 
be missed when only the catalytic activity of the protein would be neutralized. 
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6 CONCLUSIONS 
 
Bronchopulmonary dysplasia (BPD) is a chronic lung disease of premature infancy, 
characterized mainly by an arrest in alveolarization and aberrant pulmonary microvascular 
development. The pathogenic pathways driving BPD include physical forces, inflammation, 
altered gene expression programs, cell-to-cell communication and extracellular matrix (ECM) 
deposition and remodeling. Deregulation of lysyl oxidases, a five-member family of collagen 
and elastin cross-linking enzymes, was reported in both BPD and experimental animal 
models of BPD. Although, a number of studies have suggested a role for lysyl oxidases in the 
pathogenesis of BPD, the causal role for lysyl oxidases in aberrant elastin and collagen 
formation has not yet been fully studied. In addition, nuclear, gene regulatory roles for lysyl 
oxidases have been recently proposed. However no study addressing the non-matrix related 
roles of lysyl oxidases in context of lung development or BPD exists.  
The study presented here describes a successful neutralization of lysyl oxidases catalytic 
activity in an in vivo murine model of BPD. Daily administration of β-aminopropionitrile, an 
inhibitor of lysyl oxidases activity, led to the restoration of normal levels of collagen in the 
lungs of diseased animals. Similarly, the abundance of elastin cross-links was restored and 
formation of elastin foci was improved. However no improvement in lung structure was 
found. Furthermore, the possible non-matrix nuclear roles of three lysyl oxidase family 
members: Lox, Loxl1 and Loxl2 were explored in the primary mouse pulmonary fibroblasts. 
The present study revealed a catalytic activity-independent, lysyl oxidases-mediated gene 
regulation of numerous genes, including genes implicated in ECM metabolism, such as 
Mmp3, Mmp9, Rarres1 or Eln. 
In summary, data presented here support the role of lysyl oxidases in ECM stability and 
pathogenesis of BPD. In addition the present study describes, for the first time, a 
transcriptome-wide analysis of gene regulatory effects of Lox, Loxl1 and Loxl2 in primary 
murine lung fibroblasts, independent from their catalytic activity. 
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ABSTRACT 
 
The emergence of microRNA as regulators of organogenesis and tissue differentiation has 
stimulated interest in the ablation of microRNA expression and function during discrete 
periods of development. To this end, inducible, conditional modulation of microRNA 
expression with doxycycline-based tetracycline-controlled transactivator and tamoxifen-based 
estrogen receptor systems has found widespread use. However, the induction agents and 
components of genome recombination systems negatively impact pregnancy, parturition, and 
post-natal development; thereby limiting the use of these technologies between late gestation 
and the early post-natal period. An alternative means of regulating microRNA expression and 
function is described here: the maternal-placental-fetal transmission of microRNA 
antagomiRs, which, when administered to pregnant dams results in a pronounced and 
persistent reduction in steady-state microRNA levels in the heart, kidney, liver and lungs, and 
to a very limited extent, the brain. This effect was comparable to direct injection of newborn 
mouse pups with antagomiRs. Furthermore, depletion of steady-state microRNA levels via the 
maternal route resulted in concomitant increases in steady-state levels of microRNA targets.  
This novel methodology permits the temporal regulation of microRNA function during late 
gestation and in neonates, without recourse to conventional approaches that rely on 
doxycycline and tamoxifen, which may confound studies on developmental processes. 
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of lung ﬁbroblasts
Ivana Mižíková,1,2 Francesco Palumbo,1,2 Tamás Tábi,3 Susanne Herold,2 István Vadász,2
Konstantin Mayer,2 Werner Seeger,1,2 and Rory E. Morty1,2
1Department of Lung Development and Remodelling, Max Planck Institute for Heart and Lung Research, Bad Nauheim,
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Mižíková I, Palumbo F, Tábi T, Herold S, Vadász I, Mayer K,
Seeger W, Morty RE. Perturbations to lysyl oxidase expression
broadly inﬂuence the transcriptome of lung ﬁbroblasts. Physiol
Genomics 49: 416–429, 2017. First published July 10, 2017; doi:
10.1152/physiolgenomics.00026.2017.—Lysyl oxidases are credited
with pathogenic roles in lung diseases, including cancer, ﬁbrosis,
pulmonary hypertension, congenital diaphragmatic hernia, and bron-
chopulmonary dysplasia (BPD). Lysyl oxidases facilitate the covalent
intra- and intermolecular cross-linking of collagen and elastin ﬁbers,
thereby imparting tensile strength to the extracellular matrix (ECM).
Alternative ECM-independent roles have recently been proposed for
lysyl oxidases, including regulation of growth factor signaling, chro-
matin remodeling, and transcriptional regulation, all of which impact
cell phenotype. We demonstrate here that three of the ﬁve lysyl
oxidase family members, Lox, Loxl1, and Loxl2, are highly expressed
in primary mouse lung ﬁbroblasts compared with other constituent
cell types of the lung. Microarray analyses revealed that small inter-
fering RNA knockdown of Lox, Loxl1, and Loxl2 was associated with
apparent changes in the expression of 134, 3,761, and 3,554 genes,
respectively, in primary mouse lung ﬁbroblasts. The impact of lysyl
oxidase expression on steady-state Mmp3, Mmp9, Eln, Rarres1,
Gdf10, Ifnb1, Csf2, and Cxcl9 mRNA levels was validated, which is
interesting, since the corresponding gene products are relevant to lung
development and BPD, where lysyl oxidases play a functional role. In
vivo, the expression of these genes broadly correlated with Lox, Loxl1,
and Loxl2 expression in a mouse model of BPD. Furthermore,
-aminopropionitrile (BAPN), a selective lysyl oxidase inhibitor, did
not affect the steady-state mRNA levels of lysyl oxidase target genes,
in vitro in lung ﬁbroblasts or in vivo in BAPN-treated mice. This
study is the ﬁrst to report that lysyl oxidases broadly inﬂuence the cell
transcriptome.
bronchopulmonary dysplasia; ﬁbroblast; lung; lysyl oxidase; tran-
scriptome
LYSYL OXIDASES ARE a family of copper-dependent amine oxi-
dases with acknowledged roles in the cross-linking of the
extracellular matrix (ECM) (20). These activities are under-
taken by ﬁve different family members, namely LOX, the ﬁrst
described member of the family, as well as the LOX-like
enzymes, LOXL1, LOXL2, LOXL3, and LOXL4 (11, 28). All
ﬁve lysyl oxidases have a common COOH-terminal catalytic
domain that undertakes the oxidative deamination of the ε-amino
groups of lysine and hydroxylysine residues in collagen and
elastin, which facilitate intra- and intermolecular cross-linking,
and thus imparts tensile strength to the ECM (32, 47). The ﬁve
lysyl oxidases exhibit substantial structural heterogeneity in the
NH2-terminal regions, which is thought to confer functional spec-
iﬁcity to each members of the family (11, 28).
Lysyl oxidases are important mediators of both organogenesis
and tissue remodeling during disease and have emerged as key
mediators of lung development and pathophysiology in particular.
Of the ﬁve family members, LOX (5, 17, 29, 30), LOXL1 (24),
and LOXL3 (49) all play a functional role in the development of
the respiratory tract, in early and late phases of lung development.
Regarding lung pathophysiology, lysyl oxidases are implicated in
adult lung diseases including lung ﬁbrosis (4), pulmonary hyper-
tension (37, 51), and lung cancer (40), leading to lysyl oxidases
being considered candidate therapeutic targets for a spectrum of
lung and other diseases (41, 45). Given the pivotal roles played by
lysyl oxidases in lung development, deregulation of lysyl oxidase
activity disturbs lung maturation, and consequently, lysyl oxidases
have been implicated in congenital diaphragmatic hernia (46), as
well as in clinical (21) and experimental (6–8, 16, 21, 33, 34)
bronchopulmonary dysplasia (BPD), a common complication of
preterm birth where the late phases of lung development are
stunted. In general, physiological and pathological roles for lysyl
oxidases in the lung have been related to ECM assembly, matu-
ration, and metabolism.
Apart from lysyl oxidase effects on the ECM, several studies
have highlighted “nonmatrix” roles for lysyl oxidases, which
include the modulation of intracellular signaling and transcrip-
tional regulation. Concerning cell signaling, by virtue of catalytic
activity, lysyl oxidases can modulate growth factor activity, such
as that of basic ﬁbroblast growth factor (23) and transforming
growth factor- (3), thereby inﬂuencing cell signaling, and cell
properties such as proliferation, differentiation, and migration.
Furthermore, the LOX propeptide inhibits vascular smooth mus-
cle cell proliferation, ostensibly by inhibiting ERK1/2 phosphor-
ylation in response to tumor necrosis factor- (18).
Address for reprint requests and other correspondence: R. E. Morty,
Dept. of Lung Development and Remodelling, Max Planck Inst. for Heart
and Lung Research, Parkstr. 1, D-61231 Bad Nauheim, Germany (e-mail:
rory.morty@mpi-bn.mpg.de).
Physiol Genomics 49: 416–429, 2017.
First published July 10, 2017; doi:10.1152/physiolgenomics.00026.2017.
1094-8341/17 Copyright © 2017 the American Physiological Society416
Downloaded from www.physiology.org/journal/physiolgenomics by ${individualUser.givenNames} ${individualUser.surname} (194.094.244.250) on February 12, 2018.
Copyright © 2017 American Physiological Society. All rights reserved.
RESEARCH ARTICLE
Stereological monitoring of mouse lung alveolarization from the early
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Pozarska A, Rodríguez-Castillo JA, Surate Solaligue DE, Nto-
kou A, Rath P, Mižíková I, Madurga A, Mayer K, Vadász I,
Herold S, Ahlbrecht K, Seeger W, Morty RE. Stereological mon-
itoring of mouse lung alveolarization from the early postnatal period
to adulthood. Am J Physiol Lung Cell Mol Physiol 312: L882–L895,
2017. First published March 17, 2017; doi:10.1152/ajplung.00492.
2016.—Postnatal lung maturation generates a large number of small
alveoli, with concomitant thinning of alveolar septal walls, generating
a large gas exchange surface area but minimizing the distance tra-
versed by the gases. This demand for a large and thin gas exchange
surface area is not met in disorders of lung development, such as
bronchopulmonary dysplasia (BPD) histopathologically characterized
by fewer, larger alveoli and thickened alveolar septal walls. Diseases
such as BPD are often modeled in the laboratory mouse to better
understand disease pathogenesis or to develop new interventional
approaches. To date, there have been no stereology-based longitudinal
studies on postnatal mouse lung development that report dynamic
changes in alveoli number or alveolar septal wall thickness during
lung maturation. To this end, changes in lung structure were quanti-
ﬁed over the ﬁrst 22 mo of postnatal life of C57BL/6J mice. Alveolar
density peaked at postnatal day (P)39 and remained unchanged at 9
mo (P274) but was reduced by 22 mo (P669). Alveoli continued to be
generated, initially at an accelerated rate between P5 and P14, and at
a slower rate thereafter. Between P274 and P669, loss of alveoli was
noted, without any reduction in lung volume. A progressive thinning
of the alveolar septal wall was noted between P5 and P28. Pronounced
sex differences were observed in alveoli number in adult (but not
juvenile) mice, when comparing male and female mouse lungs. This
sex difference was attributed exclusively to the larger volume of male
mouse lungs.
THE ALVEOLUS is the primary gas exchange unit of the lung, ﬁrst
described by Marcello Malpighi in 1661 (29, 30). The forma-
tion and maturation of alveoli occur during the ﬁnal phase of
lung development, where the process of secondary septation
generates alveolar septa that subdivide the primitive sacculi
and generate the walls of the mature alveoli (5, 49). This
process generates a large number of small alveoli, thus impart-
ing a large gas exchange surface area to the lung and occurs
concomitantly with the thinning of the alveolar walls, to
minimize the distance traversed by gases during gas exchange.
Despite much consideration over the past 100 years, how
lung alveoli develop remains poorly understood. As early as
1881, Albert von Kölliker at the University of Würzburg
(Würzburg, Germany) suggested that the structure of the adult
lung was already present in newborn infants, and growth
proceeded exclusively by expansion (23). This view was coun-
tered by the German anatomist Robert Heiss in 1919 (12) and
by the Swedish anatomist Ivar Broman in 1923 (4), who both
suggested that in mammals, the number of alveoli in the lung
continued to increase after birth. The latter idea was validated
by Herbert Willson in 1928 (64), who demonstrated that infant
mouse and human lungs had both fewer and larger alveoli and
more connective tissue “between the airspaces” (i.e., thicker
septa) than did corresponding adult lungs of both species. Thus
Willson captured the concept of late lung development and the
process of alveolarization, namely, the generation of a large
gas exchange surface area and thinning of the alveolar septal
walls. The exponential growth of alveoli in human lungs in
utero was subsequently documented in the 1960s, when a
quantitative increase in alveolar density in lungs from 28 wk to
40 wk gestation in humans was demonstrated (8), as was the
fact that preterm birth leads to fewer alveoli in the infant lung
(32). Building on these studies, Dunnill (7) demonstrated a
10-fold increase in the number of alveoli in the human lung
between birth and adult life, occurring primarily over the ﬁrst
8 years of life (7). Later, researchers estimated that the adult
human lung harbored ~300 million alveoli (57), a number later
revised to 480 million (45). Subsequent studies demonstrated
the exponential generation of alveoli in humans over the ﬁrst
two years of life, after which alveoli continue to be generat-
ed—at a reduced rate—into adolescence (13). Alveolar growth
has also been studied in mice and rats (2, 5, 6); the rat lung also
demonstrated a biphasic growth pattern, with a period of bulk
alveolarization in the early postnatal period (day 4 to day 21 in
rats), followed by a period of late or “continued” alveolariza-
tion up to day 60 (59), with the number of acini remaining
constant (3).
Variance in the experimental methodologies applied—in-
cluding tissue processing, sampling, and analyses—have led to
a broad range in the total number of alveoli in the lung being
reported in humans, as well as in rodent models. In response to
this, concomitant with advances in our knowledge of lung
development, the past decade has seen tremendous advances in
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Abstract Bronchopulmonary dysplasia (BPD) is the most
common complication of preterm birth, with appreciable mor-
bidity and mortality in a neonatal intensive care setting. Much
interest has been shown in the identification of pathogenic
pathways that are amenable to pharmacological manipulation
(1) to facilitate the development of novel therapeutic and med-
ical management strategies and (2) to identify the basic mech-
anisms of late lung development, which remains poorly un-
derstood. A number of animal models have therefore been
developed and continue to be refined with the aim of recapit-
ulating pathological pulmonary hallmarks noted in lungs from
neonates with BPD. These animal models rely on several in-
jurious stimuli, such as mechanical ventilation or oxygen tox-
icity and infection and sterile inflammation, as applied in
mice, rats, rabbits, pigs, lambs and nonhuman primates. This
review addresses recent developments in modeling BPD in
experimental animals and highlights important neglected
areas that demand attention. Additionally, recent progress in
the quantitative microscopic analysis of pathology tissue is
described, together with new in vitro approaches of value for
the study of normal and aberrant alveolarization. The need to
examine long-term sequelae of damage to the developing neo-
natal lung is also considered, as is the need to move beyond
the study of the lungs alone in experimental animal models of
BPD.
Keywords Bronchopulmonary dysplasia . Animal model .
Hyperoxia . Ventilation .Mouse
Introduction
The lung is the key organ of gas exchange in mammals; it
undertakes the transport of oxygen from inspired air into the
bloodstream and, concomitantly, the transport of carbon diox-
ide out of the circulating blood, which is subsequently exhaled
and thus removed from the body. This gas exchange is facil-
itated by the highly organized structure of the alveolus, the
gas-exchange unit of the lung, where the inspired air is
brought into close proximity to the circulating blood (Hsia
et al. 2016). The close proximity of air and blood is facilitated
by the delicate alveolo-capillary barrier, a double-layered bar-
rier consisting of alveolar epithelial cells that line the alveolar
units containing the inspired air and that are intimately asso-
ciated with the endothelial cells that form the capillaries of the
pulmonary circulation carrying deoxygenated blood through
the lung (Hsia et al. 2016). The blood-air barrier is very thin,
namely 200 nm–2 μm and is permeable to many gases includ-
ing oxygen and carbon dioxide, thus facilitating gas exchange.
Gas exchange occurs by Fick’s Law (Fick 1855) and is a
passive process that is directly determined by (1) the surface
area available over which the gases can diffuse, (2) the dis-
tance across which the gas molecules must diffuse and (3) the
concentration gradient. The broader objective of lung devel-
opment is to generate a gas-exchange structure that satisfies
these three conditions. The structure should have a large sur-
face area and a thin diffusion barrier and should facilitate the
establishment of a steep concentration gradient for gas diffu-
sion in the correct direction. To this end, lung development is
initiated with the emergence of the respiratory diverticulum,
which is a ventral outgrowth of the foregut endoderm, very
* Rory E. Morty
rory.morty@mpi-bn.mpg.de
1 Department of Lung Development and Remodelling, Max Planck
Institute for Heart and Lung Research, Parkstrasse 1, 61231 Bad
Nauheim, Germany
2 Department of Internal Medicine (Pulmonology), University of
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Standardisation of oxygen exposure in the development of mouse
models for bronchopulmonary dysplasia
Claudio Nardiello1,2, IvanaMižıḱová1,2, DiogoM. Silva1,2, Jordi Ruiz-Camp1,2, Konstantin Mayer2, István Vadász2,
Susanne Herold2, Werner Seeger1,2 and Rory E. Morty1,2,*
ABSTRACT
Progress in developing new therapies for bronchopulmonary dysplasia
(BPD) is sometimes complicated by the lack of a standardised animal
model. Our objective was to develop a robust hyperoxia-based mouse
model of BPD that recapitulated the pathological perturbations to lung
structure noted in infants with BPD. Newborn mouse pups were
exposed to a varying fraction of oxygen in the inspired air (FiO2) and a
varying window of hyperoxia exposure, after which lung structure was
assessed by design-based stereology with systemic uniform random
sampling. The efficacy of a candidate therapeutic intervention using
parenteral nutrition was evaluated to demonstrate the utility of the
standardised BPDmodel for drug discovery. AnFiO2 of 0.85 for the first
14 days of life decreased total alveoli number and concomitantly
increased alveolar septal wall thickness, which are two key
histopathological characteristics of BPD. A reduction in FiO2 to 0.60
or 0.40 also caused a decrease in the total alveoli number, but the
septal wall thickness was not impacted. Neither a decreasing oxygen
gradient (from FiO2 0.85 to 0.21 over the first 14 days of life) nor an
oscillation in FiO2 (between 0.85 and 0.40 on a 24 h:24 h cycle) had an
appreciable impact on lung development. The risk ofmissing beneficial
effects of therapeutic interventions at FiO2 0.85, using parenteral
nutrition as an intervention in the model, was also noted, highlighting
the utility of lower FiO2 in selected studies, and underscoring the need
to tailor the model employed to the experimental intervention. Thus,
a state-of-the-art BPD animal model that recapitulates the two
histopathological hallmark perturbations to lung architecture
associated with BPD is described. The model presented here, where
injurious stimuli have been systematically evaluated, provides a most
promising approach for the development of new strategies to drive
postnatal lung maturation in affected infants.
KEY WORDS: BPD, Hyperoxia, Alveolarisation, Structure, Animal
model
INTRODUCTION
Precise modelling of human disease using animal models is a major
challenge in translating bench science to the bedside, as (1) animal
models must accurately recapitulate disease processes to facilitate
the identification of pathogenic pathways, and (2) animal models
represent the limiting step in assessing which therapeutic
interventions hold promise for subsequent study. This is
particularly evident in animal models of human diseases that are
characterised by perturbations to the architecture of an organ.
Modelling disease pathogenesis in experimental animals is
problematic from multiple perspectives. Amongst these, the
injurious insult employed in the experimental model might not
recapitulate key elements of disease, thereby limiting the ability to
evaluate the efficacy of candidate therapeutic agents. Furthermore,
the precision of the readout that is employed might be inadequate to
detect small changes in anatomical structures that are targeted
by both the injurious insult and candidate therapeutic intervention.
A further confounding variable is the use of experimental animals in
medical research, as emphasis must be placed on ‘reduction,
refinement and replacement’ (the 3R concept) (Curzer et al., 2016),
where the number of experimental animals employed and the level
of stress to which the animal is subjected must be maintained at the
minimum level possible, while still retaining the translational
viability of the animal model.
Modelling bronchopulmonary dysplasia (BPD) in experimental
animals is a textbook illustration of these concerns. BPD is the most
common complication of preterm birth and represents significant
morbidity and mortality in the neonatal intensive care unit (Jobe,
2011; Jobe and Tibboel, 2014). BPD is caused by a combination of
the toxic effects of oxygen supplementation used to manage
respiratory failure in preterm infants, baro- and volu-trauma from
mechanical ventilation (Greenough et al., 2008), as well as other
disease-modifying variables such as infection and inflammation
(Balany and Bhandari, 2015). BPD results in long-term
complications in respiratory function that persist into adulthood
(Hilgendorff and O’Reilly, 2015). The pathology of BPD has
changed over time; where ‘old’ BPD, which is particularly
characterised by fibrosis, thickened septa and some alveolar
simplification, results from aggressive mechanical ventilation with
high oxygen levels. In contrast, ‘new’ BPD, which is the prevalent
form today, is largely characterised by alveolar simplification,
where preterm infants are less aggressively ventilated, with lower
oxygen levels (Jobe, 2011). As a result of improvements in the
medical management of BPD, the incidence of BPD is increasing
because preterm infants delivered earlier have increasingly
improved survival (Stoll et al., 2015). This underscores a pressing
need to develop new medical management strategies. However,
these efforts might be hampered by the lack of appropriate animal
models of BPD. In affected individuals, two key elements of the
lung structure are impacted: the oxygen supplementation arrests
lung development, which causes fewer alveoli of a larger size to be
generated. Concomitantly, the thickness of the delicate barrier
between the alveolar airspaces in the lung and the capillary network
of the lung is thickened, which compromises gas exchange, and isReceived 9 July 2016; Accepted 24 November 2016
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BACKGROUND: Caﬀeine is widely used to manage apnea 
of prematurity, and reduces the incidence of bronchopulmo-
nary dysplasia (BPD). Deregulated transforming growth factor 
(TGF)-β signaling underlies arrested postnatal lung maturation 
in BPD. It is unclear whether caﬀeine impacts TGF-β signaling 
or postnatal lung development in aﬀected lungs.
METHODS: The impact of caﬀeine on TGF-β signaling in pri-
mary mouse lung ﬁbroblasts and alveolar epithelial type II 
cells was assessed in vitro. The eﬀects of caﬀeine administra-
tion (25 mg/kg/d for the ﬁrst 14 d of postnatal life) on aberrant 
lung development and TGF-β signaling in vivo was assessed in 
a hyperoxia (85% O
2
)-based model of BPD in C57BL/6 mice.
RESULTS: Caﬀeine downregulated expression of type I and 
type III TGF-β receptors, and Smad2; and potentiated TGF-β sig-
naling in vitro. In vivo, caﬀeine administration normalized body 
mass under hyperoxic conditions, and normalized Smad2 
phosphorylation detected in lung homogenates; however, 
caﬀeine administration neither improved nor worsened lung 
structure in hyperoxia-exposed mice, in which postnatal lung 
maturation was blunted.
CONCLUSION: Caﬀeine modulated TGF-β signaling in vitro 
and in vivo. Caﬀeine administration was well-tolerated by new-
born mice, but did not inﬂuence the course of blunted postna-
tal lung maturation in a hyperoxia-based experimental mouse 
model of BPD.
Caffeine is a member of the methylxanthine class of cen-tral nervous system stimulants, which along with amino-
phylline and theophylline are nonspecific antagonists of the 
adenosine receptor (at low concentrations) and inhibitors of 
phosphodiesterases (at higher concentrations). Aminophylline 
was proposed for the treatment of Cheyne-Stokes respiration 
by the Austrian physician Alfred Vogl in 1927 (1) and was first 
used to treat apnea of prematurity in 1973 (2), which remains 
the indication for caffeine administration in a neonatal inten-
sive care setting. Since then, the utility of caffeine in preterm 
infants has been the subject of intense study, due to the lower 
toxicity of caffeine compared with other methylxanthines (3). 
Aranda et al. (4) first administered caffeine for apnea of pre-
maturity in 1977, and this idea culminated in the Caffeine for 
Apnea of Prematurity (CAP) trial, where caffeine therapy ini-
tiated during the first 10 d of life decreased the incidence of 
bronchopulmonary dysplasia (BPD) and decreased the dura-
tion of mechanical ventilation in infants weighing 500–1,250 g 
at birth (5). The major reason that caffeine reduces BPD is 
by reducing apnea and increasing respiratory drive, thereby 
reducing ventilation-induced lung injury (5). Subsequent 
studies have highlighted that caffeine therapy also leads to 
improved long-term neurodevelopmental outcome in affected 
patients (6), and that the timing of caffeine therapy was impor-
tant, where early initiation of caffeine therapy (within the first 
3 d of life) may be of more benefit than late caffeine therapy (7).
The ability of caffeine to influence the course of aberrant 
lung development that occurs in patients with BPD is less well 
understood (8). Blunted secondary septation leading to an 
arrest of alveolar development is a histopathological character-
istic of the lungs of infants with BPD. Thus, it is of interest to 
know whether caffeine may impact postnatal lung maturation 
in general, and alveolarization in particular. It has been dem-
onstrated in vitro that caffeine has concentration-dependent 
effect on cell-cycle progression and cell viability in MLE-12 
mouse lung and A549 human lung epithelial cell-lines, in the 
background of hyperoxia (9). Furthermore, in vivo, caffeine 
application to newborn FVB/n mice worsened lung hypoplasia 
in a hyperoxia-based model of BPD, and this was accompanied 
by increased epithelial cell apoptosis, and loss of alveolar type 
II (ATII) cells (10). These two reports indicated a deleterious 
impact of caffeine in BPD animal models. In contrast, caffeine 
application to 6-d old rats blunted the inflammatory response 
provoked by hyperoxia, limiting proinflammatory cytokine 
expression and inflammatory cell infiltration into the lung 
(11). This study thus indicated a potential benefit of caffeine 
application in experimental BPD; however, lung structure was 
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Caffeine administration modulates TGF-β signaling but does 
not attenuate blunted alveolarization in a hyperoxia-based 
mouse model of bronchopulmonary dysplasia
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Madurga A, Golec A, Pozarska A, Ishii I, Mižíková I, Nardiello
C, Vadász I, Herold S, Mayer K, Reichenberger F, Fehrenbach H,
Seeger W, Morty RE. The H2S-generating enzymes cystathionine
-synthase and cystathionine -lyase play a role in vascular develop-
ment during normal lung alveolarization. Am J Physiol Lung Cell Mol
Physiol 309: L710–L724, 2015. First published July 31, 2015;
doi:10.1152/ajplung.00134.2015.—The gasotransmitter hydrogen sul-
ﬁde (H2S) is emerging as a mediator of lung physiology and disease.
Recent studies revealed that H2S administration limited perturbations
to lung structure in experimental animal models of bronchopulmonary
dysplasia (BPD), partially restoring alveolarization, limiting pulmo-
nary hypertension, limiting inﬂammation, and promoting epithelial
repair. No studies have addressed roles for endogenous H2S in lung
development. H2S is endogenously generated by cystathionine -syn-
thase (Cbs) and cystathionine -lyase (Cth). We demonstrate here that
the expression of Cbs and Cth in mouse lungs is dynamically regu-
lated during lung alveolarization and that alveolarization is blunted in
Cbs/ and Cth/ mouse pups, where a 50% reduction in the total
number of alveoli was observed, without any impact on septal thick-
ness. Laser-capture microdissection and immunoﬂuorescence staining
indicated that Cbs and Cth were expressed in the airway epithelium
and lung vessels. Loss of Cbs and Cth led to a 100–500% increase in the
muscularization of small- and medium-sized lung vessels, which was
accompanied by increased vessel wall thickness, and an apparent de-
crease in lung vascular supply. Ablation of Cbs expression using small
interfering RNA or pharmacological inhibition of Cth using propargylg-
lycine in lung endothelial cells limited angiogenic capacity, causing a
30–40% decrease in tube length and a 50% decrease in number of tubes
formed. In contrast, exogenous administration of H2S with GYY4137
promoted endothelial tube formation. These data conﬁrm a key role for
the H2S-generating enzymes Cbs and Cth in pulmonary vascular devel-
opment and homeostasis and in lung alveolarization.
lung development; gasotransmitter; hydrogen sulﬁde; H2S; alveolar-
ization
THE FORMATION OF THE ALVEOLAR gas exchange units occurs
during late lung development and results in the generation of a
thin alveolo-capillary barrier with a large surface area, repre-
senting an optimal interface for gas exchange (11, 22). The
processes that drive the formation of alveoli remain poorly
understood and are believed to involve the concerted action of
transcription factors, growth factors, the lung extracellular matrix,
and physical forces such as breathing motions (42). There is
currently much interest in better understanding what factors reg-
ulate formation of alveoli and how these factors act (17). In
addition to providing a better understanding of the complex
process of alveolarization, this might reveal pathways that can be
targeted in an effort to drive alveolar formation in pathologies
such as bronchopulmonary dysplasia (BPD), where alveolariza-
tion is blocked, or emphysema (49), where driving neoalveolar-
ization in diseased lungs would be desirable (16, 34).
One novel group of candidate mediators of lung develop-
ment and homeostasis is the endogenous gasotransmitters,
which comprises hydrogen sulﬁde (H2S), nitric oxide (NO),
and carbon monoxide (CO) (41). Both CO and H2S have
recently been implicated in lung alveolarization. CO and the
CO-generating enzyme hemeoxygenase-1 (Hmox1) are vascu-
loprotective (10) in a popular rodent model of BPD (5, 25).
Two recent reports have also indicated that H2S may play an
important role in late lung development. Both of these studies
have relied on the exogenous application of chemical donors of
H2S in the same hyperoxia-based rodent models of BPD. The
Thébaud group (40) ﬁrst documented that exogenous H2S
administration protected rat pups against the injurious effects
of hyperoxia exposure, namely, alveolar growth was improved
and pulmonary hypertension was limited. Building on those
studies, our group subsequently demonstrated that exogenous
H2S administration partially restored alveolar growth in hyper-
oxia-exposed mouse pups, stimulated epithelial wound repair,
and dramatically limited macrophage, neutrophil, and eosino-
phil recruitment to the lungs, possibly through the normaliza-
tion of interleukin (IL)-10 levels (18). Particularly intriguing
was the observation that H2S administration to healthy, nor-
mally developing lungs also increased the total number of
alveoli in the lung. H2S is also known to modulate alveolar ion
and ﬂuid transport (9), which is disturbed in BPD patients;
however, this aspect has not yet been explored in experimental
BPD. Together, these data document that exogenous H2S can
improve alveolarization.
All of the aforementioned reports have examined exogenous
H2S application, largely in diseased lungs. However, mamma-
lian lungs do have the capacity to generate H2S endogenously,
primarily via two enzymatic systems: cytosolic cystathionine
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The Extracellular Matrix in 
Bronchopulmonary Dysplasia: Target 
and Source
Ivana Mižíková1,2 and Rory E. Morty1,2*
1 Department of Lung Development and Remodelling, Max Planck Institute for Heart and Lung Research, Bad Nauheim, 
Germany, 2 Pulmonology, Department of Internal Medicine, University of Giessen and Marburg Lung Center, Giessen, 
Germany
Bronchopulmonary dysplasia (BPD) is a common complication of preterm birth that 
contributes signiﬁcantly to morbidity and mortality in neonatal intensive care units. BPD 
results from life-saving interventions, such as mechanical ventilation and oxygen sup-
plementation used to manage preterm infants with acute respiratory failure, which may 
be complicated by pulmonary infection. The pathogenic pathways driving BPD are not 
well-delineated but include disturbances to the coordinated action of gene expression, 
cell–cell communication, physical forces, and cell interactions with the extracellular 
matrix (ECM), which together guide normal lung development. Efforts to further delineate 
these pathways have been assisted by the use of animal models of BPD, which rely 
on infection, injurious mechanical ventilation, or oxygen supplementation, where histo-
pathological features of BPD can be mimicked. Notable among these are perturbations 
to ECM structures, namely, the organization of the elastin and collagen networks in the 
developing lung. Dysregulated collagen deposition and disturbed elastin ﬁber organi-
zation are pathological hallmarks of clinical and experimental BPD. Strides have been 
made in understanding the disturbances to ECM production in the developing lung, 
but much still remains to be discovered about how ECM maturation and turnover are 
dysregulated in aberrantly developing lungs. This review aims to inform the reader about 
the state-of-the-art concerning the ECM in BPD, to highlight the gaps in our knowledge 
and current controversies, and to suggest directions for future work in this exciting and 
complex area of lung development (patho)biology.
Keywords: bronchopulmonary dysplasia, extracellular matrix, hyperoxia, mechanical ventilation, collagen, elastin, 
lung development
BRONCHOPULMONARY DYSPLASIA IN CONTEXT
The lung is the key organ of gas exchange in air-breathing mammals. This gas exchange structure 
is derived from the primitive foregut and proceeds through a phase of early (embryonic) develop-
ment (1–3), when the conducting airways and conducting vessels are generated and organized (4). 
Early lung development initiates with the embryonic stage that occurs 4–7 weeks post-conception in 
humans [embryonic day (E)9–E12 in the mouse]. The embryonic stage is followed by the pseudog-
landular stage, which occurs at 5–17 weeks post-conception in humans (E12–E17 in mice). The final 
stage of early lung development is the canalicular stage, occurring at 16–26 weeks post-conception 
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Mižíková I, Ruiz-Camp J, Steenbock H, Madurga A, Vadász I,
Herold S, Mayer K, Seeger W, Brinckmann J, Morty RE. Colla-
gen and elastin cross-linking is altered during aberrant late lung
development associated with hyperoxia. Am J Physiol Lung Cell Mol
Physiol 308: L1145–L1158, 2015. First published April 3, 2015;
doi:10.1152/ajplung.00039.2015.—Maturation of the lung extracellu-
lar matrix (ECM) plays an important role in the formation of alveolar
gas exchange units. A key step in ECM maturation is cross-linking of
collagen and elastin, which imparts stability and functionality to the
ECM. During aberrant late lung development in bronchopulmonary
dysplasia (BPD) patients and animal models of BPD, alveolarization
is blocked, and the function of ECM cross-linking enzymes is dereg-
ulated, suggesting that perturbed ECM cross-linking may impact
alveolarization. In a hyperoxia (85% O2)-based mouse model of BPD,
blunted alveolarization was accompanied by alterations to lung col-
lagen and elastin levels and cross-linking. Total collagen levels were
increased (by 63%). The abundance of dihydroxylysinonorleucine
collagen cross-links and the dihydroxylysinonorleucine-to-hydroxy-
lysinonorleucine ratio were increased by 11 and 18%, respectively,
suggestive of a proﬁbrotic state. In contrast, insoluble elastin levels
and the abundance of the elastin cross-links desmosine and isodes-
mosine in insoluble elastin were decreased by 35, 30, and 21%,
respectively. The lung collagen-to-elastin ratio was threefold in-
creased. Treatment of hyperoxia-exposed newborn mice with the lysyl
oxidase inhibitor -aminopropionitrile partially restored normal col-
lagen levels, normalized the dihydroxylysinonorleucine-to-hydroxy-
lysinonorleucine ratio, partially normalized desmosine and isodes-
mosine cross-links in insoluble elastin, and partially restored elastin
foci structure in the developing septa. However, -aminopropionitrile
administration concomitant with hyperoxia exposure did not improve
alveolarization, evident from unchanged alveolar surface area and
alveoli number, and worsened septal thickening (increased by 12%).
These data demonstrate that collagen and elastin cross-linking are
perturbed during the arrested alveolarization of developing mouse
lungs exposed to hyperoxia.
lung development; elastin; collagen; lysyl oxidase; alveolarization
POSTNATAL LUNG DEVELOPMENT in mice is characterized by a
period of intensive growth and remodeling of the lung paren-
chyma, which rapidly (over a period of days) generates a large
number of small alveoli and thus maximizes the alveolar
surface area over which gas exchange can take place. Second-
ary septation, the generation of new septa from preexisting
septa, which then divide the air spaces, peaks in mice between
4 and 7 days after birth and is largely complete 21 days after
birth. In humans, secondary septation is already well underway
during late stages of pregnancy, and thus occurs in utero, and
continues several years into postnatal life. Disturbances to the
formation of secondary septa, such as the arrested secondary
septation associated with bronchopulmonary dysplasia (BPD)
in humans, leads to malformed lungs with fewer and larger
alveoli. This common complication of premature birth is asso-
ciated with signiﬁcant morbidity and mortality.
The molecular mechanisms underlying the generation of
secondary septa remain poorly understood, but most likely rely
on the coordinated action of transcription factors, growth factor
signaling, extracellular matrix (ECM) deposition and remod-
eling, and physical forces, such as breathing motions (41, 42).
The generation and shaping of the lung ECM has received
much attention in the context of normal and aberrant lung
alveolarization (20, 38, 45). Infants with BPD exhibit increased
collagen abundance in the lung (14), and collagen ﬁbers and
the lung collagen scaffold are malformed (60). There is also
evidence of altered elastin turnover, as assessed by urinary
excretion of the desmosine elastin cross-link, in infants with
BPD (12). These data point to disturbances to ECM production
and processing in BPD, which may be mimicked in animal
models, employing either hyperoxia, caloric restriction, me-
chanical ventilation, or preterm delivery as an injurious stim-
ulus in rats, mice, lambs, and baboons (6, 13, 49, 66). The lung
histopathology that results is reminiscent of that of BPD in
humans, with evident air space enlargement, septal wall thick-
ening, and a reduced number of alveoli, as well as perturba-
tions to ECM structures. Increased collagen levels have been
reported in the lungs of hyperoxia-exposed adult rats (44).
Elastin has received more attention, since normal elastin pro-
duction and deposition are critical for proper development of
alveoli (43, 57, 58). In hyperoxia-exposed or calorie-restricted
mice, late lung development is impeded, and elastic ﬁbers are
described to be “irregularly distributed, tortuous, and abruptly
terminating” (11). Similarly, in mechanically ventilated pre-
term lambs, late lung development is also impeded, and ex-
cessive production of elastin and accumulation of short, brush-
like elastin ﬁbers in the developing lung has been noted (2, 52).
To date, the underlying reasons for these perturbations to
ECM structures have remained elusive. Excessive elastase
activity has been considered as a mediator of pathological
elastin degradation, which might underlie the paucity of elastin
and bizarre elastin ﬁber patterns seen in affected lungs (21–23,
36). Additionally, the altered expression of proteins required
for proper elastin ﬁber assembly has also been suggested to
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Madurga A, Mižíková I, Ruiz-Camp J, Vadász I, Herold S,
Mayer K, Fehrenbach H, Seeger W, Morty RE. Systemic hydrogen
sulﬁde administration partially restores normal alveolarization in an
experimental animal model of bronchopulmonary dysplasia. Am J
Physiol Lung Cell Mol Physiol 306: L684–L697, 2014. First pub-
lished February 7, 2014; doi:10.1152/ajplung.00361.2013.—Arrested
alveolarization is the pathological hallmark of bronchopulmonary
dysplasia (BPD), a complication of premature birth. Here, the impact
of systemic application of hydrogen sulﬁde (H2S) on postnatal alveo-
larization was assessed in a mouse BPD model. Exposure of newborn
mice to 85% O2 for 10 days reduced the total lung alveoli number by
56% and increased alveolar septal wall thickness by 29%, as assessed
by state-of-the-art stereological analysis. Systemic application of H2S
via the slow-release H2S donor GYY4137 for 10 days resulted in
pronounced improvement in lung alveolarization in pups breathing
85% O2, compared with vehicle-treated littermates. Although without
impact on lung oxidative status, systemic H2S blunted leukocyte
inﬁltration into alveolar air spaces provoked by hyperoxia, and re-
stored normal lung interleukin 10 levels that were otherwise depressed
by 85% O2. Treatment of primary mouse alveolar type II (ATII) cells
with the rapid-release H2S donor NaHS had no impact on cell
viability; however, NaHS promoted ATII cell migration. Although
exposure of ATII cells to 85% O2 caused dramatic changes in mRNA
expression, exposure to either GYY4137 or NaHS had no impact on
ATII cell mRNA expression, as assessed by microarray, suggesting
that the effects observed were independent of changes in gene expres-
sion. The impact of NaHS on ATII cell migration was attenuated by
glibenclamide, implicating ion channels, and was accompanied by
activation of Akt, hinting at two possible mechanisms of H2S action.
These data support further investigation of H2S as a candidate inter-
ventional strategy to limit the arrested alveolarization associated with
BPD.
lung development; gasotransmitter; inﬂammation; alveolar type II cell
BRONCHOPULMONARY DYSPLASIA (BPD) is a chronic lung disorder
encountered in prematurely born infants, particularly in very
low birth weight infants, and infants that receive oxygen
therapy. Currently, the clinical diagnosis of BPD is based on a
need for oxygen supplementation at a deﬁned postmenstrual
age, which does not reﬂect the pathological characteristics of
BPD (6). Since the ﬁrst description of BPD in 1967 (57), these
pathological characteristics have changed, in response to the
medical management of infants at risk for BPD, such as
surfactant replacement therapy. Today, BPD is characterized
largely by an arrest of alveolarization and the development of
a dysmorphic pulmonary circulation (34–36, 52, 54). The
pathogenic mechanisms that underlie the development of BPD
are not well deﬁned (29); however, candidates include oxida-
tive stress and oxygen toxicity (10, 64), barotrauma (28),
volutrauma (13, 14, 18), perinatal infection (33, 39), and
inﬂammation (16, 45, 71, 72, 80, 86). BPD also has a vascular
component, which may be both a contributor to and a conse-
quence of perturbed alveolarization (15, 74–76).
The endogenous gasotransmitters hydrogen sulﬁde (H2S),
nitric oxide (NO), and carbon monoxide (CO) (84) are emerg-
ing as potentially interesting contributors to pulmonary phys-
iology and pathology. Additionally, because of the ease of
local delivery of gas directly to lung via the trachea, there is
much interest in the exploitation of these gases in therapeutic
or management strategies for lung diseases. The gases are
credited with anti-inﬂammatory, antioxidant, antibacterial, and
vasodilatory properties. Given that infection, inﬂammation,
oxidative stress, and vasoconstriction form the basis of many
lung diseases, including BPD, these gases have potentially
exciting applications in the management of lung disease, pro-
vided they can be employed at doses that are not toxic.
Inhaled NO (iNO) has found widespread clinical use (5, 7,
62, 63), although the use iNO in preterm infants with
respiratory failure remains controversial (69). Additionally,
overexpression of Hmox1 (which can generate CO) in the
alveolar epithelium may offer protection against perturbed
lung and pulmonary vascular development associated with
hyperoxia (25).
To date, systemic H2S administration has not been evaluated
in an experimental animal model of BPD. H2S is currently
under evaluation as a therapeutic modality in a spectrum of
other lung diseases. Inhaled H2S has been evaluated in exper-
imental mouse models of acute lung injury (21, 23), and in an
experimental model of ventilator-induced acute lung injury
(22) a protective effect was observed (at 80 ppm) and attributed
to the anti-inﬂammatory properties of H2S, although another
study employing 70 ppm inhaled H2S (but more injurious
mechanical ventilation) reported deleterious effects of H2S
inhalation (26). Additionally, parenteral administration of the
H2S donor NaHS attenuated acute lung injury in adult mice,
ostensibly through the antioxidant properties of H2S (22).
Systemic administration of H2S with NaHS also attenuates
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Pulmonary arterial hypertension (PAH) is a life-threatening disease characterized by elevated pulmonary artery pres-
sure caused by increased pulmonary vascular resistance, ulti-
mately leading to right heart failure and death.1 A combination 
of vasoconstriction, and vascular wall remodeling, which 
includes excessive extracellular matrix (ECM) deposition, 
and smooth muscle cell hyperplasia leads to occlusion of the 
small pulmonary arteries.2 Therapeutic options for the clini-
cal management of PAH are limited, and the disease remains 
essentially untreatable, underscoring the need for a better 
understanding of the pathogenic mechanisms at play that 
give rise to increased pulmonary vascular resistance.3 In this 
regard, 1 key area of interest is to clarify the causes and nature 
of the pulmonary vascular remodeling associated with PAH.
To date, most studies that have explored vascular remod-
eling in pulmonary hypertension (PH) have focused on 
increased cell proliferation and apoptosis resistance as an 
underlying cause of medial hypertrophy and neointimal 
formation. Regulation of pulmonary artery smooth muscle 
cell (PASMC) proliferation, apoptosis, and contraction has 
received much attention, with potassium and calcium chan-
nels, growth factors (including transforming growth factor-β, 
© 2014 American Heart Association, Inc.
Arterioscler Thromb Vasc Biol is available at http://atvb.ahajournals.org DOI: 10.1161/ATVBAHA.114.303534
Objective—Pulmonary vascular remodeling, the pathological hallmark of pulmonary arterial hypertension, is attributed 
to proliferation, apoptosis resistance, and migration of vascular cells. A role of dysregulated matrix cross-linking and 
stability as a pathogenic mechanism has received little attention. We aimed to assess whether matrix cross-linking 
enzymes played a causal role in experimental pulmonary hypertension (PH).
Approach and Results—All 5 lysyl oxidases were detected in concentric and plexiform vascular lesions of patients with 
idiopathic pulmonary arterial hypertension. Lox, LoxL1, LoxL2, and LoxL4 expression was elevated in lungs of patients 
with idiopathic pulmonary arterial hypertension, whereas LoxL2 and LoxL3 expression was elevated in laser-capture 
microdissected vascular lesions. Lox expression was hypoxia-responsive in pulmonary artery smooth muscle cells and 
adventitial ﬁbroblasts, whereas LoxL1 and LoxL2 expression was hypoxia-responsive in adventitial ﬁbroblasts. Lox 
expression was increased in lungs from hypoxia-exposed mice and in lungs and pulmonary artery smooth muscle cells of 
monocrotaline-treated rats, which developed PH. Pulmonary hypertensive mice exhibited increased muscularization and 
perturbed matrix structures in vessel walls of small pulmonary arteries. Hypoxia exposure led to increased collagen cross-
linking, by dihydroxylysinonorleucine and hydroxylysinonorleucine cross-links. Administration of the lysyl oxidase inhibitor 
β-aminopropionitrile attenuated the effect of hypoxia, limiting perturbations to right ventricular systolic pressure, right 
ventricular hypertrophy, and vessel muscularization and normalizing collagen cross-linking and vessel matrix architecture.
Conclusions—Lysyl oxidases are dysregulated in clinical and experimental PH. Lysyl oxidases play a causal role in 
experimental PH and represent a candidate therapeutic target. Our proof-of-principle study demonstrated that modulation 
of lung matrix cross-linking can affect pulmonary vascular remodeling associated with PH.  (Arterioscler Thromb 
Vasc Biol. 2014;34:1446-1458.)
Key Words: anoxia ◼ extracellular matrix ◼ hypertension, pulmonary ◼ muscle, smooth ◼ protein-lysine 6-oxidase
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Madurga A, Mižíková I, Ruiz-Camp J, Morty RE. Recent advances in
late lung development and the pathogenesis of bronchopulmonary dysplasia.
Am J Physiol Lung Cell Mol Physiol 305: L893–L905, 2013. First published
November 8, 2013; doi:10.1152/ajplung.00267.2013.—In contrast to early
lung development, a process exempliﬁed by the branching of the
developing airways, the later development of the immature lung
remains very poorly understood. A key event in late lung development
is secondary septation, in which secondary septa arise from primary
septa, creating a greater number of alveoli of a smaller size, which
dramatically expands the surface area over which gas exchange can
take place. Secondary septation, together with architectural changes to
the vascular structure of the lung that minimize the distance between
the inspired air and the blood, are the objectives of late lung devel-
opment. The process of late lung development is disturbed in bron-
chopulmonary dysplasia (BPD), a disease of prematurely born infants
in which the structural development of the alveoli is blunted as a
consequence of inﬂammation, volutrauma, and oxygen toxicity. This
review aims to highlight notable recent developments in our under-
standing of late lung development and the pathogenesis of BPD.
BPD; lung development; alveolarization; hypoxia; growth factor;
oxidative stress
THE PRIMARY FUNCTION OF THE lung is to transport oxygen from
the inspired air into the blood and to clear accumulated carbon
dioxide from the blood. The alveolus is the site of this gas
exchange in the lung, which takes place across the alveolocap-
illary barrier, a double barrier that consists of the alveolar
epithelium and the capillary endothelium located in close
proximity to one another, and supported by the extracellular
matrix (ECM). To facilitate effective gas exchange across this
barrier, it is desirable that this barrier is as thin as possible to
give the gas molecules a short distance to traverse, and also
that the functional surface area of the barrier is as large as
possible, to maximize the functional gas exchange capacity of
the lung. It is the objective of late lung development, through
the process of alveolarization, to deliver these two essential
elements of a mature, functional lung (114).
This is achieved ﬁrst by the establishment of the core lung
structure, during airway branching in the embryonic (4–7 wk
postconception) and pseudoglandular (5–17 wk postconcep-
tion) stages of early lung development. Late lung development
follows with the canalicular stage (16–24 wk postconception),
which is marked by the thinning of the interstitial tissue and the
“opening” of air spaces in the developing lung. This is fol-
lowed by the formation of saccular units by the developing
airways in the saccular stage (24–35 wk postconception), after
which secondary septa divide the saccular units during the
alveolar stage (36 wk postconception to several years postna-
tal), increasing the number and reducing the size of the alveoli.
Alveolar septal formation, the key event in alveolarization,
proceeds from 34 wk postconception. This process remains
very poorly understood and is thought to be regulated by the
concerted action of gene expression programs, growth factor
signaling, ECM production and maturation, and physical
forces, such as those generated by breathing motions (112, 113,
178).
When late lung development is disturbed, the lung architec-
ture is malformed. Depending on the severity of the architec-
tural malformation, there may be serious consequences in
terms of respiratory function, as well as long-term conse-
quences in later life. This is exempliﬁed by diseases such as
bronchopulmonary dysplasia (BPD) (124), a common compli-
cation of preterm birth, which is characterized by perturbations
to lung structure that include reduced alveolar number, thick-
ened septa, and a malformed pulmonary circulation. These
structural abnormalities lead to respiratory complications dur-
ing infancy, which may persist into adulthood (14, 188, 189).
Improved medical management of BPD has dramatically in-
creased the survival of BPD patients and has changed the
pathophysiological picture of BPD today. BPD is now charac-
terized less by ﬁbroproliferative airway damage and parenchy-
mal ﬁbrosis and more by alveolar hypoplasia and a dysmorphic
pulmonary circulation, making BPD today largely a disease of
arrested lung development (84, 85). This has underscored an
urgent need to better understand the molecular basis of late
lung development. Additionally, improved perinatal care has
increased the survival of very premature infants (61), which
has also led to an increase in the incidence of BPD, highlight-
ing the need for a better understanding of the pathogenic
mechanisms at play, which might be targeted in the medical
management and treatment of BPD. This review, which com-
plements a recent Update article in the American Journal of
Respiratory and Critical Care Medicine (105), aims to provide
a perspective on very recent advances in our understanding of
late lung development and BPD.
Hyperoxia and Oxidative Stress
Adult patients with compromised respiratory function are
often ventilated with high oxygen concentrations for life sup-
port. Similarly, prematurely born infants have lungs that are
insufﬁciently developed to allow for proper gas exchange, and
oxygen supplementation thus also represents a life-saving in-
tervention in the neonatal intensive care unit. However, high
oxygen levels are also very toxic and damage the lung, either
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